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FOREWORDForeword
This second edition of Health at a Glance: Europe presents the most recent key indicators of
health and health systems across 35 countries: the 27 European Union member states, five
candidate countries and three European Free Trade Association countries. The report comes at a
difficult time for European health systems. The economic crisis is increasing poverty, unemployment
and stress, all of which are associated with worse health outcomes, yet public and private budgets
are under great strain. The report highlights the marked slowdown (sometimes even reduction) in
health spending over recent years in many countries, as part of broader efforts to reduce large
budgetary deficits. If the report does not yet show any worsening health outcomes due to the crisis,
there is no cause for complacency – it takes time for poor social conditions or poor quality care to take
its toll from people’s health. Policy makers have often done what they could to ensure that access to
high quality care remains the norm in Europe; whether this is enough to protect the health of the
population will only become clear in years to come.
The indicators presented in this report are based largely on the European Community Health
Indicators (ECHI), a set of indicators used by the European Commission to guide the development of
health information systems in Europe. Additional indicators examine health expenditure trends as
well as quality of care, building on OECD expertise in these domains.
The publication at hand reflects the long and fruitful collaboration between the OECD and the
European Commission in the development and reporting of health statistics. Since 2005, a joint data
collection between the OECD, the European Commission and the World Health Organization has
improved the availability of comparable data on health expenditure, based on a common System of
Health Accounts. Furthermore, since 2010, these three organisations have gathered additional data on
the health workforce as well as on the physical and technical resources required to deliver health services.
The OECD and the European Commission will continue to work closely together to improve the
quality and comparability of data to monitor population health and the performance of health
systems across European countries.
In the meantime, we hope that this publication will be useful to you and that it will stimulate
action to improve the health of European citizens by learning from each others’ experience.
Yves Leterme Paola Testori Coggi
Deputy Secretary-General Director-General
Organisation for Economic Co-operation Directorate-General for Health and Consumers
and Development European CommissionHEALTH AT A GLANCE: EUROPE 2012 © OECD 2012 3
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European countries have achieved major gains in population health in recent decades.
Life expectancy at birth in European Union (EU) member states has increased by more than
six years since 1980, to reach 79 years in 2010, while premature mortality has reduced
dramatically. Over three-quarters of these years of life can be expected to be lived free of
activity limitation. Gains in life expectancy can be explained by improved living and
working conditions and some health-related behaviours, but better access to care and
quality of care also deserves much credit, as shown, for instance, by sharply reduced
mortality rates following a heart attack or stroke.
Many health improvements have come at considerable financial cost. Until 2009, health
spending in European countries grew at a faster rate than the rest of the economy, and the
health sector absorbed a growing share of the gross domestic product (GDP). Following the
onset of the financial and economic crisis in 2008, many European countries reduced health
spending as part of broader efforts to reign in large budgetary deficits and growing debt-to-GDP
ratios. Although these cuts might have been unavoidable, some measures may have an impact
on the fundamental goals of health systems. Continuous monitoring of data and indicators on
health and health systems is therefore important; it provides indications of the potential short
and longer-term impact of changing economic circumstances and health policies on health
care access, quality and health outcomes.
This second edition of Health at a Glance: Europe presents the most recent comparable data for
selected indicators of health and health systems in 35 European countries – the 27 member
states of the European Union, five candidate countries and three EFTA countries – up to 2010.
The selection of indicators has been based on the European Community Health Indicators
(ECHI) shortlist, a list of indicators that has been developed by the European Commission to
guide the development and reporting of health statistics. In addition, the publication provides
detailed information on health expenditure and financing trends, using results from the OECD,
Eurostat and WHO annual joint health accounts questionnaire. It also includes a new chapter
on quality of health care, reflecting the progress achieved under the OECD Health Care Quality
Indicators project. The data presented here come mainly from official national statistics,
collected individually or jointly by the OECD, Eurostat or WHO-Europe, as well as multi-country
surveys such as the Health Behaviour in School-aged Children (HBSC) survey.
Health at a Glance: Europe 2012 presents trends over time and variations across European
countries under five broad topics: 1) population health status; 2) risk factors to health;
3) resources and activities of health care systems; 4) quality of care for chronic and acute
conditions; and 5) health expenditure and financing sources. It offers some explanation for
these variations, providing background for further research and analysis to understand
more fully the causes underlying such variations and to develop policy options to reduce
gaps with those countries that are achieving better results. Many indicators provide a
breakdown by sex and age in each country, and several include a further breakdown by7
EXECUTIVE SUMMARYincome or education levels. These indicators show that there may be as much variation
within a country by sub-national regions, socio-economic groups or ethnic/racial groups as
there is across countries.
Health status has improved dramatically 
in European countries, although large gaps persist
● Life expectancy at birth in EU member states has increased by over 6 years between 1980
and 2010. On average across the European Union, life expectancy at birth for the three-year
period 2008-10 was 75.3 years for men and 81.7 years for women. France had the highest life
expectancy for women (85.0 years), and Sweden for men (79.4 years). Life expectancy at birth
in the EU was lowest in Bulgaria and Romania for women (77.3 years) and Lithuania for men
(67.3 years). The gap between EU member states with the highest and lowest life
expectancies at birth is around 8 years for women and 12 years for men (Figure 1.1.1).
● On average across the European Union, healthy life years (HLY) at birth, defined as the
number of years of life free of activity limitation, was 62.2 years for women and
61.0 years for men in 2008-10. The gender gap is much smaller than for life expectancy,
reflecting the fact that a higher proportion of the life of women is spent with some
activity limitations. HLY at birth in 2008-10 was greatest in Malta for women and Sweden
for men, and shortest in the Slovak Republic for both women and men (Figure 1.1.1).
● Life expectancy at age 65 has also increased substantially in European countries, averaging
16.5 years for men and 20.1 years for women in the European Union in 2008-10. As for life
expectancy at birth, France had the highest life expectancy at age 65 for women
(23.2 years) but also for men (18.7 years). Life expectancy at age 65 in the European Union
was lowest in Bulgaria for women (16.9 years) and Latvia for men (13.2 years) (Figure 1.2.1).
● Large inequalities in life expectancy persist between socio-economic groups. For both
men and women, highly educated persons are likely to live longer; in the Czech Republic
for example, 65-year-old men with a high level of education can expect to live seven
years longer than men of the same age with a low education level (Figure 1.2.3).
● It is difficult to estimate the relative contribution of the numerous non-medical and
medical factors that might affect variations in life expectancy across countries. Higher
national income is generally associated with higher (healthy) life expectancy, although
the relationship is less pronounced at the highest income levels, suggesting a
“diminishing return” (Figure 1.1.2).
● Chronic diseases such as diabetes, asthma and dementia are increasingly prevalent, due
either to better diagnosis or more underlying disease. More than 6% of people aged
20-79 years in the European Union, or 30 million people, had diabetes in 2011 (Figure 1.14.1).
Better management of chronic diseases has become a health policy priority for many
EU member states.
Risk factors to health are changing
● Most European countries have reduced tobacco consumption via public awareness
campaigns, advertising bans and increased taxation. The percentage of adults who
smoke daily is below 15% in Sweden and Iceland, from over 30% in 1980. At the other end
of the scale, over 30% of adults in Greece smoke daily. Smoking rates continue to be high
in Bulgaria, Ireland and Latvia (Figure 2.5.1).HEALTH AT A GLANCE: EUROPE 2012 © OECD 20128
EXECUTIVE SUMMARY● Alcohol consumption has also fallen in many European countries. Curbs on advertising,
sales restrictions and taxation have all proven to be effective measures. Traditional
wine-producing countries, such as France, Italy and Spain, have seen consumption per
capita fall substantially since 1980. Alcohol consumption per adult rose significantly in a
number of countries, including Cyprus, Finland and Ireland (Figure 2.6.1).
● In the European Union, 52% of the adult population is now overweight, of which 17% is
obese. At the country level, the prevalence of overweight and obesity exceeds 50% in 18
of the 27 EU member states. Rates are much lower in France, Italy and Switzerland,
although increasing there as well. The prevalence of obesity – which presents greater
health risks than overweight – ranges from 8% in Romania and Switzerland to over 25%
in Hungary and the United Kingdom (Figure 2.7.1). The obesity rate has doubled
since 1990 in many European countries (Figure 2.7.2). Rising obesity has affected all
population groups, to varying extents. Obesity tends to be more common among
disadvantaged social groups, and especially women.
The number of doctors and nurses per capita 
is higher than ever before in most countries, 
but there are concerns about current or future 
shortages
● Ensuring proper access to health care is a fundamental policy objective in all EU member
states. It requires, among other things, having the right number of health care providers
in the right places to respond to the population’s needs. There are concerns in many
European countries about shortages of doctors and nurses, although recent public
spending cuts on health in some countries may have led to at least a temporary
reduction in demand.
● Since 2000, the number of doctors per capita has increased in almost all EU member
states. On average across the European Union, the number of doctors grew from 2.9 per
1 000 population in 2000 to 3.4 in 2010. Growth was particularly rapid in Greece and the
United Kingdom (Figure 3.1.1).
● In nearly all countries, the balance between generalist and specialist doctors has
changed such that there are now more specialists (Figure 3.1.2). This may be explained
by a reduced interest in traditional “family medicine” practice, combined with a growing
remuneration gap between generalists and specialists. The slow growth or reduction in
the number of generalists raises concerns in many countries about access to primary
care for certain population groups.
● There are also concerns about possible shortages of nurses, and this may well intensify
in the future as the demand for nurses continues to increase and the ageing of the
“baby boom” generation precipitates a wave of retirements among nurses. Over the past
decade, the number of nurses per capita has increased in nearly all EU member states
(Figure 3.3.1). The increase was particularly large in Demark, France, Portugal and Spain.
However, recently there has been a reduction in nurses employed in some countries
hardest hit by the economic crisis. In Estonia, the number of nurses increased to 2008,
but has decreased since then, with a resulting fall from 6.4 per 1 000 population in 2008
to 6.1 in 2010.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012 9
EXECUTIVE SUMMARYQuality of care has improved in most European 
countries, though all countries can do better, 
particularly to avoid hospital admissions 
for people with chronic diseases
● There has been progress in the treatment of life-threatening conditions such as heart
attack, stroke and cancer in all reporting European countries. Mortality rates following
hospital admissions for heart attack (acute myocardial infarction) have fallen by
nearly 50% between 2000 and 2009 (Figure 4.3.3) and for stroke by over 20% (Figure 4.4.3).
These improvements reflect better acute care and greater access to dedicated stroke
units in countries like Denmark and Sweden.
● Survival rates for different types of cancer have also improved in most countries, reflecting
earlier detection and greater treatment effectiveness (Figures 4.7.2 and 4.8.2). While survival
rates for breast cancer remain below 80% in the Czech Republic and Slovenia, they have
increased by over 10 percentage points between 1997-2002 and 2004-09. These two countries
also witnessed substantial gains in survival rates for colorectal cancer (Figure 4.9.2).
● It is more difficult to monitor quality of care in the primary care sector, as in most
countries there are fewer data than in the hospital sector. Avoidable hospital admission is
often used as an indicator of either access problems to primary care or the quality and
continuity of care. There is general consensus that asthma and diabetes should largely be
managed through proper primary care interventions to avoid exacerbation and costly
hospitalisation. While hospital admissions for asthma are low in certain countries, they
are much higher in others, such as the Slovak Republic (Figure 4.1.1). In all European
countries, there are too many hospital admissions for uncontrolled diabetes (Figure 4.2.1).
Growth in health expenditure has slowed or fallen 
in many European countries
● Growth in health spending per capita slowed or fell in real terms in 2010 in almost all
European countries, reversing a trend of steady increases. Spending had already started
to fall in 2009 in countries hardest hit by the economic crisis (e.g. Estonia and Iceland),
but this was followed by deeper cuts in 2010 in response to growing budgetary pressures
and rising debt-to-GDP ratios. On average across the EU, health spending per capita
increased by 4.6% per year in real terms between 2000 and 2009, followed by a fall of 0.6%
in 2010 (Figure 5.2.2).
● Reductions in public spending on health were achieved through a range of measures,
including reductions in wages and/or employment levels, increasing direct payments by
households for certain services and pharmaceuticals, and imposing severe budget
constraints on hospitals. Gains in efficiency have also been pursued through mergers of
hospitals or accelerating the move from inpatient care to outpatient care and day surgery.
● As a result of the negative growth in health spending in 2010, the percentage of GDP devoted
to health stabilised or declined slightly in many EU member states. In 2010, EU member
states devoted on average 9.0% (unweighted) of their GDP to health spending (Figure 5.3.1),
up significantly from 7.3% in 2000, but down slightly from the peak of 9.2% in 2009.
● The Netherlands allocated the highest share of GDP to health in 2010 (12%), followed by
France and Germany (both at 11.6%). In terms of health spending per capita, the
Netherlands (EUR 3 890), Luxembourg (EUR 3 607) and Denmark (EUR 3 439) were theHEALTH AT A GLANCE: EUROPE 2012 © OECD 201210
EXECUTIVE SUMMARYhighest spenders among EU member states. Austria, France and Germany followed, at
over EUR 3 000 per capita. Bulgaria and Romania were the lowest spending countries, at
around EUR 700.
● The public sector is the main source of health care financing in all European countries,
except Cyprus (Figure 5.6.1). In 2010, nearly three-quarter (73%) of all health spending
was publicly financed on average in EU member states. Public financing accounted for
over 80% in the Netherlands, the Nordic countries (except Finland), Luxembourg, the
Czech Republic, the United Kingdom and Romania. The share was the lowest in Cyprus
(43%), and Bulgaria, Greece and Latvia (55-60%).
● The economic crisis has affected the mix of public and private health financing in some
countries. Public spending has been cut for certain goods and services, often combined with
increases in the share of direct payments by households. In Ireland, the share of public
financing of health spending decreased by nearly 6 percentage points between 2008
and 2010, and stands now at 70%, while the share of out-of-pocket payments by households
increased. There have also been substantial falls in Bulgaria and the Slovak Republic.
● After public financing, the main source of funding for health expenditure in most
countries is out-of-pocket payments. Private health insurance financing only plays a
significant role in a few countries. In 2010, the share of out-of-pocket payments was
highest in Cyprus (49%), Bulgaria (43%) and Greece (38%). It was the lowest in the
Netherlands (6%), France (7%) and the United Kingdom (9%). Its share has increased over
the past decade in about half of EU member states, most notably in Bulgaria, Cyprus,
Malta and the Slovak Republic (Figure 5.6.3).
● The economic crisis and growing budgetary constraints have put additional pressures on
health systems in many European countries. Several countries that have been hardest
hit by the crisis have taken a series of measures to reduce public spending on health. It
will be important to monitor closely the short and longer-term impact of these measures
on the fundamental goals of health systems in European countries of ensuring proper
access and quality of care.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012 11
INTRODUCTIONIntroduction
Health at a Glance: Europe 2012 presents key indicators of health and health systems in
35 European countries, including the 27 European Union member states, 5 candidate
countries and 3 European Free Trade Association countries. The selection of indicators is
based largely on the European Community Health Indicators (ECHI) shortlist, a set of
indicators that has been developed to guide the reporting of health statistics in the
European Union (ECHIM, 2012). It is complemented by additional indicators on health
expenditure and quality of care in the related chapters.
The first edition of this report was released in 2010. This second edition includes a
larger number of ECHI indicators (notably in the first chapter on health status and in the
chapter on health care resources and activities), reflecting progress in data availability and
comparability. There is also a new chapter on quality of care combining certain ECHI
indicators with selected indicators on quality of care and patient safety developed under
the OECD Health Care Quality Indicators project (OECD, 2010c).
The data presented in this publication are mostly official national statistics and have
been collected through questionnaires administered by the OECD, Eurostat and WHO. The
data have been validated by the three organisations to ensure that they meet standards of
data quality and comparability. In certain cases, the data come from regular cross-national
surveys, such as the Health Behaviour in School-aged Children surveys for the set of
indicators on health risk factors among children. All indicators are presented in the form
of easy-to-read figures and explanatory text, based on a two-page format per indicator.
Structure of the publication
The publication is structured around five chapters:
● Chapter 1 on Health status highlights the variations across countries in life expectancy
and healthy life expectancy, and also presents other indicators of causes of mortality
and morbidity, including both communicable and non-communicable diseases.
● Chapter 2 on Determinants of health focuses on non-medical determinants of health
related to modifiable lifestyles and behaviours among children and adults, such as
smoking and alcohol drinking, nutrition, physical activity, and overweight and obesity.
●  Chapter 3 on Health care resources and activities reviews some of the inputs and outputs of
health care systems, including the supply of doctors and nurses, different types of
equipment used for diagnosis or treatment, and the provision of a range of services to
prevent the transmission of communicable diseases or to treat acute conditions.
● Chapter 4 is a new chapter on Quality of care, providing comparisons on care for chronic
and acute conditions, cancers and communicable diseases. The chapter also includes a
set of indicators on patient safety, building on the developmental work and data
collection carried out under the OECD Health Care Quality Indicators project.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201212
INTRODUCTION● Chapter 5 on Health expenditure and financing examines trends in health spending across
European countries, both overall and for different types of health services and goods,
including pharmaceuticals. It also looks at how these health services and goods are paid
for and the different mix between public funding, private health insurance, and direct
out-of-pocket payments by households.
An annex provides some additional tables on the demographic and economic context
within which different health systems operate, as well as additional data on health
expenditure trends.
Presentation of indicators
Each of the topics covered in this publication is presented over two pages. The first
provides a brief commentary highlighting the key findings conveyed by the data, defines
the indicator(s) and discusses any significant national variations from that definition
which might affect data comparability. On the facing page is a set of figures. These typically
show current levels of the indicator and, where possible, trends over time. In some cases,
an additional figure relating the indicator to another variable is included.
The average in the figures includes only European Union (EU) member states, and is
calculated as the unweighted average of those EU member states presented (up to 27, if there
is full data coverage). Some weighted averages are also presented in the tables on health
expenditure and GDP in the annex.
Data and limitations
Limitations in data comparability are indicated both in the text (in the box related to
“Definition and comparability”) as well as in footnotes to charts.
Readers interested in using the data presented in this publication for further analysis
and research are encouraged to consult the full documentation of definitions, sources and
methods contained in OECD Health Data 2012 for all OECD member countries, including
21 EU member states and 4 additional countries (Iceland, Norway, Switzerland and Turkey).
This information is available on OECD.Stat (http://stats.oecd.org/index.aspx?DataSetCode=
HEALTH_STAT).
For ten other countries (Bulgaria, Croatia, Cyprus, Former Yugoslav Republic of
Macedonia, Latvia, Lithuania, Malta, Montenegro, Romania and Serbia), readers should
consult the Eurostat database for more information on sources and methods: http://
epp.eurostat.ec.europa.eu/portal/page/portal/statistics/search_database.
Readers interested in an interactive presentation of the ECHI indicators can also consult
the DG SANCO HEIDI data tool at: http://ec.europa.eu/health/indicators/indicators/index_en.htm.
Population figures
The population figures for all EU member states and candidate countries presented in
the annex and used to calculate rates per capita in this publication come from the Eurostat
demographics database. The data were extracted in June 2012, and relate to mid-year
estimates (calculated as the average between the beginning and end of year population
figures). Population estimates are subject to revision, so they may differ from the latest
population figures released by Eurostat or national statistical offices.
Some member states such as France and the United Kingdom have overseas colonies,
protectorates and territories. These populations are generally excluded. However, the
calculation of GDP per capita and other economic measures may be based on a different
population in these countries, depending on the data coverage.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012 13
INTRODUCTIONCountry codes (ISO codes)
Austria AUT Lithuania LTU
Belgium BEL Luxembourg LUX
Bulgaria BGR Malta MLT
Croatia HRV Montenegro MNE
Cyprus1 CYP Netherlands NLD
Czech Republic CZE Norway NOR
Denmark DNK Poland POL
Estonia EST Portugal PRT
Finland FIN Romania ROU
France FRA Serbia SRB
FYR of Macedonia MKD Slovenia SVN
Germany DEU Slovak Republic SVK
Greece GRC Spain ESP
Hungary HUN Sweden SWE
Iceland ISL Switzerland CHE
Ireland IRL Turkey TUR
Italy ITA United Kingdom GBR
Latvia LVA
1. Note by Turkey: The information in this document with reference to “Cyprus” relates to the southern part of the
Island. There is no single authority representing both Turkish and Greek Cypriot people on the Island. Turkey
recognises the Turkish Republic of Northern Cyprus (TRNC). Until a lasting and equitable solution is found within
the context of United Nations, Turkey shall preserve its position concerning the “Cyprus” issue.
Note by all the European Union member states of the OECD and the European Commission: The Republic of Cyprus
is recognised by all members of the United Nations with the exception of Turkey. The information in this document
relates to the area under the effective control of the Government of the Republic of Cyprus.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201214
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1.1. LIFE EXPECTANCY AND HEALTHY LIFE EXPECTANCY AT BIRTHLife expectancy at birth continues to increase in
European countries, reflecting reductions in mortality rates
at all ages. These gains in longevity can be attributed to a
number of factors, including rising living standards,
improved lifestyle and better education, as well as greater
access to quality health services. Better nutrition, sanita-
tion and housing also play a role, particularly in countries
with developing economies (OECD, 2011b).
Average life expectancy at birth for 2008-10 across the
27 member states of the European Union reached 75.3 years
for men and 81.7 years for women (Figure 1.1.1), a rise of 2.7
and 2.3 years respectively over the decade from 1998-2010. In
more than two-thirds of EU member states, life expectancy
exceeded 80 years for women and 75 years for men. France
had the highest life expectancy at birth for women in 2008-10
(85.0 years), and Sweden for men (79.4 years). Life expectancy
was lowest in Bulgaria and Romania for women (77.3 years)
and in Lithuania for men (67.3 years). The gap between
EU member states with the highest and lowest life expectan-
cies is around eight years for women and 12 years for men.
The gender gap in life expectancy at birth in 2008-10
stood at 6.4 years, around half a year less than a decade
earlier. However, this hides a large range among countries,
with the smallest gap in Sweden, the Netherlands and the
United Kingdom, along with Iceland (about four years) and
the largest in Lithuania (over 11 years). The recent narrow-
ing of this gap in most countries can be attributed at least
partly to the narrowing of differences in risk-increasing
behaviours between men and women, such as smoking,
accompanied by sharp reductions in mortality rates from
cardiovascular diseases among men.
Looking ahead, Eurostat projects that life expectancy
will continue to increase in the European Union in coming
decades, to reach 84.6 years for males and 89.1 for females
in 2060. Convergence among countries is expected to
continue, with the largest increases in life expectancy to
take place in those countries with the lowest life expec-
tancy in 2010 (EC, 2012a).
In a context of increasing life expectancy and popula-
tion ageing, healthy life years (HLY) has been endorsed as an
important European policy indicator to address whether
years of longer life are lived in good health (Joint Action:
EHLEIS, 2012). The current leading indicator of HLY is a
measure of disability-free life expectancy which indicates
how long people can expect to live without disability. On
average for EU member states, HLY at birth in 2008-10 was
62.2 years for women and 61.0 years for men. It was greatest
in Malta for women, and in Sweden for men, and shortest in
the Slovak Republic for both men and women (Figure 1.1.1).
Women in Malta can expect to live 86% of life expectancy
without limitations in usual activities. For men in Sweden,
the value is even higher at 89%. In the Slovak Republic, only
66% of female and 73% of male life expectancy is free from
activity limitation.
The spread of values for HLY at birth among
EU member states are much greater than for life expec-
tancy, being 19 years for women and 18 years for men.
Since the HLY indicator has only recently been developed,
there is as yet no long time series. In contrast to the 6.4 year
gap in life expectancy at birth for EU member states on
average, the gender gap in HLY at birth was only around
1.2 years in 2008-10. For life expectancy at birth the gender
gap has always favoured women. However, seven countries
had a gender gap in HLY which favoured men, the greatest
being 2.0 more HLY for men in Portugal. Of the remaining
countries, Lithuania had the largest gender gap in HLY
favouring women. The European Innovation Partnership on
Active and Healthy Ageing, part of the Europe 2020 initia-
tive, has set an objective of increasing the average number
of healthy life years by two, by 2020 (EC, 2011b).
A wide range of factors affect life expectancy and HLY.
Higher national income (as measured by GDP per capita) is
generally associated with higher life expectancy at birth
and also with HLY, although the relationship is less pro-
nounced at higher levels of national income (Figure 1.1.2).
Similarly, Figure 1.1.3 shows that higher health spending
per capita tends to be associated with higher HLY, although
there is much variation for a given level of health spending,
confirming that many other factors play a role in determin-
ing the number of healthy life years.
Definition and comparability
Life expectancy measures how long, on average,
people would live based on a given set of age-specific
death rates. However, the actual age-specific death
rates of any particular birth cohort cannot be known
in advance. If age-specific death rates are falling (as
has been the case over the past decades), actual life
spans will, on average, be higher than life expectancy
calculated with current death rates.
Healthy life years (HLY) are the number of years
spent free of activity limitation, being equivalent to
disability-free life expectancy. HLY are calculated
annually by Eurostat and EHLEIS for each EU country
using the Sullivan (1971) method. The underlying
health measure is the Global Activity Limitation
Indicator (GALI), which measures limitation in usual
activities, and comes from the European Union Statis-
tics on Income and Living Conditions (EU-SILC) survey.
Comparing trends in HLY and life expectancy can
show whether extra years of life are healthy years.
However, valid comparisons depend on the underlying
health measure being truly comparable. While HLY is
the most comparable indicator to date, there are still
problems with translation of the GALI question,
although it does appear to satisfactorily reflect other
health and disability measures (Jagger et al., 2010).HEALTH AT A GLANCE: EUROPE 2012 © OECD 201216
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1.1.1. Life expectancy (LE) and healthy life years (HLY) at birth, by gender, 2008-10 average
Source: Eurostat Statistics Database; Joint Action: EHLEIS (2012).
1 2 http://dx.doi.org/10.1787/888932702879
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1.1.2. Healthy life years (HLY) at birth
and GDP per capita, 2008-10 average
Source: Eurostat Statistics Database; OECD Health Data 2012; WHO Global
Health Expenditure Database.
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1.1.3. Healthy life years (HLY) at birth 
and health spending per capita, 2008-10 average
Source: Eurostat Statistics Database; OECD Health Data 2012; WHO Global
Health Expenditure Database.
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1.2. LIFE EXPECTANCY AND HEALTHY LIFE EXPECTANCY AT AGE 65Life expectancy at age 65 has increased significantly
among both women and men over the past several decades
in all EU member states. Some of the factors explaining the
gains in life expectancy at age 65 include advances in
medical care, greater access to health care, healthier life-
styles and improved living conditions before and after
people reach age 65.
The average life expectancy at age 65 in 2008-10 for the
27 member states of the European Union was 16.5 years for
men and 20.1 years for women (Figure 1.2.1). As for life expec-
tancy at birth, France had the highest life expectancy at age 65
for women (23.2 years), but also for men (18.7 years). Among
other countries, life expectancy at 65 was highest in
Switzerland for both men and women. Life expectancy at
age 65 in the European Union was lowest in Latvia for men
(13.2 years) and in Bulgaria for women (16.9 years).
The average gender gap in life expectancy at age 65
in 2008-10 stood at 3.6 years, unchanged since 1998-2000.
Greece had the smallest gender gap of 2 years and Estonia
the largest at 5.2 years.
Gains in longevity at older ages in recent decades,
combined with the trend reduction in fertility rates are
contributing to a steady rise in the proportion of older
persons (see Annex Table A.2). Whether longer life expec-
tancy is accompanied by good health and functional status
among ageing populations has important implications for
health and long-term care systems.
Healthy life years (HLY) at age 65 in 2008-10 for
EU member states was similar for men and women, being
8.4 years for men and 8.6 years for women. HLY at age 65
in 2008-10 was greatest in Sweden and shortest in the
Slovak Republic for both men and women (Figure 1.2.1).
HLY is based on the Global Activity Limitation (GALI)
question, which is one of three indicators included in the
Minimum European Health Module along with global items
on self-perceived health and chronic morbidity. Since the
HLY indicator has only been developed relatively recently,
there is as yet no long time series.
The relationship between life expectancy and HLY at
age 65 is not clear-cut (Figure 1.2.2). Higher life expectancy
at age 65 is generally associated with higher HLY, although
longer life expectancy at age 65 does not necessarily imply
more HLY. Central and Eastern European countries have
both lower life expectancy and HLY than other European
countries.
Life expectancy at age 65 years also varies by educa-
tional status (Figure 1.2.3). For both men and women, highly
educated people are likely to live longer (Corsini, 2010).
Again, differences in life expectancy are particularly large in
Central and Eastern European countries, and are more
pronounced for men. In the Czech Republic, 65-year-old men
with a high level of education can expect to live seven years
longer than those with a low education level. Not only is
education a general measure of socio-economic status, it
can also provide the means to improve the social and
economic conditions in which people live and work.
A recent study showed that higher educational levels
are not only associated with higher life expectancy but also
with higher disability-free life expectancy at age 65 in ten
EU member states. For both men and women, differences
were larger for disability-free life expectancy than life
expectancy (Majer et al., 2011).
In several European countries, occupation is used as a
measure of socio-economic status. In the United Kingdom
for the period 2002-06, 65-year-old men classified as “Higher
managerial and professional” could expect to live 3.5 years
longer than men in “Routine occupations”, and this gap
had widened over the previous two decades. The gap
for women was similar at 3.2 years. In France, in 2003,
65-year-old men who had highly qualified occupations could
expect to live 3.1 years longer in total and 3.7 years longer
without disability than men who were manual workers.
These gaps were respectively 1.7 years and 3.2 years for
women (Cambois et al., 2011).
Definition and comparability
Life expectancy measures how long, on average,
people would live based on a given set of age-specific
death rates. However, the actual age-specific death
rates of any particular birth cohort cannot be known
in advance. If age-specific death rates are falling (as
has been the case over the past decades), actual life
spans will, on average, be higher than life expectancy
calculated with current death rates.
Healthy life years (HLY) are the number of years
spent free of activity limitation, being equivalent to
disability-free life expectancy. HLY are calculated
annually by Eurostat and EHLEIS for each EU country
using the Sullivan (1971) method. The underlying
health measure is the Global Activity Limitation Indi-
cator (GALI), which measures limitation in usual
activities, and comes from the European Union
Statistics on Income and Living Conditions (EU-SILC)
survey.
Comparing trends in HLY and life expectancy can
show whether extra years of life are healthy years.
However, valid comparisons depend on the underlying
health measure being truly comparable. While HLY is
the most comparable indicator to date, there are still
problems with translation of the GALI question,
although it does appear to satisfactorily reflect other
health and disability measures (Jagger et al., 2010).HEALTH AT A GLANCE: EUROPE 2012 © OECD 201218
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1.2.1. Life expectancy (LE) and healthy life years (HLY) at 65, by gender, 2008-10 average
Source: Eurostat Statistics Database; Joint Action: EHLEIS (2012).
1 2 http://dx.doi.org/10.1787/888932702936
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2008-10 average
Source: Eurostat Statistics Database.
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1.3. MORTALITY FROM ALL CAUSESStatistics on deaths remain one of the most widely
available and comparable sources of information on health.
Registering deaths is compulsory in all European countries,
and the data collected through the process of registration
can be used by statistical and health authorities to monitor
diseases and health status, and to plan health services. In
order to compare levels of mortality across countries and
over time, the data need to be standardised to remove the
effect of differences in age structure.
In 2010 there were large variations in age-standardised
mortality rates for all causes of death across European
countries. Death rates were lowest in Spain and Italy, at
less than 500 deaths per 100 000 population (Figure 1.3.1).
The rate in Switzerland was also low. Rates in northern,
western and southern European countries were lower than
the EU average rate of 663. They were highest in Baltic and
central European countries – Bulgaria, Latvia, Lithuania
and Romania, for instance, had age-standardised rates
almost twice those of the lowest countries at over
900 deaths per 100 000 population. Rates in Estonia,
Hungary and the Slovak Republic were above 800.
Male mortality rates were lowest in Malta, Sweden and
Italy, and among other countries, in Iceland and Switzerland.
They were high in Latvia and Lithuania. Female rates were
low in France, Italy and Spain, as well as in Switzerland, and
high in Bulgaria and Romania, along with the Former
Yugoslav Republic of Macedonia. A significant gender gap
exists in mortality rates (Figure 1.3.1). Across all EU member
states, the male mortality rate was, on average, 70% higher
than the female rate in 2010. But large differences exist
among countries – in Estonia, Latvia and Lithuania, male
rates were more than twice those of females, whereas in the
Denmark, the Netherlands, Sweden and the United Kingdom,
they were only around 40% higher.
Lower mortality rates translate into higher life expec-
tancies (see Indicator 1.1 “Life expectancy and healthy life
expectancy at birth”). Differences in life expectancy among
countries with the lowest and highest mortality rates are in
the order of 8 years for females and 12 years for males.
Some important causes of mortality that have been
influenced through effective public health measures
include ischemic heart disease, lung cancer, alcohol-
related mortality, suicide, transport accidents, cervical
cancer and AIDS (Cayotte and Buchow, 2009).
Although mortality rates in central Europe are still
comparatively high, significant declines have occurred in
a number of these countries since 1995 (Figures 1.3.2
and 1.3.3). Mortality rates in the Czech Republic, Estonia,
Hungary, Poland and Slovenia have fallen by more than
25%, a decline that is greater than the EU average. Ireland
has also seen a decline of close to 40%, driven largely by
reductions in cardiovascular and respiratory diseases mor-
tality, which in turn may be linked to rising living standards
and increased expenditure on public and private health
services in recent decades. In contrast, declines in the
Slovak Republic, Bulgaria and Lithuania have been smaller.
Declines in Belgium, Greece and Sweden have also been
modest, although these countries began the period with
rates that were already low.
The leading causes of death in Europe include cardio-
vascular diseases (such as heart attack and stroke), and
cancer. Deaths from these diseases, plus selected external
causes of death (transport accidents and suicide), are
examined more closely in the following four indicators.
Definition and comparability
Mortality rates are based on numbers of deaths
registered in a country in a year divided by the size of
the corresponding population. The rates have been
directly age-standardised to the WHO European
standard population to remove variations arising
from differences in age structures across countries
and over time. The source is the Eurostat Statistics
Database.
Deaths from all causes are classified to ICD-10
Codes A00-Y89, excluding S00-T98. Mathers et al.
(2005) have provided a general assessment of the
coverage, completeness and reliability of data on
causes of death.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201220
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1.3.1. Mortality rates from all causes of death, 2010 (or nearest year)
Source: Eurostat Statistics Database. Data are age-standardised to the WHO European standard population.
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1.3.2. Decline in mortality rates from all causes,
1995-2010 (or nearest year)
Source: Eurostat Statistics Database. Data are age-standardised to the
WHO European standard population.
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1.3.3. Trends in mortality rates from all causes, 
selected EU member states, 1995-2010
Source: Eurostat Statistics Database. Data are age-standardised to the
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1.4. MORTALITY FROM HEART DISEASE AND STROKECardiovascular diseases are the main cause of mortal-
ity in almost all EU member states, accounting for 36% of
all deaths in the region in 2010. They cover a range of
diseases related to the circulatory system, including
ischemic heart disease (known as IHD, or heart attack) and
cerebro-vascular disease (or stroke). Together, IHD and
stroke comprise 60% of all cardiovascular deaths, and
caused more than one-fifth of all deaths in EU member
states in 2010.
Ischemic heart disease is caused by the accumulation
of fatty deposits lining the inner wall of a coronary artery,
restricting blood flow to the heart. IHD alone was respon-
sible for 13% of all deaths in EU member states in 2010. Mor-
tality from IHD varies considerably, however (Figure 1.4.1);
Baltic countries report the highest IHD mortality rates,
Lithuania for both males and females, followed by Latvia,
the Slovak Republic and Estonia. IHD mortality rates are also
relatively high in Finland and Malta, with rates several times
higher than in France, Portugal, the Netherlands and Spain.
There are regional patterns to the variability in IHD mortal-
ity rates. Besides the Netherlands and Luxembourg, the
countries with the lowest IHD mortality rates are four
countries located in Southern Europe: France, Italy, Portugal
and Spain, with Cyprus and Greece also having low rates.
This lends support to the commonly held hypothesis that
there are underlying risk factors, such as diet, which explain
differences in IHD mortality across countries.
Death rates for IHD are much higher for men than for
women in all countries (Figure 1.4.1). On average across
EU member states, IHD mortality rates in 2010 were nearly
two times greater for men. The disparity was greatest in
Cyprus, France and Luxembourg, with male rates two-to-
three times higher, and least in Malta, Romania and the
Slovak Republic, at 60% higher.
Since the mid-1990s, IHD mortality rates have
declined in nearly all countries (Figure 1.4.3). The decline
has been most remarkable in Denmark, Ireland, the
Netherlands and the United Kingdom. Estonia and Norway
also saw IHD mortality rates cut by one-half or more,
although rates in Estonia are still high. Declining tobacco
consumption contributed significantly to reducing the inci-
dence of IHD, and consequently to reducing mortality rates.
Improvements in medical care have also played a part [see
Indicator 3.8 “Cardiac procedures (coronary angioplasty)”].
A small number of countries, however, have seen little or
no decline since 1995. Declines in Hungary, Poland and the
Slovak Republic have been moderate, at under 20%.
Stroke was the underlying cause for about 9% of all
deaths in 2010. It is a loss of brain function caused by the dis-
ruption of the blood supply to the brain. In addition to being
an important cause of mortality, the disability burden from
stroke is substantial (Moon et al., 2003). As with IHD, there are
large variations in stroke mortality rates across countries
(Figure 1.4.2). Again, the rates are highest in Baltic and central
European countries, including Bulgaria, Hungary, Latvia,
Lithuania, Romania and the Slovak Republic. They are the
lowest in Cyprus, France, Ireland and the Netherlands. Rates
are also low in Switzerland, Iceland and Norway.
Looking at trends over time, stroke mortality has
decreased in all EU member states since 1995, with a more
pronounced fall after 2003 (Figure 1.4.4). Rates have
declined by around 60% in Austria, Estonia and Portugal.
The decline has only been moderate in Lithuania, Poland
and the Slovak Republic. As with IHD, the reduction in
stroke mortality can be attributed at least partly to a reduc-
tion in risk factors. Tobacco smoking and hypertension are
the main modifiable risk factors for stroke. Improvements
in medical treatment for stroke have also increased
survival rates (see Indicator 4.4 “In-hospital mortality
following stroke”).
Definition and comparability
Mortality rates are based on numbers of deaths
registered in a country in a year divided by the size of
the corresponding population. The rates have been
directly age-standardised to the WHO European
standard population to remove variations arising
from differences in age structures across countries
and over time. The source is the Eurostat Statistics
Database.
Deaths from ischemic heart disease are classified to
ICD-10 Codes I20-I25, and stroke to I60-I69. Mathers
et al. (2005) have provided a general assessment of the
coverage, completeness and reliability of data on
causes of death.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201222
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1.4.1. Ischemic heart disease, mortality rates, 
2010 (or nearest year)
Source: Eurostat Statistics Database. Data are age-standardised to the
WHO European standard population.
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1.4.2. Stroke, mortality rates,
2010 (or nearest year)
Source: Eurostat Statistics Database. Data are age-standardised to the
WHO European standard population.
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1.4.3. Trends in ischemic heart disease mortality rates, 
selected EU member states, 1995-2010
Source: Eurostat Statistics Database. Data are age-standardised to the
WHO European standard population.
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1.4.4. Trends in stroke mortality rates, 
selected EU member states, 1995-2010
Source: Eurostat Statistics Database. Data are age-standardised to the
WHO European standard population.
1 2 http://dx.doi.org/10.1787/888932703107
250
200
150
100
50
0
1995 1997 1999 2001 2003 2005 2007 2009
FranceEstoniaBulgaria EU
Age-standardised rates per 100 000 population
1.5. MORTALITY FROM CANCERCancer is the second leading cause of mortality in
EU member states after diseases of the circulatory system,
accounting for 28% of all deaths in 2010. In 2010, cancer
mortality rates were the lowest in Cyprus, Finland and
Sweden, as well as Switzerland, at under 150 deaths per
100 000 population. They were the highest in central
European countries, including the Czech Republic,
Hungary, Poland, the Slovak Republic and Slovenia, at close
to or above 200 deaths per 100 000 population.
Cancer mortality rates are higher for men than for
women (Figure 1.5.1). In 2010, the gender gap was parti-
cularly wide in Estonia, Latvia, Lithuania, Portugal, the
Slovak Republic and Spain, with mortality rates among
men more than twice those for women. This gap can be
explained partly by the greater prevalence of risk factors
among men, as well as the lesser availability or use of
screening programmes for cancers affecting men, leading
to lower survival rates after diagnosis.
Lung cancer still accounts for the greatest number of
cancer deaths among men in EU member states, except in
Sweden. Lung cancer is also one of the main causes of
cancer mortality among women. Smoking is the most
important risk factor for lung cancer. In 2010, death
rates from lung cancer among men were the highest in
Baltic and central European countries (Hungary, Latvia,
Lithuania, Poland, as well as Croatia) (Figure 1.5.2). These
are all countries where smoking rates among men are
relatively high. Death rates from lung cancer among men
are low in Nordic countries (Finland, Iceland, Norway and
Sweden) as well as in Cyprus, countries with low smoking
rates among men (see Indicator 2.5 “Smoking among
adults”). Denmark and Iceland, however, have high rates of
lung cancer mortality among women.
Breast cancer is the most common form of cancer
among women in all European countries (Ferlay et al., 2010).
It accounted for around 30% of cancer incidence among
women in 2008, and 18% of female cancer deaths in 2010.
While there has been an increase in incidence rates of
breast cancer over the past decade, death rates have
declined or remained stable, indicating increases in
survival rates due to earlier diagnosis and better treatment
(see Indicator 4.8 “Screening, survival and mortality for
breast cancer”). The lowest mortality rates from breast
cancer are in Bulgaria, Portugal, Spain and Sweden, as well
as Norway (below 20 deaths per 100 000 females), while the
highest rates are in Belgium and Denmark (close to 30)
(Figure 1.5.3).
Prostate cancer has become the most commonly
occurring cancer among men in many European countries,
particularly for those aged over 65 years of age, although
death rates from prostate cancer remain lower than for lung
cancer in all countries except Sweden. The rise in the
reported incidence of prostate cancer in many countries
during the 1990s and 2000s was largely due to the greater use
of prostate-specific antigen (PSA) diagnostic tests. Death rates
from prostate cancer in 2010 varied from lows of less than 15
per 100 000 males in Malta and Luxembourg – although
annual numbers of deaths are small in these countries – to
highs of more than 30 per 100 000 males in a range of central
European and Nordic countries (Figure 1.5.4). The causes of
prostate cancer are not well understood. Some evidence
suggests that environmental and dietary factors might
influence the risk of prostate cancer (Institute of Cancer
Research, 2012).
Death rates from all types of cancer for males and
females have declined at least slightly in most member
states since 1995, although the decline has been more
modest than for cardiovascular diseases, explaining why
cancer now accounts for a larger share of all deaths. The
exceptions to this declining pattern are among Baltic and
central European countries – Bulgaria, Latvia, Lithuania,
Romania and the Former Yugoslav Republic of Macedonia –
where cancer mortality has remained static or increased.
Definition and comparability
Mortality rates are based on numbers of deaths
registered in a country in a year divided by the size of
the corresponding population. The rates have been
directly age-standardised to the WHO European
standard population to remove variations arising
from differences in age structures across countries
and over time. The source is the Eurostat Statistics
Database.
Deaths from all cancers are classified to ICD-10
Codes C00-C97, lung cancer to C32-C34, breast cancer
to C50 and prostate cancer to C61. The international
comparability of cancer mortality data can be affected
by differences in medical training and practices as
well as in death certification procedures across coun-
tries. Mathers et al. (2005) have provided a general
assessment of the coverage, completeness and
reliability of data on causes of death.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201224
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1.5.1. All cancers mortality rates, males and females, 
2010 (or nearest year)
Source: Eurostat Statistics Database. Data are age-standardised to the
WHO European standard population.
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1.5.2. Lung cancer mortality rates, males and females, 
2010 (or nearest year)
Source: Eurostat Statistics Database. Data are age-standardised to the
WHO European standard population.
1 2 http://dx.doi.org/10.1787/888932703145
0 25 50 75 100 125
23
10
15
28
19
32
9
13
20
17
43
15
16
19
32
11
10
20
15
20
13
12
13
20
9
10
24
40
37
25
19
13
19
29
42
45
48
50
50
50
51
52
55
56
61
62
64
65
67
68
70
70
71
73
76
78
80
82
83
92
116
39
44
45
76
88
FemalesMales
Age-standardised rates per 100 000 population
EU27
Sweden
Cyprus
Finland
Ireland
Austria
United Kingdom
Portugal
Malta
Germany
Luxembourg
Denmark
Italy
France
Netherlands
Spain
Bulgaria
Czech Republic
Slovak Republic
Slovenia
Greece
Estonia
Romania
Belgium
Lithuania
Latvia
Poland
Hungary
Iceland
Norway
Switzerland
FYR of Macedonia
Croatia
1.5.3. Breast cancer mortality rates, females, 
2010 (or nearest year)
Source: Eurostat Statistics Database. Data are age-standardised to the
WHO European standard population.
1 2 http://dx.doi.org/10.1787/888932703164
0 10 20 30 40
17.7
19.1
19.4
19.8
20.0
20.6
21.1
21.2
21.5
22.0
22.1
22.6
22.8
23.0
23.2
23.6
24.0
24.2
24.5
24.8
25.0
25.2
25.5
25.8
26.2
26.8
28.3
28.9
19.0
20.1
22.1
23.7
27.6
Age-standardised rates per 100 000 females
EU27
Spain
Sweden
Bulgaria
Poland
Portugal
Czech Republic
Greece
Finland
Cyprus
Slovak Republic
Estonia
Romania
Austria
Italy
France
Germany
Lithuania
United Kingdom
Slovenia
Hungary
Latvia
Luxembourg
Malta
Ireland
Netherlands
Belgium
Denmark
Norway
Iceland
Switzerland
FYR of Macedonia
Croatia
1.5.4. Prostate cancer mortality rates, males, 
2010 (or nearest year)
Source: Eurostat Statistics Database. Data are age-standardised to the
WHO European standard population.
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1.6. MORTALITY FROM TRANSPORT ACCIDENTSInjuries from transport accidents – most of which are
due to road traffic – are a major public health problem in the
European Union, causing the premature deaths of some
40 000 people every year. In addition to these deaths, more
than 1.5 million people are estimated to be so seriously
injured as to require hospital admission each year (OECD/ITF,
2011a). Around 4 000-5 000 transport accident deaths
occurred in each of France, Germany, Italy and Poland in 2010.
Mortality from road accidents is the leading cause of
death among children and young people, and especially
young men, in many countries. Most fatal traffic injuries
occur in passenger vehicles, although the fatality risk for
motor cycles and scooters is highest among all modes of
transport.
The direct and indirect financial costs of transport
accidents are substantial; one estimate put these at up to
3% of gross national product annually in highly-motorised
countries (WHO, 2009a).
Death rates were the highest in Romania, Greece
and Lithuania in 2010, all in excess of 12 deaths per
100 000 population (Figure 1.6.1). They were the lowest in
Malta, the Netherlands, Sweden and the United Kingdom,
at less than four deaths per 100 000 population, much
lower than the EU average of 7.7. A four-fold difference
exists between the countries with the lowest and highest
rates.
In all EU member states, death rates from transport
accidents are much higher for males than for females, with
disparities ranging from three times higher in Denmark,
Germany, Ireland, Luxembourg, and the Netherlands, to
around five times higher in Cyprus and Greece. On average,
around four times as many males than females die in
transport accidents (Figure 1.6.1).
Much transport accident injury and mortality is
preventable. Road security has increased greatly over the
past decades in many countries through improvements of
road systems, education and prevention campaigns, the
adoption of new laws and regulations and the enforcement
of these laws through more traffic controls. As a result,
death rates due to transport accidents have been more
than halved across the European Union since 1995
(Figures 1.6.2 and 1.6.3). Estonia and Luxembourg have
seen the largest declines at 71% since 1995, with most of
the fall in Estonia occurring in the mid-1990s. Reductions in
Ireland, Portugal and Slovenia and a number of other
countries are more than 60% since 1995, although vehicle
kilometers travelled have increased substantially in the
same period (OECD/ITF, 2011a). Death rates have also
declined in Belgium, Greece and Bulgaria, but at a slower
pace, and therefore remain well above the EU average.
The effects of the economic crisis may have a favour-
able outcome on transport accident mortality. Many
countries had a slight decrease or stagnation in traffic
volumes since 2008, accompanied by a much more signifi-
cant reduction in fatalities. However, in the long-term,
effective road safety policies are the main contributor to
reduced mortality (OECD/ITF, 2011b).
Definition and comparability
Mortality rates are based on numbers of deaths
registered in a country in a year divided by the size of
the corresponding population. The rates have been
directly age-standardised to the WHO European
standard population to remove variations arising
from differences in age structures across countries
and over time. The source is the Eurostat Statistics
Database.
Deaths from transport accidents are classified to
ICD-10 Codes V01-V99. The majority of deaths from
transport accidents are due to road traffic accidents.
Mortality rates from transport accidents in Luxembourg
are biased upward because of the large volume of traffic
in transit, resulting in a significant proportion of non-
residents killed. Mathers et al. (2005) have provided a
general assessment of the coverage, completeness and
reliability of data on causes of death.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201226
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1.6.1. Transport accident mortality rates, 2010 (or nearest year)
Source: Eurostat Statistics Database. Data are age-standardised to the WHO European standard population.
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1.6.2. Trends in transport accident mortality rates, 
selected EU member states, 1995-2010
Source: Eurostat Statistics Database. Data are age-standardised to the
WHO European standard population.
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1.7. SUICIDEThe intentional killing of oneself can be seen as
evidence not only of personal breakdown, but also of a
deterioration of the social context in which an individual
lives. Suicide may be the end-point of a number of different
contributing factors. It is more likely to occur during crisis
periods associated with upheavals in personal relation-
ships, through alcohol and drug abuse, unemployment,
clinical depression and other forms of mental illness.
Because of this, suicide is often used as a proxy indicator of
the mental health status of a population. However, the
number of suicides in certain countries may be under-
reported because of the stigma that is associated with the
act, or because of data issues associated with reporting
criteria (see “Definition and comparability”).
Suicide is a significant cause of death in many
EU member states, with approximately 60 000 such deaths
in 2010. Rates of suicide were low in southern European
countries – Cyprus, Greece, Italy, Malta, Portugal and Spain –
as well as in the United Kingdom, at eight deaths or less per
100 000 population (Figure 1.7.1). They were highest in the
Baltic States and Central Europe; in Estonia, Hungary, Latvia,
Lithuania and Slovenia there were more than 17 deaths per
100 000 population. There is more than a ten-fold difference
between Lithuania and Greece, the countries with the lowest
and highest death rates.
Death rates from suicide are four-to-five times greater
for men than for women across the European Union,
although in those countries with the highest rates, male
deaths are up to seven times as common (Figure 1.7.1). The
gender gap is narrower for attempted suicides, reflecting
the fact that women tend to use less fatal methods than
men. Suicide is also related to age, with young people aged
under 25 and elderly people especially at risk. While
suicide rates among the latter have generally declined over
the past two decades, little progress has been observed
among younger people.
Since 1995, suicide rates have decreased in many
countries, with pronounced declines of 40% or more in
Bulgaria, Estonia and Latvia (Figure 1.7.2). Despite this
progress, Estonia and Latvia still have among the highest
suicide rates in Europe. On the other hand, death rates
from suicides have increased since 1995 in Malta, Poland
and Portugal, as well as Iceland, although rates in Iceland
and Malta are dependent on small numbers. Iceland, Malta
and Portugal still remain below the EU average. There is no
strong evidence that national suicide rates have increased
since the onset of the economic crisis.
Suicide rates in Lithuania increased steadily
after 1990, especially among young men, peaking in 1996
(Figure 1.7.3). The high suicide rates in Lithuania have been
associated with a wide range of factors including rapid
socio-economic transition, increasing psychological and
social insecurity and the absence of a national suicide pre-
vention strategy. Similarly in Hungary, societal factors
including employment and socio-economic circumstances,
as well as individual demographic and clinical factors have
been cited as determinants of suicide (Almasi et al., 2009).
Mental health problems are rising in the European
Union. The European Pact for Mental Health and Well-
being, launched in 2008, recognised the prevention of
depression and suicide as one of five priority areas. It called
for action through improved training of mental health
professionals, restricted access to potential means for
suicide, measures to raise mental health awareness, mea-
sures to reduce risk factors for suicide such as excessive
drinking, drug abuse and social exclusion, depression and
stress, and provision of support mechanisms after suicide
attempts and for those bereaved by suicide, such as
emotional support helplines (EC, 2009b).
Definition and comparability
The World Health Organization defines “suicide” as
an act deliberately initiated and performed by a person
in the full knowledge or expectation of its fatal outcome.
Comparability of suicide data between countries is
affected by a number of reporting criteria, including
how a person’s intention of killing themselves is ascer-
tained, who is responsible for completing the death
certificate, whether a forensic investigation is carried
out, and the provisions for confidentiality of the cause
of death. Caution is required therefore in interpreting
variations across countries.
Mortality rates are based on numbers of deaths
registered in a country in a year divided by the size of
the corresponding population. The rates have been
directly age-standardised to the WHO European
standard population to remove variations arising
from differences in age structures across countries
and over time. The source is the Eurostat Statistics
Database.
Deaths from suicide are classified to ICD-10
Codes X60-X84. Mathers et al. (2005) have provided a
general assessment of the coverage, completeness
and reliability of data on causes of death.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201228
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1.7.1. Suicide mortality rates, 2010 (or nearest year)
Source: Eurostat Statistics Database. Data are age-standardised to the WHO European standard population.
1 2 http://dx.doi.org/10.1787/888932703259
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1.8. INFANT MORTALITYInfant mortality, the rate at which babies and children
of less than one year of age die, reflects the effect of eco-
nomic and social conditions on the health of mothers and
newborns, as well as the effectiveness of health systems.
In most European countries, infant mortality is low
and there is little difference in rates (Figure 1.8.1). A small
group of countries, however, have infant mortality rates
above five deaths per 1 000 live births. In 2010, rates ranged
from a low of less than three deaths per 1 000 live births
in Nordic countries (with the exception of Denmark),
Portugal, Slovenia and the Czech Republic, up to a high
of 9.8 and 9.4 in Romania and Bulgaria respectively, and
13.6 in Turkey. Infant mortality rates were also relatively
high (more than six deaths per 1 000 live births) in Serbia
and the Former Yugoslav Republic of Macedonia. The
average across the 27 EU member states in 2010 was
4.2 deaths per 1 000 live births. Infant mortality rates tend
to be higher than the EU average in central European
countries, with the exceptions of the Czech Republic and
Slovenia, both of which have had consistently lower rates.
Around two-thirds of the deaths that occur during the
first year of life are neonatal deaths (i.e. during the first
four weeks). Birth defects, prematurity and other condi-
tions arising during pregnancy are the principal factors
contributing to neonatal mortality in developed countries.
With an increasing number of women deferring child-
bearing and the rise in multiple births linked with fertility
treatments, the number of pre-term births has tended
to increase (see Indicator 1.9 “Infant health: Low birth
weight”). In a number of higher-income countries, this has
contributed to a leveling-off of the downward trend in
infant mortality rates over the past few years. For deaths
beyond one month (post neonatal mortality), there tends to
be a greater range of causes – the most common being SIDS
(Sudden Infant Death Syndrome), birth defects, infections
and accidents.
All European countries have achieved remarkable
progress in reducing infant mortality rates from the levels
of 1970, when the average was 25 deaths per 1 000 live
births, to the current average of 4.2 (Figure 1.8.1). This
equates to a cumulative reduction of over 80% since 1970.
Portugal has seen its infant mortality rate reduced by 7.5%
per year on average since 1970, moving from the country
with the highest rate in Europe to an infant mortality rate
among the lowest in Europe in 2010 (Figure 1.8.2). Large
reductions in infant mortality rates have also been
observed in Slovenia, Italy, Cyprus and Greece, as well as
the Former Yugoslav Republic of Macedonia and Croatia.
The reduction in infant mortality rates has been slower in
Bulgaria, Latvia and the Netherlands, although rates in the
latter two countries were low in 1970. Infant mortality rates
in Poland declined rapidly in the early 1990s to approach
the EU average.
Numerous studies have used infant mortality rates as a
health outcome to examine the effect of a variety of medical
and non-medical determinants of health (e.g. OECD, 2010a).
Although most analyses show an overall negative relation-
ship between infant mortality and health spending, the fact
that some countries with a high level of health expenditure
do not exhibit low levels of infant mortality suggests that
more health spending is not necessarily required to obtain
better results (Retzlaff-Roberts et al., 2004). A body of research
also suggests that many factors beyond the quality and effi-
ciency of the health system – such as income inequality, the
social environment, and individual lifestyles and attitudes –
influence infant mortality rates (Schell et al., 2007).
Definition and comparability
The infant mortality rate is the number of deaths of
children under one year of age in a given year,
expressed per 1 000 live births. Neonatal mortality
refers to the death of children under 28 days.
Some of the international variation in infant and
neonatal mortality rates may be due to variations
among countries in registering practices of premature
infants. Most countries have no gestational age or
weight limits for mortality registration. Minimal
limits exist for Norway (to be counted as a death
following a live birth, the gestational age must exceed
12 weeks) and in the Czech Republic, the Netherlands
and Poland a minimum gestational age of 22 weeks
and/or a weight threshold of 500 grams is applied. HEALTH AT A GLANCE: EUROPE 2012 © OECD 201230
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1.8.1. Infant mortality rates, 2010 and decline 1970-2010
Source: Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932703316
1.8.2. Infant mortality rates, selected European countries, 1970-2010
Source: Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932703335
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1.9. INFANT HEALTH: LOW BIRTH WEIGHTLow birth weight – defined as a newborn weighing less
than 2 500 grams – is an important indicator of infant
health because of the close relationship between birth
weight and infant morbidity and mortality. There are two
categories of low birth weight babies: those occurring as a
result of restricted foetal growth and those resulting from
pre-term birth. Low birth weight infants have a greater risk
of poor health or death, require a longer period of hospital-
isation after birth, and are more likely to develop signifi-
cant disabilities (UNICEF and WHO, 2004).
Risk factors for low birth weight include adolescent
motherhood, a previous history of low weight births,
engaging in harmful behaviours such as smoking and
excessive alcohol consumption, having poor nutrition, a
background of low parental socio-economic status, and
having had in-vitro fertilisation treatment.
One-in-fifteen babies born in the European Union
in 2010 – or 6.9% of all births – weighed less than
2 500 grams at birth. A north-south gradient is evident for
low birth weight in Europe, in that the Nordic countries and
Baltic States – including Estonia, Finland, Iceland, Latvia,
Lithuania and Sweden – reported the smallest proportions
of low weight births, with less than 5.0% of live births so
defined. Countries from Southern Europe including Cyprus,
Greece, Portugal and Spain, as well as Bulgaria, Hungary,
Romania, Turkey and the Former Yugoslav Republic of
Macedonia, are at the other end of the scale with rates of
low birth weight infants above 7.5%. The proportion of low
birth weight among European countries varies by a factor
of almost three (Figure 1.9.1).
Since 1980, and more so after 1995, the prevalence of
low birth weight infants has increased in most European
countries (Figure 1.9.1). There are several reasons for this
rise. The number of multiple births, with the increased
risks of pre-term births and low birth weight, has risen
steadily, partly as a result of the rise in fertility treatments.
Other factors which may have influenced the rise in low
birth weight are older age at childbearing and increases in
the use of delivery management techniques such as induc-
tion of labour and caesarean delivery, which have increased
the survival rates of low birth weight babies.
Greece, Malta, Portugal and Spain have seen great
increases in the past three decades (Figure 1.9.2). As a
result, the proportion of low birth weight babies in these
countries is now above the European average. Low birth
weight proportions in Poland and Hungary have declined
over the same time period. Little change occurred in
Nordic countries including Denmark, Finland, Iceland and
Sweden, although a rise was observed in Norway.
 Figure 1.9.3 shows some correlation between the
percentage of low birth weight infants and infant mortality
rates. In general, countries reporting a low proportion of
low birth weight infants also report relatively low infant
mortality rates. This is the case for instance for the Nordic
countries. Greece, however, is an exception, reporting a
high proportion of low birth weight infants but a low infant
mortality rate.
Despite the widespread use of a 2 500 grams limit for
low birthweight, physiological variations in size occur
among different countries and population groups, and
these need to be taken into account when interpreting
differences (EURO-PERISTAT, 2008). Some populations may
have lower than average birth weights than others because
of genetic differences. Comparisons of different population
groups within countries show that the proportion of low
birth weight infants is also influenced by non-medical
factors. In England and Wales, mothers’ marital status at
birth, being a mother from non-White ethnic group and
living in a deprived area were associated with low birth-
weight (Bakeo and Clarke, 2006). In Greece, marital status,
education, maternal occupation and region of residence
were significant factors (Lekea-Karanika et al., 1999).
Definition and comparability
Low birth weight is defined by the World Health
Organization (WHO) as the weight of an infant at birth
of less than 2 500 grams (5.5 pounds), irrespective of
the gestational age of the infant. This is based on
epidemiological observations regarding the increased
risk of death to the infant and serves for international
comparative health statistics. The number of low
weight births is then expressed as a percentage of
total live births.
The majority of the data comes from birth registers.
A small number of countries supply data for selected
regions or from surveys.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201232
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1.9.1. Low birth weight infants, 2010 and change 1980-2010
Source: OECD Health Data 2012; WHO European Health for All Database.
1 2 http://dx.doi.org/10.1787/888932703354
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1.10. SELF-REPORTED HEALTH AND DISABILITYMost European countries conduct regular health
surveys which allow respondents to report on different
aspects of their health. A commonly-asked question relates
to self-perceived health status, of the type: “How is your
health in general?”. Despite the subjective nature of this
question, indicators of perceived general health have been
found to be a good predictor of people’s future health care
use and mortality (DeSalvo et al., 2005; Bond et al., 2006).
For the purpose of international comparisons how-
ever, cross-country differences in perceived health status
are difficult to interpret because responses may be affected
by social and cultural factors. Since they rely on the subjec-
tive views of the respondents, self-reported health status
may reflect cultural biases or other influences. Also, since
the elderly report poor health more often than younger
people, countries with a larger proportion of aged persons
will also have a lower proportion of people reporting good
or very good health. In addition, the institutionalised
population, which has poorer health than the rest of the
population, is often not surveyed.
With these limitations in mind, in almost all European
countries a majority of the adult population rate their
health as good or very good (Figure 1.10.1). In Ireland and
Sweden, as well as Switzerland, more than eight out of ten
people report good or very good health. Across the
European Union, two-thirds (67%) of all adults rated their
health as good or better, with France, Germany and Italy
close to this average. Adults in central European countries,
along with Portugal, report the lowest rates of good or very
good health. In Croatia, Estonia, Hungary, Latvia, Lithuania,
Poland and Portugal, less than 60% of all adults consider
themselves to be in good health. These differences, how-
ever, do not necessarily mean that the general health of
people in Ireland or Sweden is objectively better than that
of citizens in Latvia or Portugal (Baert and de Norre, 2009).
In all European countries, men are more likely than
women to rate their health as good or better, with the
largest differences in Portugal and Bulgaria. Unsurprisingly,
people’s rating of their own health tends to decline with
age. In many countries there is a particularly marked
decline in a positive rating of one’s own health after age 45
and a further decline after age 65. People who are unem-
ployed, retired or inactive more often report bad or very bad
health (Baert and de Norre, 2009). People with a lower level
of education or income do not rate their health as
positively as people with higher levels (OECD, 2012a;
Mackenbach et al., 2008).
Another common health interview survey question
asks whether respondents had any long-standing illnesses
or health problems. Three-in-ten adults in EU member
states reported having illnesses or health problems
(Figure 1.10.1). Adults in Finland and Estonia were more
likely to report having illnesses or health problems, while
these conditions were less commonly reported in Romania
and Bulgaria. Women reported long-standing illnesses or
health problems more often than men (an average of
33% vs. 28% across EU member states), with the gender
divide greatest in Finland and Latvia. Reporting increased
with age, from an average of 7% of young people aged
16-24 years, to 73% of older persons aged 85 years or more.
There is a moderate negative association between adults
reporting good/very good health, and reporting a long-
standing illness or health problem (R2 =  –0.28).
When adults were asked whether they had been limited
in their usual daily activities because of a health problem
– which is one definition of disability – 24% answered that
they had, with 8% of respondents “strongly limited” and
17% “limited to some extent” (Figure 1.10.2). Adults most
commonly reported activity limitation in Estonia, Finland,
Germany, Latvia, Portugal, Slovenia and the Slovak Republic,
as well as Croatia (30% or more of respondents), and less so in
Malta and Sweden (less than 15%). Severe activity limitation
was more prevalent in Germany, Slovenia and the Slovak
Republic, as well as Croatia (10% or more of respondents), and
less so in Bulgaria and Malta (less than 5%). Adults with
activity limitations were also less likely to report good or very
good health (R2 = 0.53).
Definition and comparability
Self-reported health reflects people’s overall percep-
tions of their own health, including both physical and
psychological dimensions. Typically ascertained
through health interview surveys, respondents are
asked a number of questions on their health and
functioning. The three questions used in the EU-SILC
survey, and some other national surveys are: i) “How is
your health in general? Is it very good, good, fair, bad,
very bad”; ii) “Do you have any longstanding illness or
health problem which has lasted, or is expected to last
for six months or more?”; and iii) “For at least the past
six months, have you been hampered because of a
health problem in activities people usually do? Yes,
strongly limited/Yes, limited/No, not limited”.
Persons in institutions are not surveyed. Caution is
required in making cross-country comparisons of
perceived general health, since people’s assessment
of their health is subjective and can be affected by
their social and cultural backgrounds.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201234
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1.10.1. Adults’ self-reported health status, 2010
Source: EU Statistics on Income and Living Conditions survey; OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932703411
1.10.2. Adults reporting a limitation in usual activities, 2010
Source: EU Statistics on Income and Living Conditions survey.
1 2 http://dx.doi.org/10.1787/888932703430
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1.11. INCIDENCE OF SELECTED COMMUNICABLE DISEASESCommunicable diseases such as chlamydia, pertussis
and hepatitis B still pose major threats to the health of
European citizens. Chlamydia is the most common sexually
transmitted infection in Europe. Three-quarters of all cases
are reported among young people aged 15-24 years, and
numbers are steadily increasing. It can be controlled
through prevention, reducing risk behaviour, early detection
and effective management. Pertussis (or whooping cough) is
highly infectious, and is caused by the bacterium Bordetella
pertussis. The disease derives its name from the sound made
from the intake of air after a cough. Hepatitis B is an infec-
tion of the liver caused by the hepatitis B virus. The virus is
transmitted by contact with blood or body fluids of an
infected person. A small proportion of infections become
chronic, and these people are at high risk of death from
cancer or cirrhosis of the liver. Protection against pertussis
and hepatitis B is available through vaccination (see
Indicator 4.10 “Childhood vaccination programmes”).
Over 285 000 chlamydia cases were reported annually
in EU member states during 2007-09, with almost all infec-
tions reported by five countries (the United Kingdom, and
the Nordic countries of Denmark, Finland, Norway and
Sweden). The true number of chlamydia cases is likely to be
much higher, since the infection is liable to underreporting
and asymptomatic disease. Confirmed case rates were
highest in Iceland (655 per 100 000 population), Denmark
(514), Sweden (458), the United Kingdom (290) and Finland
(258) (Figure 1.11.1). Between 2006 and 2009, incidence of
reported and confirmed cases increased by 42%, although
much of this was a result of improved case detection in a
number of countries (ECDC, 2011).
Over 14 000 pertussis cases were reported annually
among EU member states in 2007-09, with an overall inci-
dence of 5 per 100 000 population (Figure 1.11.2). The highest
incidences were reported in Norway (104 cases per
100 000 population), the Netherlands (44), Estonia (38) and
Slovenia (17). Most cases were reported from the Netherlands,
Norway and Poland, which together contributed almost
three-quarters (71%) of all cases reported in 2009. Pertussis
incidence has more than halved since 1991-93, when the
average rate among EU member states was 11.3 notified cases
per 100 000 population.
Two-thirds of all pertussis cases in 2008 occurred
among children aged 5-14 years of age, although the
disease may be underdiagnosed in adolescents and adults.
The highest incidence occurred among infants aged less
than one year, many of whom are too young to be vacci-
nated, and children aged 10-14 years, who may have not
had a full course of vaccination, or who may have lost their
immunity. Vaccination status was known in only half of all
reported cases, but of these 21% were unvaccinated
(EUVAC.NET, 2010).
Around 6 000 hepatitis B cases were reported annually
in EU member states during 2007-09. The highest incidence
rates occurred among Iceland (13.8 notified cases per
100 000 population, including both acute and chronic cases),
Bulgaria (8.2) and Latvia (6.3) (Figure 1.11.3). The EU average
was 2.0 cases per 100 000 population. The notification
rate has declined since 1991-93, when it was 8.3 cases per
100 000 population on average. Hepatitis B infection is more
common in the southern parts of Eastern and Central
Europe, and low in prevalence in most of Western Europe.
Around twice as many cases of hepatitis B occurred among
males than females in 2009, with the majority reported in
the age group 25-44 years (49% of the total), followed by
15-24 year-olds. The disease has the characteristics of both a
sexually transmitted and a blood-borne disease, although
the disease pattern and risk groups differ widely across
Europe (ECDC, 2011). Enhanced surveillance systems will
provide the better information which is needed to monitor
the disease.
The European Centre for Disease Prevention and
Control (ECDC) was set up in 2005 to assist the European
Union by identifying and assessing the risk of current and
emerging threats to human health posed by infectious
diseases.
Definition and comparability
Although notification of chlamydia is compulsory
in most European countries, national surveillance
systems for sexually transmitted infections consist of
voluntary, sentinel or laboratory systems, and often
do not provide full country coverage. Countries also
differ in reporting systems, diagnosis, testing and
screening programmes. Underreporting is likely.
Mandatory notification systems for pertussis and
hepatitis B also exist in most European countries,
although again case definitions, laboratory confirma-
tion requirements and reporting systems may differ.
Pertussis notification was voluntary in Belgium and
France, and France had a sentinel surveillance system. HEALTH AT A GLANCE: EUROPE 2012 © OECD 201236
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1.11.1. Notification rate of chlamydia infection, 2007-09
Source: ECDC (2011).
 2 http://dx.doi.org/10.1787/888932703449
0 200 400 600 800
514
458
290
258
166
116
94
55
37
25
19
11
9
7
7
3
2
2
1
1
0
0
655
483
Per 100 000 population
Denmark
Sweden
United Kingdom
Finland
Estonia
Ireland
EU21
Netherlands
Latvia
Belgium
Malta
Lithuania
Austria
Slovenia
Hungary
Slovak Republic
Poland
Greece
Spain
Romania
Luxembourg
Cyprus
Iceland
Norway
1.11.2. Notification rate of pertussis, 2007-09
Source: ECDC (2011).
 2 http://dx.doi.org/10.1787/888932703468
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1.11.3. Notification rate of hepatitis B, 2007-09
Source: ECDC (2011).
1 2 http://dx.doi.org/10.1787/888932703487
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1.12. HIV/AIDSThe first cases of Acquired Immunodeficiency
Syndrome (AIDS) were diagnosed more than 30 years ago.
The onset of AIDS is caused as a result of HIV (human
immunodeficiency virus) infection and can manifest itself
as any number of different diseases, such as pneumonia
and tuberculosis, as the immune system is no longer able
to defend the body, leaving it susceptible to opportunistic
infections and tumors. There is a time lag between
HIV infection, AIDS diagnosis and death, which can be any
number of years depending on the treatment administered.
Despite worldwide research, there is no cure currently
available. HIV remains a major public health issue in
Europe, with continuing transmission.
In 2010, almost 27 000 cases of newly diagnosed HIV
infection were reported by EU member states, and another
1 600 cases in the six EU candidate countries, Norway and
Switzerland. Estonia had the highest rate of new cases, at
27.8 per 100 000 population, followed by Belgium, Latvia and
the United Kingdom, all at over ten (Figure 1.12.1). On average
across EU member states, 6.2 new cases of HIV infection were
diagnosed per 100 000 population in 2010. One quarter of
cases were female, although the ratio varied greatly between
countries, from Hungary (16 male cases for each female case)
to Sweden (two). Approximately 800 000 persons were living
with HIV infection in the European Union in 2010. The
predominant mode of transmission of HIV was through men
having sex with men (38%), followed by heterosexual contact
(24%). However, in certain countries injecting drug use is also
a common mode. Approximately 75% of heterosexually
acquired HIV infection in Western and Central Europe is
among migrants.
The number of newly reported cases of AIDS in
EU member states in 2010 was 4 643, representing an
average incidence rate of 1.1 per 100 000 population
(Figure 1.12.1). Following the first reporting of AIDS in the
early 1980s, the number of cases rose rapidly to reach an
average of almost four new cases per 100 000 population
across EU member states at its peak in the middle of
the 1990s, four times the current incidence rate. Public
awareness campaigns contributed to steady declines in
reported cases through the second half of the 1990s. In
addition, the development and greater availability of anti-
retroviral drugs, which reduce or slow down the develop-
ment of the disease, led to a sharp decrease in incidence
from 1996 onward.
The highest AIDS incidence rates among EU member
states in 2010 were reported in Latvia, followed by Portugal
and Spain, at two or more cases per 100 000 population.
Spain had the highest incidence rates in the first decade
following the outbreak, although there was a sharp decline
from 1994 onwards. Incidence rates in Portugal peaked
somewhat later, towards the end of the 1990s. AIDS inci-
dence rates in Latvia increased rapidly to the mid-2000s
(Figure 1.12.2). Central European countries such as
Bulgaria, the Czech and Slovak Republics, Hungary, Poland
and Slovenia report the lowest incidence rates of AIDS,
although incomplete reporting may lead to underestimates
(ECDC and WHO Regional Office for Europe, 2011).
In recent years, the number of AIDS cases reported in
the EU has steadily declined. However, continuing trans-
mission of HIV and increases in reported rates in some
countries reinforce the need for evidence-based interven-
tions which are adapted to the situation of each country.
A European Commission Communication details the
policy priorities regarding HIV in Europe for 2009-13. The
main objectives are to reduce new HIV infections across all
European countries by 2013; improve access to prevention,
treatment, care and support; and to improve the quality of
life of people affected by HIV/AIDS in the European Union
and neighbouring countries. The Communication also
highlights priority regions and priority groups and empha-
sises the improvement of knowledge, including surveil-
lance, monitoring, evaluation and research (ECDC, 2012).
Definition and comparability
The incidence rates of HIV (human immunodefi-
ciency virus) and AIDS (acquired immunodeficiency
syndrome) are the number of new cases per
100 000 population at year of diagnosis. However,
since newly reported HIV diagnoses may also include
persons infected several years ago, the data do not
represent real incidence. Underreporting and under-
diagnosis also affect incidence rates, and could be as
much as 40% in some countries (ECDC, 2011).
Note that data for recent years are provisional due
to reporting delays, which can sometimes be for
several years. Reporting is voluntary in some
countries. Others report regional data only.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201238
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1.12.1. HIV and AIDS incidence rates in 2010
Source: ECDC and WHO Regional Office for Europe (2011).
1 2 http://dx.doi.org/10.1787/888932703506
1.12.2. Trends in AIDS incidence rates, selected EU member states, 2000-10
Source: ECDC and WHO Regional Office for Europe (2011).
1 2 http://dx.doi.org/10.1787/888932703525
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1.13. CANCER INCIDENCEIn 2008, an estimated 2.4 million new cases of cancer
(excluding non-melanoma skin cancers) were diagnosed in
EU member states (Ferlay et al., 2010), and of these 55%
occurred among males and 45% among females. The most
commonly diagnosed cancers were prostate, colorectal,
breast and lung cancer. The risk of getting cancer before
the age of 75 years was 26.5%, or around one in four. How-
ever, because the population of Europe is ageing, the rate of
new cases of cancer is also expected to increase (EC, 2008b).
Large regional inequalities exist in cancer incidence
across European countries. In 2008, the incidence rate for
all cancers combined was highest in Northern and Western
Europe – Belgium, Denmark, France, Iceland, Ireland and
Norway – at over 290 per 100 000 population, but was lower
in some Mediterranean countries such as Cyprus, Greece,
Malta and Turkey, at less than 220. Rates in Italy were above
the EU average of 255 new cases per 100 000 population.
Rates in central European countries varied, being highest in
the Czech Republic and Hungary (around 290), similar to
the EU average in Slovenia and the Slovak Republic (260),
and below average in Bulgaria, Poland and Romania and
other countries.
Cancer incidence rates are higher for men in all EU
member states (Figure 1.13.1). Here too there is great
variation between countries; in Spain and Turkey, male
incidence rates are 60% higher than female rates, whereas
in Cyprus, Denmark and the United Kingdom they are less
than 10% higher. In 2008, the average all cancer incidence
rate among EU member states was 296 per 100 000 males
and 227 per 100 000 females.
In 2008, lung cancer was one of the most common
cancers in Europe, being responsible for around 12% of all
new cancer diagnoses, 16% for males and 7% for females.
Ten of the 15 countries with male rates higher than the EU
average were located in central Europe (Figure 1.13.2). Rates
in Hungary, Poland, Slovenia were higher than 60 per
100 000 population. Male lung cancer incidence rates in
Northern Europe (Finland, Iceland, Norway and Sweden)
and some southern European countries (Cyprus, Malta and
Portugal) were less than 40 per 100 000 population. Among
females, lung cancer incidence was high in Denmark, but
also Hungary, Iceland and the Netherlands, at over 25.
Thirty per cent of all new cancer cases among women
diagnosed in 2008 were cancers of the breast – the most
common form of cancer among women. Incidence rates
were high in Denmark and western European countries
such as Belgium, France, Ireland and the Netherlands, at
over 90 cases per 100 000 population (Figure 1.13.3). Rates
in Central and Southern Europe were lower, with Greece,
Latvia, Lithuania, Poland, Romania and Turkey all reporting
less than 50 new cases per 100 000 population. There has
been an increase in measured incidence rates of breast
cancer over the past decade, although death rates have
declined or remained stable. Survival rates have also
increased, due to earlier diagnosis and/or better treatment
(see Indicator 4.8 “Screening, survival and mortality for
breast cancer”).
Prostate cancer has become the most commonly
diagnosed cancer among males in most OECD countries,
particularly among men over 65 years of age. Prostate
cancer comprised one quarter (25%) of all new diagnoses
in 2008. Rates were highest in Belgium, France and Ireland
and northern European countries (Finland, Iceland, Norway
and Sweden) (Figure 1.13.4). Rates were lower in a range of
central and southern European countries, including
Bulgaria, Greece, Romania and Turkey. At least part of the
five-fold difference between countries with the highest and
lowest incidence rates is due to under-registration of
prostate cancer in some countries, as well as the use of
sensitive diagnostic tests for early detection in others
(Ferlay et al., 2007). The rise in the reported incidence of
prostate cancer in many countries since the 1990s is due
largely to the greater use of prostate specific antigen (PSA)
tests, although the use of these has also fluctuated because
of their cost and uncertainty about the long-term benefit to
patients.
Definition and comparability
Cancer incidence rates are based on numbers of new
cases of cancer registered in a country in a year divided
by the size of the corresponding population. The rates
have been directly age-standardised to Segi’s world
population to remove variations arising from differ-
ences in age structures across countries and over time.
The source is GLOBOCAN 2008, at http://globocan.iarc.fr/.
GLOBOCAN estimates for 2008 may differ to actual
incidence for some countries, due to the projection
methods used.
Cancer registration is well established in a majority of
EU member states, although the quality and comple-
teness of cancer registry data may vary. In some
countries, cancer registries only cover subnational
areas. The international comparability of cancer
incidence data can also be affected by differences in
medical training and practice.
The incidence of all cancers is classified to ICD-10
Codes C00-C97 (excluding non-melanoma skin
cancer C44), lung cancer to C33-C34, breast cancer to
C50 and prostate cancer to C61.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201240
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1.13.1. All cancers incidence rates,
males and females, 2008
Source: Ferlay et al. (2010).
1 2 http://dx.doi.org/10.1787/888932703544
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1.13.2. Lung cancer incidence rates,
males and females, 2008
Source: Ferlay et al. (2010).
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1.13.3. Breast cancer incidence rates, females, 2008
Source: Ferlay et al. (2010).
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1.13.4. Prostate cancer incidence rates, males, 2008
Source: Ferlay et al. (2010).
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1.14. DIABETES PREVALENCE AND INCIDENCEDiabetes is a chronic metabolic disease, characterised
by high levels of glucose in the blood. It occurs either
because the pancreas stops producing the hormone insulin
(Type 1 diabetes), or through a combination of the pancreas
having reduced ability to produce insulin alongside the
body being resistant to its action (Type 2 diabetes). People
with diabetes are at a greater risk of developing cardio-
vascular diseases such as heart attack and stroke if the
disease is left undiagnosed or poorly controlled. They also
have elevated risks for sight loss, foot and leg amputation
due to damage to the nerves and blood vessels, and renal
failure requiring dialysis or transplantation.
Diabetes was the principal cause of death of more
than 100 000 persons in EU member states in 2011, and is a
leading cause of death in most developed countries.
However, only a minority of persons with diabetes die from
diseases uniquely related to the condition – in addition,
about 50% of persons with diabetes die of cardiovascular
disease, and 10-20% of renal failure (IDF, 2011).
Diabetes is increasing rapidly in every part of the world,
to the extent that it has now assumed epidemic proportions.
Estimates suggest that more than 6% of the population aged
20-79 years in EU member states, or 30 million people, had
diabetes in 2011, with 42% of diabetic adults aged less than
60 years (IDF, 2011; Whiting et al., 2011). If left unchecked, the
number of people with diabetes in EU member states will
reach more than 35 million in less than 20 years.
Less than 5% of adults aged 20-79 years in Belgium,
Iceland, Luxembourg, Norway and Sweden have diabetes,
according to the International Diabetes Federation. This
contrasts with Portugal, Cyprus and Poland, where 9% or
more of the population of the same age have the disease
(Figure 1.14.1). In Europe, abnormal glucose tolerance
shows little association with affluence, except in a few
countries.
Type 1 diabetes accounts for only 10-15% of all diabetes
cases. It is the predominant form of the disease in younger
age groups in most developed countries. Based on disease
registers and recent studies, the annual number of new
cases of Type 1 diabetes in children aged under 15 years is
high at 25 or more per 100 000 population in Nordic coun-
tries (Finland, Norway and Sweden) (Figure 1.14.2). Bulgaria,
Croatia and Switzerland have less than ten new cases per
100 000 population. Alarmingly, there is evidence that Type 1
diabetes is developing at an earlier age among children.
The economic impact of diabetes is substantial. Health
expenditure in EU member states in 2011 to treat and
prevent diabetes and its complications was estimated at
USD 110 billion (IDF, 2011). Around one-quarter of medical
expenditure is spent on controlling elevated blood glucose,
another quarter on treating long-term complication of
diabetes, and the remainder on additional general medical
care. Increasing costs reinforce the need to provide quality
care for the management of diabetes and its complications.
In April 2012, the European Diabetes Leadership Forum
brought together a wide range of stakeholders to produce
the Copenhagen Roadmap, outlining initiatives to improve
diabetes prevention, early detection and intervention as well
as management and control (European Diabetes Leadership
Forum, 2012).
Type 2 diabetes is largely preventable. A number of
risk factors, such as overweight and obesity and physical
inactivity are modifiable, and can also help reduce the
complications that are associated with diabetes. But in
most countries, the prevalence of overweight and obesity
also continues to increase (see Indicator 2.7 “Overweight
and obesity among adults”).
Definition and comparability
The sources and methods used by the International
Diabetes Federation for publishing national prevalence
estimates of diabetes are outlined in their Diabetes
Atlas, 5th edition (IDF, 2011; Guariguata et al., 2011).
Country-level data were derived from studies pub-
lished up to April 2011, and were only included if they
met several criteria for reliability.
Countries without national data sources are
excluded. Studies from several European countries
only provided self-reported data on diabetes. Studies
only reporting known diabetes were adjusted to
account for undiagnosed diabetes, based on sources
with available data.
Prevalence rates were adjusted to the World Standard
Population to facilitate cross-national comparisons.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201242
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1.14.1. Prevalence estimates of diabetes, adults aged 20-79 years, 2011
Note: The data are age-standardised to the World Standard Population.
Source: IDF (2011).
1 2 http://dx.doi.org/10.1787/888932703620
1.14.2. Incidence estimates of Type 1 diabetes, children aged 0-14 years, 2011
Source: IDF (2011).
1 2 http://dx.doi.org/10.1787/888932703639
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1.15. DEMENTIA PREVALENCEDementia describes a variety of brain disorders which
progressively lead to brain damage, and cause a gradual
deterioration of the individual’s functional capacity and
social relations. It is one of the most important causes of
disability among the elderly, placing a large burden not only
on sufferers, but also on carers. Alzheimer’s disease is the
most common form of dementia, representing about 60% to
80% of cases. Successive strokes that lead to multi-infarct
dementia are another common cause. Currently, there is no
treatment that can halt dementia, but pharmaceutical drugs
and other interventions can help treat symptoms.
In 2009, there were an estimated 6.8 million people
aged 60 years and over suffering from dementia in
EU member states, accounting for around 6% of the popula-
tion in that age group, according to estimates by Wimo et al.
(2010) (Figure 1.15.1). France, Italy, Spain, Sweden and
Switzerland had the highest prevalence, with 6.3% to 6.6%
of the population aged 60 years or older. This contrasts
with less than 5% in Bulgaria, the Czech and Slovak
Republics, Malta and Romania, as well as the Former
Yugoslav Republic of Macedonia, Montenegro and Turkey.
Clinical symptoms of dementia usually begin after the
age of 60, and the prevalence increases markedly with age
(Figure 1.15.2). The disease affects more women than men.
In Europe, 14% of men and 16% of women aged 80-84 years
were estimated as having dementia in 2009, compared to
less than 4% among those under 75 years of age (Alzheimer
Europe, 2009). For the very elderly aged 90 years and over,
the figures rise to 31% of men and 47% of women. Early-
onset dementia among people aged younger than 65 years
is rare; they comprise less than 2% of the total number of
people with dementia.
People with Alzheimer’s disease and other dementias
are high users of long-term care services. Wimo and
colleagues (2010) used cost-of-illness studies from different
countries to estimate the direct costs of dementia, includ-
ing only the resources used to care for people with demen-
tia. In 2009, the direct costs of dementia were estimated at
0.5% of GDP on average among EU member states.
As the number of older persons suffering from dementia
is already large, and is expected to grow in the future,
dementia has become a health policy priority in many coun-
tries. National policies typically involve measures to improve
early diagnosis, promote quality of care for people with
dementia, and support informal caregivers (Wortmann, 2009;
Juva, 2009; Ersek et al., 2009; Kenigsberg, 2009).
In January 2011, the European Parliament adopted a
resolution calling for dementia to be made an EU health
priority and urging member states to develop dedicated
national plans and strategies (only a small number of
countries including France and the United Kingdom, along
with Norway, currently have national strategies in place).
These strategies should address the social and health
consequences, as well as services and support for sufferers
and their families.
A Joint Action between European member states aims
to improve knowledge on dementia and its consequences
and to promote the exchange of information to preserve
health, quality of life, autonomy and dignity of people
living with dementia and their carers (ALCOVE, 2012).
Definition and comparability
Dementia prevalence rates are based on estimates
of the total number of persons aged 60 years and over
living with dementia divided by the size of the corre-
sponding population. Estimates by Wimo et al. (2010)
are based on previous national epidemiological
studies and meta-analyses.
Given the divergence in scale and accuracy of the
sources used across countries, the estimates should
be used with caution.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201244
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1.15.1. Prevalence of dementia, population aged 60 years and over, 2009
Source: Wimo et al. (2010).
1 2 http://dx.doi.org/10.1787/888932703658
1.15.2. Age- and sex-specific prevalence of dementia in EU member states, 2009
Source: Alzheimer Europe (2009).
1 2 http://dx.doi.org/10.1787/888932703677
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1.16. ASTHMA AND COPD PREVALENCEAsthma is a disease of the bronchial tubes character-
ised by “wheezing” during breathing, shortness of breath or
coughing. Asthma is the single most common chronic
disease among children, and also affects many adults. It is
a significant public health problem and a high-burden
disease for which prevention is partly possible and treat-
ment can be effective. Its causes are not well understood,
but effective medicines are available to help in maintaining
quality of life and avoiding disability and death (The Union/
ISAAC, 2011).
Chronic obstructive pulmonary disease (COPD) – the
term now used to describe chronic bronchitis and emphy-
sema – is another high-burden disease causing disability
and impairing quality of life, as well as generating high
costs. COPD is characterised by difficult breathing that is
not fully reversible and usually progressive. Patients are
often smokers or ex-smokers, and their symptoms rarely
develop before age 40. COPD is among the leading causes of
chronic morbidity and mortality in the EU. Approximately
200 000 to 300 000 people die each year in Europe because
of COPD, and among respiratory diseases, it is the leading
cause of lost work days (European Lung Foundation, 2012).
COPD is preventable and treatable. Proper management of
both asthma and COPD in primary care settings can reduce
exacerbation and costly hospitalisation (see Indicator 4.1
“Avoidable admissions: Respiratory diseases”).
In response to a health survey question asking whether
adults aged 15 years and over had asthma during the last
12 months, prevalence ranged from 1.6% in Romania, to
7.0% in France (Figure 1.16.1). Rates also exceeded 5% in
Germany, Hungary and Malta, and were less than 3% in
Bulgaria, Estonia, Latvia, Romania and the Slovak Republic.
Among 17 EU member states the average prevalence rate
was 3.8%. Asthma was more commonly reported by females
(4.3% vs. 3.3% for males). Slovenia is an exception, with a
slightly higher male prevalence. The largest female-male
disparity was in Turkey (5% vs. 2.5%), whereas no disparity
existed in Cyprus (both 3.9%).
The reported prevalence of COPD among adults aged
15 years and over ranged from 1.2% in Malta, to 4.7% in
Hungary, and 6.2% in Turkey (Figure 1.16.2). Among
16 EU member states, average prevalence was 3.1%, with
slightly higher prevalence among females (3.5% vs. 2.9%). In
Cyprus, France, Romania and Spain, however, prevalence
was higher among males. The prevalence of COPD also
increases with age.
Persons with low levels of education are more than
twice as likely to report COPD than those with high levels
(Figure 1.16.3). Large disparities in COPD rates between
persons with higher and lower levels of education are
evident in Belgium, Romania, Spain and Estonia. Persons
from low socio-economic groups also report higher rates of
smoking, which is the major risk factor for COPD.
The lower reported asthma and COPD prevalence
among new EU member states in all likelihood reflects
underdiagnosis and undertreatment, although rates in
these countries have increased sharply in recent years,
possibly reflecting greater awareness of this condition
along with changes in diagnostic practice (Braman, 2006;
The Union/ISAAC, 2011).
A number of EU actions reflect an increased focus on
asthma and COPD. These include the Council Conclusions
on prevention, early diagnosis and treatment of chronic
respiratory diseases in children (12/2011), and the Commis-
sion Reflection Paper on Chronic Diseases (03/2012). Both
aim to identify issues, gaps and suggestions for action to
improve current policies and activities on chronic diseases
such as asthma and COPD.
Definition and comparability
Estimates of the prevalence of asthma and chronic
obstructive pulmonary disease (COPD) are derived
from European Health Interview Survey questions,
conducted in many EU member states between 2006
and 2010. Typically, respondents were asked: “Do you
have or have you ever had any of the following
diseases or conditions? 1) Asthma (allergic asthma
included) (yes/no). 2) Chronic bronchitis, chronic
obstructive pulmonary disease, emphysema (yes/no).
If yes: Was this disease/condition diagnosed by a
medical doctor? (yes/no). Have you had this disease/
condition in the past 12 months? (yes/no).”
The same survey also asked for information on age,
sex and educational level. Data rely on self-report,
and are subject to errors in recall. Data are not
age-standardised, with aggregate country estimates
representing crude rates among respondents aged
15 years and over. The data, therefore, exclude the
prevalence of childhood asthma (age 0-14 years).HEALTH AT A GLANCE: EUROPE 2012 © OECD 201246
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1.16.1. Self-reported asthma, 2008 (or nearest year)
Source: Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932703696
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1.16.2. Self-reported COPD, 2008 (or nearest year)
Source: Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932703715
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1.16.3. Self-reported COPD by highest attained level of education, 2008 (or nearest year)
Source: Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932703734
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2.1. SMOKING AND ALCOHOL CONSUMPTION AMONG CHILDRENRegular smoking or excessive drinking in adolescence
has both immediate and long-term health consequences.
Children who establish smoking habits in early adoles-
cence increase their risk of cardiovascular diseases, respi-
ratory illnesses and cancer. They are also more likely to
experiment with alcohol and other drugs. Alcohol misuse
is itself associated with a range of social, physical and
mental health problems, including depressive and anxiety
disorders, obesity and accidental injury (Currie et al., 2012).
Results from the Health Behaviour in School-aged
Children (HBSC) surveys, a series of collaborative cross-
national studies conducted in most EU member states,
allow for monitoring of smoking and drinking behaviours
among adolescents. Across all EU member states who
responded to the survey, the proportions of 15-year-old
boys and girls who smoke are similar, but more boys get
drunk.
Boys and girls in Austria, Croatia, the Czech Republic,
Hungary, Latvia and Lithuania smoke most, with more
than 25% reporting that they smoke at least once a week
(Figure 2.1.1). In contrast, less than 15% of 15-year-olds in
Nordic countries (Denmark, Iceland, Norway and Sweden),
Ireland, Poland, Portugal and the United Kingdom smoke
weekly. A number of countries report higher rates of
smoking for girls, although only in the Czech Republic and
Spain is the difference in excess of 5%. Smoking is more
prevalent among boys in Latvia, Lithuania and Romania,
where the difference is 10% or greater.
Drunkenness at least twice in their lifetime is reported
by more than 40% of 15-year-olds in the Czech Republic,
Denmark, Estonia, Finland, Hungary, Latvia, Lithuania,
Slovenia and the United Kingdom (Figure 2.1.2). Much lower
rates (less than 20%) are reported in Italy, Luxembourg and
the Netherlands, as well as Iceland and the Former Yugoslav
Republic of Macedonia. Across all surveyed EU member
states, boys are more likely than girls to report repeated
drunkenness (36% vs. 31%). Croatia, Hungary, Lithuania and
Romania have the biggest differences, with rates of alcohol
abuse among boys at least 10% higher than those of girls. In
four countries, Finland, Spain, Sweden and the United
Kingdom, around 5% more girls than boys report repeated
drunkenness.
Recent smoking and drinking rates for 15-year-old
boys and girls are compared in Figure 2.1.3. Countries
above the 45 degree line have higher rates for boys, and
countries below the line higher rates for girls. Countries
with higher rates of smoking among boys also tend to
report higher rates for girls, with the same finding for
drinking rates.
Rates of smoking and drunkenness are also available
for 13-year-olds (Currie et al., 2012). At this age, around 5% of
children surveyed across the entire European Union smoke
weekly, and in the Czech Republic, Estonia, Latvia, Romania
and the Slovak Republic, the figure is higher at 8% or more.
Over one in ten children in a range of countries including
Croatia, the Czech Republic, Greece, Italy, Romania, the
Slovak Republic and the United Kingdom have experienced
drunkenness at least twice. In Croatia, the Czech Republic,
Greece, Italy and Romania, high rates of repeated drunken-
ness at 13 are seen for boys.
Risk-taking behaviours among adolescents are falling,
with regular smoking for both boys and girls and drunken-
ness rates for boys showing some decline from the levels of
the late 1990s (Figure 2.1.4). Levels of smoking for both
sexes are at their lowest for a decade with, on average,
fewer than one in five children of either sex smoking regu-
larly. However, increasing rates of smoking and drunken-
ness among adolescents in Estonia, Hungary, Latvia,
Lithuania and Poland are cause for concern.
Definition and comparability
Estimates for smoking refer to the proportion of
15-year-old children who self-report smoking at least
once a week. Estimates for drunkenness record the
proportions of 15-year-old children saying they have
been drunk twice or more in their lives.
Data for 24 European Union member states and five
other countries are from the Health Behaviour in
School-aged Children (HBSC) surveys undertaken
between 1993-94 and 2009-10. Data are drawn from
school-based samples of 1 500 in each age group (11-,
13- and 15-year-olds) in most countries. Turkey was
included in the 2009-10 HBSC survey, but children
were not questioned on drinking and smoking.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201250
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2.1.1. Smoking among 15-year-olds, 2009-10
Smoking at least once a week
Source: Currie et al. (2012).
1 2 http://dx.doi.org/10.1787/888932703753
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2.1.2. Drunkenness among 15-year-olds, 2009-10
Drunk at least twice in life
Source: Currie et al. (2012).
1 2 http://dx.doi.org/10.1787/888932703772
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2.1.3. Risk behaviours of 15-year-olds by sex,
2009-10
Source: Currie et al. (2012).
1 2 http://dx.doi.org/10.1787/888932703791
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2.1.4. Trends in repeated drunkenness and regular 
smoking among 15-year-olds, 14 EU countries
Source: Currie et al. (2000); Currie et al. (2004); Currie et al. (2008); Currie
et al. (2012); WHO (1996).
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2.2. OVERWEIGHT AND OBESITY AMONG CHILDRENChildren who are overweight or obese are at greater risk
of poor health in adolescence and also in adulthood. Among
young people, orthopaedic problems and psychosocial
problems such as low self-image, depression and impaired
quality of life can result from overweight. Excess weight
problems in childhood are associated with an increased risk
of being an obese adult, at which point cardiovascular
disease, diabetes, certain forms of cancer, osteoarthritis, a
reduced quality of life and premature death become health
concerns (Sassi, 2010; Currie et al., 2012).
Evidence suggests that even if excess childhood
weight is lost, adults who were obese children retain an
increased risk of cardiovascular problems. And although
dieting can combat obesity, children who diet are at a
greater risk of putting on weight following periods of
dieting. Eating disorders, symptoms of stress and post-
poned physical development can also be products of
dieting (WHO Europe, 2009).
Among 15-year-olds in EU member states, boys tend to
report excess weight more often than girls; one-in-six boys
and one-in-ten girls reported being overweight or obese
in 2009-10 (Figure 2.2.1). More than 15% of adolescents in
southern European countries (Greece, Italy, Portugal and
Spain), as well as in Croatia, Iceland, Luxembourg and
Slovenia report being overweight or obese. Fewer than 10%
of children in Latvia and Lithuania, as well as in Denmark,
France and the Netherlands report overweight or obesity.
Boys’ and girls’ perceptions of having weight problems
often differ from their reported weight. Among 15-year-olds,
40% of girls and 22% of boys across EU member states
thought they were too fat. Further, there is also no clear
association between weight problems and weight reduction
behaviours, with 22% of girls and 9% of boys reporting that
they engage in weight-reduction behaviour; twice the rate of
girls who report being overweight or obese, but only half that
of boys.
Young people who report being overweight are more
likely to miss eating breakfast, are less physically active, and
spend more time watching television (Currie et al., 2012).
Reported rates of excess weight have increased
slightly over the past decade in most EU member states
(Figure 2.2.2). Average reported rates of overweight and
obesity across the EU increased between 2001-02
and 2009-10 from 11% to 13% of 15-year-olds. The largest
increases during the eight year period were found in the
Czech Republic, Estonia, Poland, Romania and Slovenia, all
greater than 5%. Only Denmark and the United Kingdom
report any significant reductions in the proportion of over-
weight or obese at age 15 between 2001-02 and 2009-10,
although non-response rates to questions about self-
reported height and weight require cautious interpretation.
Childhood is an important period for forming healthy
behaviours, and the increased focus on obesity at both
national and international levels has stimulated the
implementation of many community-based initiatives in
European countries in recent years. Studies show that
locally focused interventions, targeting children to 12 years
of age can be effective in changing behaviours. Schools
provide an opportunity to ensure that children understand
the importance of good nutrition and physical activity, and
can benefit from both. Teachers and health professionals are
often involved as providers of health and nutrition activities,
and the most frequent community-based initiatives target
professional training, the social or physical environment
and actions for parents (Bemelmans et al., 2011).
Definition and comparability
Estimates of overweight and obesity are based on
body mass index (BMI) calculations using child self-
reported height and weight. Overweight and obese
children are those whose BMI is above a set of age-
and sex-specific cut-off points (Cole et al., 2000).
Self-reported height and weight is subject to under-
reporting, missing data and error, and requires
cautious interpretation.
Data for 24 EU member states and six other coun-
tries are from the Health Behaviour in School-aged
Children (HBSC) surveys undertaken between 2001-02
and 2009-10. Data are drawn from school-based
samples of 1 500 in each age group (11-, 13- and
15-year-olds) in most countries.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201252
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2.2.1. Reported overweight (including obesity) among 15-year-olds, 2009-10
Source: Currie et al. (2012), based on HBSC survey.
1 2 http://dx.doi.org/10.1787/888932703829
2.2.2. Change in reported overweight among 15-year-olds, 2001-02, 2005-06 and 2009-10
Source: Currie et al. (2004); Currie et al. (2008); Currie et al. (2012), based on HBSC surveys.
1 2 http://dx.doi.org/10.1787/888932703848
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2.3. FRUIT AND VEGETABLE CONSUMPTION AMONG CHILDRENNutrition is important for children’s development and
long-term health. Eating fruit during adolescence, for
example, in place of high-fat, sugar and salt products, can
protect against health problems such as obesity, diabetes,
and heart problems. Moreover, eating fruit and vegetables
when young can be habit forming, promoting healthy
eating behaviours for later life.
A number of factors influence the amount of fruit
consumed by adolescents, including family income, the
cost of alternatives, preparation time, whether parents eat
fruit, and the availability of fresh fruit which can be linked
to the country or local climate (Rasmussen et al., 2006).
Fruit and vegetable consumption have a high priority as
indicators of healthy eating in most European countries.
In European countries in 2009-10, only around one-
third of girls and one-quarter of boys aged 15 years ate at
least one piece of fruit daily, according to the latest Health
Behaviour in School-aged Children (HBSC) survey (Currie
et al., 2012). Overall, boys in Denmark, Portugal and Italy, and
girls in Denmark, Norway, the Former Yugoslav Republic of
Macedonia and Switzerland had the highest rates of daily
fruit consumption. Fruit consumption was relatively low in
Estonia, Latvia, Lithuania and Poland, and in contrast to
other Nordic countries, Finland and Sweden, with rates of
around one-in-four among girls and one-in-five for boys
(Figure 2.3.1).
In all countries, girls were more likely to eat fruit daily.
The gap between the fruit consumption of boys and girls is
largest at age 15 for most countries, with the greatest dis-
parities found in Denmark, Finland, Germany and Norway.
Daily vegetable eating was also reported by around
one-third of girls and quarter of boys on average across
EU member states in 2009-10 (Figure 2.3.2). Girls in Belgium
most commonly ate vegetables daily (60%), followed by
Denmark, France and Switzerland (45-50%). Belgium also
led the way for boys (46%), with close to 40% in France and
Ireland. Eating vegetables daily was less common in
Austria, Estonia and Spain, as well as in Croatia (girls), and
Finland and Latvia (boys).
Similar to fruit eating, in all countries a higher propor-
tion of girls ate vegetables daily. The disparity was espe-
cially large in Finland, where 35% of girls, but only 14% of
boys reported eating vegetables each day. Denmark and
Germany also had large differences, although rates were
comparatively high for both boys and girls in Denmark.
In most countries, it was more common for 15-year-olds
to report eating fruit daily, rather than vegetables
(Figure 2.3.3). However, in a number of western European
countries, including Belgium, the Netherlands, Sweden,
Ireland and France, daily vegetable eating was more common.
Average reported rates of daily vegetable consumption
across EU member states showed some increase
between 2001-02 and 2009-10, for both girls and boys
(Figure 2.3.3). Fruit consumption however was less clear,
with a small increase among girls, while the rates for boys
have remained largely unchanged.
Effective and targeted strategies are required to ensure
that children are eating enough fruit and vegetables to
conform with recommended national dietary guidelines. A
study of European school children found that they gener-
ally hold a positive attitude toward fruit intake, and report
good availability of fruit at home, but lower availability at
school and during leisure time. Increased accessibility to
fruit and vegetables, combined with educational and
motivational activities can help in increasing both fruit and
vegetable consumption (Sandvik et al., 2005).
Definition and comparability
Dietary habits are measured here in terms of the
proportions of children who report eating fruit and
vegetables at least every day or more than once a day.
In addition to fruit and vegetables, healthy nutrition
also involves other types of foods.
Data for 24 EU member states and six other coun-
tries are from the Health Behaviour in School-aged
Children (HBSC) surveys undertaken between 2001-02
and 2009-10. Data are drawn from school-based
samples of 1 500 in each age group (11-, 13- and
15-year-olds) in most countries.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201254
2.3. FRUIT AND VEGETABLE CONSUMPTION AMONG CHILDREN
HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012 55
2.3.1. Daily fruit eating among 15-year-olds,
2009-10
Source: Currie et al. (2012).
1 2 http://dx.doi.org/10.1787/888932703867
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2.3.2. Daily vegetable eating among 15-year-olds,
2009-10
Source: Currie et al. (2012).
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2.3.3. Daily fruit and vegetable eating among
15-year-olds, 2009-10
Source: Currie et al. (2012).
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2.3.4. Trends in daily fruit and vegetable eating among 
15-year-olds, 21 EU countries, 2001-02 to 2009-10
Source: Currie et al. (2004); Currie et al. (2008); Currie et al. (2012).
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2.4. PHYSICAL ACTIVITY AMONG CHILDRENUndertaking physical activity in adolescence is benefi-
cial for health, and can set standards for adult physical
activity levels, thereby influencing health outcomes in later
life. Research supports the role that physical activity has in
child and adolescent development, learning and well-
being, and in the prevention and treatment of a range of
youth health issues including asthma, mental health, bone
health and obesity. More direct links to adult health are
found between physical activity in adolescence and its
effect on overweight and obesity and related diseases,
breast cancer rates and bone health in later life. The health
effects of adolescent physical activity are sometimes
dependent on the activity type, e.g. water physical activities
in adolescence are effective in the treatment of asthma,
and exercise is recommended in the treatment of cystic
fibrosis (Hallal et al., 2006; Currie et al., 2012).
One extensive study recommends that children partici-
pate in at least 60 minutes of moderate-to-vigorous physical
activity daily, although evidence suggests that many
children do not meet these guidelines (Strong et al., 2005;
Borraccino et al., 2009; Hallal et al., 2012). Some of the factors
influencing the levels of physical activity undertaken by
adolescents include the availability of space and equipment,
the child’s present health conditions, their school curricula
and other competing pastimes.
Only one-in-five children in EU member states report
that they undertake moderate-to-vigorous exercise regu-
larly, according to results from the 2009-10 HBSC survey
(Figure 2.4.1). At age 11, Austria, Ireland and Spain stand
out as strong performers with over 30% of children report-
ing exercising for at least 60 minutes per day over the past
week. At age 15, children in Ireland maintain their place,
along with the Czech and Slovak Republics, at 20%. Country
rankings vary according to the child’s age. Children in
Denmark, France and Italy were least likely to report exer-
cising regularly. Italy appears at the lower end for both boys
and girls, and at both ages. A higher proportion of boys
consistently reported undertaking physical activity,
whether moderate or vigorous, across all countries and all
age groups (Figures 2.4.2 and 2.4.3).
It is of concern that physical activity tends to fall
between ages 11 to 15 for most European countries, with
boys in Italy the only exception, although they have the
lowest rate of physical activity at age 15. In Austria,
Finland, Norway and Spain, the rates of exercising among
boys halve between ages 11 and 15. The rates of girls exer-
cising to recommended levels also fall between the ages
of 11 and 15 years. In many countries, rates for 15-year-old
girls are less than half of those at age 11, and in Austria,
Ireland, Romania and Spain, rates of physical activity
among girls fall by over 60%.
The change in activity levels between 11- and
15-year-olds may reflect a move to different types of
activity, since free play is more common among younger
children, and structured activities at school or in sports
clubs among older groups. Boys tend to be more physically
active than girls in all countries, also suggesting that the
opportunities to undertake physical activity may be
gender-biased (Currie et al., 2012).
Daily moderate-to-vigorous physical activity for 2005-06
and 2009-10 averaged across 21 EU member states are shown
in Figure 2.4.3. Reported levels fell slightly for both boys and
girls, and in all age groups, except boys aged 15 years.
Definition and comparability
Data for physical activity considers the regularity of
moderate-to-vigorous physical activity as reported
by 11-, 13- and 15-year-olds for the years 2005-06
and 2009-10. Moderate-to-vigorous physical activity
refers to exercise undertaken for at least an hour each
day which increases the heart rate, and leaves the
child out of breath sometimes.
Data for 24 EU member states and six other coun-
tries are from the Health Behaviour in School-aged
Children (HBSC) surveys. Data are drawn from school-
based samples of 1 500 in each age group in most
countries.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201256
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2.4.1. Daily moderate-to-vigorous physical activity, 11- and 15-year-olds, 2009-10
Source: Currie et al. (2012).
1 2 http://dx.doi.org/10.1787/888932703943
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2.4.2. Vigorous physical activity for two
or more hours per week, 15-year-olds, 2009-10
Source: Currie et al. (2012).
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2.4.3.  Trends in daily moderate-to-vigorous physical 
activity, 21 EU countries, 2005-06 to 2009-10
Source: Currie et al. (2008); Currie et al. (2012).
1 2 http://dx.doi.org/10.1787/888932703981
40
30
20
10
0
% 2005-06 2009-10
21
14
11
29
24
1919
13
9
27
23
19
Girls Boys
Age 11 Age 13 Age 15 Age 11 Age 13 Age 15
2.5. SMOKING AMONG ADULTSTobacco is responsible for about one-in-ten adult
deaths worldwide, equating to about 5 million deaths each
year (WHO, 2012a). It is a major risk factor for at least two
of the leading causes of premature mortality – circulatory
disease and cancer, increasing the risk of heart attack,
stroke, lung cancer, cancers of the larynx and mouth, and
pancreatic cancer. Smoking also causes peripheral vascular
disease and hypertension. In addition, it is an important
contributory factor for respiratory diseases such as chronic
obstructive pulmonary disease (COPD), while smoking
among pregnant women can lead to low birth weight and
illnesses among infants. It remains the largest avoidable
risk to health in European countries.
The proportion of daily smokers among the adult
population varies greatly across countries (Figure 2.5.1).
Only seven of 27 EU member states had rates of less than
20% of the adult population smoking daily in 2010. Rates
were lowest in Finland, Malta, Luxembourg, Portugal,
Slovenia, the Slovak Republic and Sweden, as well as
Iceland and Norway. Although large disparities remain,
smoking rates across most EU member states have
declined. On average, smoking rates have decreased by
about 5 percentage points since 2000, with a higher decline
among men than women. Large declines occurred in
Denmark (31% to 20%), Latvia (42% to 28%), Luxembourg
(26% to 18%), and the Netherlands (29% to 21%), as well as
in Norway and Iceland. Greece maintained the highest level
of smoking around 2010, along with Bulgaria and Ireland,
with close to 30% or more of the adult population smoking
daily. The Czech Republic is one of the few EU member
states where smoking rates appear to be increasing.
In the post-war period, most European countries
tended to follow a general pattern marked by very high
smoking rates among men (50% or more) through to
the 1960s and 1970s, while the 1980s and the 1990s were
characterised by a downturn in tobacco consumption.
Much of this decline can be attributed to policies aimed at
reducing tobacco consumption through public awareness
campaigns, advertising bans and increased taxation, in
response to rising rates of tobacco-related diseases (EC,
2012c). In addition to government policies, actions by anti-
smoking interest groups were very effective in reducing
smoking rates by changing beliefs about the health effects
of smoking.
Smoking prevalence among men is higher in all
EU member states except in Sweden (Figure 2.5.2). In other
Nordic countries (Denmark, Iceland, Norway), as well as in
the United Kingdom, male and female smoking rates are
close to equal. In 2010, the gender gap in smoking rates was
particularly large in Latvia and Lithuania, as well as in
Cyprus, Bulgaria, Romania and Turkey. Female smoking
rates continue to decline in most countries, and in several
at a faster pace than male rates. However, female smoking
rates have shown little or no decline since 2000 in three
countries: the Czech Republic, France and Italy.
Several studies provide strong evidence of socio-
economic differences in smoking and mortality (Mackenbach
et al., 2008). People in lower social groups have a greater
prevalence and intensity of smoking, a higher all-cause
mortality rate and lower rates of cancer survival (Woods et al.,
2006). The influence of smoking as a determinant of overall
health inequalities is such that, if the entire population did
not smoke, mortality differences between social groups
would be halved (Jha et al., 2006).
Definition and comparability
The proportion of daily smokers is defined as the
percentage of the population aged 15 years and over
who report smoking every day.
International comparability is limited due to the
lack of standardisation in the measurement of
smoking habits in health interview surveys across
EU member states. Variations remain in the age
groups surveyed, wording of questions, response
categories and survey methodologies, e.g. in a number
of countries, respondents are asked if they smoke
regularly, rather than daily.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201258
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2.5.1. Adult population smoking daily, 2010 and change in smoking rates, 2000-10 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO Global Infobase.
1 2 http://dx.doi.org/10.1787/888932704000
2.5.2. Females and males smoking daily, 2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932704019
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2.6. ALCOHOL CONSUMPTION AMONG ADULTSThe health burden related to excessive alcohol
consumption, both in terms of morbidity and mortality, is
considerable (Rehm et al., 2009; WHO Europe, 2012a). In
Europe, alcohol is the third leading risk factor for disease
and mortality after tobacco and high blood pressure. High
alcohol intake is associated with increased risk of heart,
stroke and vascular diseases, as well as liver cirrhosis and
certain cancers. Foetal exposure to alcohol increases the
risk of birth defects and intellectual impairments. Alcohol
also contributes to death and disability through accidents
and injuries, assault, violence, homicide and suicide. It is,
however, one of the major avoidable risk factors.
The EU region has the highest alcohol consumption in
the world. Measured through monitoring annual sales data,
it stands at 10.7 litres of pure alcohol per adult on average
across EU member states, using the most recent data avail-
able (Figure 2.6.1). Leaving aside Luxembourg – because of
the high volume of purchases by non-residents in this
country – Austria, France, Latvia, Lithuania and Romania
reported the highest consumption of alcohol, with
12.0 litres or more per adult in 2010. At the other end of the
scale, southern European countries (Cyprus, Greece, Italy,
Malta) along with Nordic countries (Iceland, Sweden, and
Norway) have relatively low levels of consumption, in the
region of 7-8 litres of pure alcohol per adult. Turkey and the
Former Yugoslav Republic of Macedonia have rates well
below four litres.
Although average alcohol consumption has gradually
fallen in many European countries over the past three
decades, it has risen in some others. There has been a degree
of convergence in drinking habits across the European
Union, with wine consumption increasing in many tradi-
tional beer-drinking countries and vice versa. The traditional
wine-producing countries of Italy, France and Spain, as well
as Greece, have seen their alcohol consumption per capita
fall substantially since 1980 (Figures 2.6.1 and 2.6.2). On the
other hand, alcohol consumption per capita in Cyprus,
Finland, Iceland and Ireland rose by a quarter or more
since 1980 although, in the case of Iceland and Cyprus, it
started from a low level and therefore remains relatively low.
Variations in alcohol consumption across countries
and over time reflect not only changing drinking habits but
also the policy responses to control alcohol use. Curbs on
advertising, sales restrictions and taxation have all proven
to be effective measures to reduce alcohol consumption
(Bennett, 2003; WHO Europe, 2012a). Strict controls on sales
and high taxation are mirrored by overall lower consump-
tion in most Nordic countries.
Although adult alcohol consumption per capita gives
useful evidence of long-term trends, it does not identify
sub-populations at risk from harmful drinking patterns.
Much of the burden of disease associated with alcohol
consumption occurs among persons who have an alcohol
dependence problem. The consumption of large quantities
of alcohol at a single session, termed “binge drinking”, is
also a particularly dangerous pattern of consumption
(Institute of Alcohol Studies, 2007), which is on the rise in
some countries and social groups, especially among young
males (see Indicator 2.1 “Smoking and alcohol consump-
tion among children”).
The 2006 Commission Communication on an EU strat-
egy to support member states in reducing alcohol-related
harm highlighted a number of priority themes, including
protecting children and young people, reducing harm from
alcohol-related road accidents, reducing the negative
impact of alcohol in the workplace, education on harmful
consumption, and developing a common alcohol evidence
base at EU level (EC, 2009a). In 2010, the World Health
Organization endorsed a global strategy to combat the
harmful use of alcohol, through direct measures such as
medical services for alcohol-related health problems, and
indirect measures, such as policy options for restricting the
availability and marketing of alcohol. This initiative was
boosted in 2011 by the adoption of a new European Action
Plan by the WHO Regional Office for Europe.
Definition and comparability
Alcohol consumption is defined as annual sales of
pure alcohol in litres per person aged 15 years and
over. The methodology to convert alcohol drinks to
pure alcohol may differ across countries. Official
statistics do not include unrecorded alcohol
consumption, such as home production.
Italy reports consumption for the population
14 years and over, resulting in a slight underestima-
tion, and Sweden for 16 years and over. In some
countries (e.g. Luxembourg), national sales do not
accurately reflect actual consumption by residents,
since purchases by non-residents may create a signif-
icant gap between national sales and consumption.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201260
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2.6.1. Alcohol consumption among population aged 15 years and over, 2010 and change, 1980-2010
Source: OECD Health Data 2012; WHO Global Information System on Alcohol and Health.
1 2 http://dx.doi.org/10.1787/888932704038
2.6.2. Trends in alcohol consumption, selected EU countries, 1980-2010
Source: OECD Health Data 2012; WHO Global Information System on Alcohol and Health.
1 2 http://dx.doi.org/10.1787/888932704057
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2.7. OVERWEIGHT AND OBESITY AMONG ADULTSThe growth in overweight and obesity rates among
adults is a major public health concern. Obesity is a known
risk factor for numerous health problems, including hyper-
tension, high cholesterol, diabetes, cardiovascular diseases,
respiratory problems (asthma), musculoskeletal diseases
(arthritis) and some forms of cancer. Mortality also increases
sharply once the overweight threshold is crossed (Sassi,
2010). Because obesity is associated with higher risks of
chronic illnesses, it is linked to significant additional health
care costs.
Based on latest available data, more than half (52%) of
the adult population in the European Union are overweight
or obese. The prevalence of overweight and obesity among
adults exceeds 50% in no less than 18 of 27 EU member
states. Obesity – which presents even greater health risks
than overweight – varies threefold among countries, from a
low of around 8% in Romania (and Switzerland) to over
25% in Hungary and the United Kingdom, although some of
the variations across countries may be due to different
methodologies in data collection (Figure 2.7.1). On average
across EU member states, 17% of the adult population is
obese.
There is little difference in the average obesity rate of
men and women (Figure 2.7.1). However, there is some
variation among individual countries, with more men than
women being obese in Malta, Iceland and Norway, whereas
a higher proportion of women are obese in Latvia, Turkey
and Hungary. The largest disparities were in Latvia, whereas
there was little, if any difference in male and female rates in
the Czech Republic, Greece and the United Kingdom.
The rate of obesity has doubled over the past 20 years
in many European countries (Figure 2.7.2), regardless of
previous levels. Obesity in 2010 is close to twice the rate
of 1990 in both France and the United Kingdom, even
though the rate in France is currently half that of the
United Kingdom.
The rise in obesity has affected all population groups,
but to varying extents. Evidence from a number of
countries, including Austria, England, France, Italy and
Spain, indicates that obesity tends to be more common in
disadvantaged socio-economic groups, and especially
among women (Sassi et al., 2009). There is also a relation-
ship between the number of years of education and obesity,
with the most educated individuals displaying lower rates.
Again, the gradient in obesity is stronger in women than in
men (Sassi, 2010).
A number of behavioural and environmental factors
have contributed to the rise in overweight and obesity
rates in industrialised countries, including the widespread
availability of energy dense foods and more time spent being
physically inactive. Overweight and obesity have risen
rapidly in children in recent decades, reaching double-figure
rates in most countries (see Indicator 2.2 “Overweight and
obesity among children”).
Many countries have stepped up efforts to tackle the
root causes of obesity, embracing increasingly comprehen-
sive strategies and involving communities and key stake-
holders. Better informed consumers, the availability of
healthy food options, encouraging physical activity and a
focus on vulnerable groups are some of the fields for action
which have seen progress (EC, 2010a). There has also been
a new interest in the use of taxes on foods rich in fat and
sugar, with several governments (Denmark, Finland,
France, Hungary) recently passing legislation aiming to
change eating habits (OECD, 2012b).
Definition and comparability
Overweight and obesity are defined as excessive
weight presenting health risks because of the high
proportion of body fat. The most frequently used
measure is based on the body mass index (BMI), which
is a single number that evaluates an individual’s
weight in relation to height (weight/height2, with
weight in kilograms and height in metres). Based on
the WHO classification (WHO, 2000), adults with a BMI
from 25 to 30 are defined as overweight, and those
with a BMI of 30 or over as obese. This classification
may not be suitable for all ethnic groups, who may
have equivalent levels of risk at lower or higher BMI.
The thresholds for adults are not suitable to measure
overweight and obesity among children.
For most countries, overweight and obesity rates
are self-reported through estimates of height and
weight from population-based health interview
surveys. The exceptions are the Czech and Slovak
Republics, Hungary, Ireland, Luxembourg and the
United Kingdom, where estimates are derived from
health examinations. These differences limit data
comparability. Estimates from health examinations
are generally higher and more reliable than from
health interviews.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201262
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2.7.1. Prevalence of obesity among adults, 2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO Global Infobase.
1 2 http://dx.doi.org/10.1787/888932704076
2.7.2. Increasing obesity rates among adults in European countries, 1990, 2000 and 2010 (or nearest years)
1. Hungary (1988, 2009), Ireland (2007), Luxembourg, the Slovak Republic (2008) and the United Kingdom figures are based on health examination
surveys, rather than health interview surveys.
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO Global Infobase.
1 2 http://dx.doi.org/10.1787/888932704095
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2.8. FRUIT AND VEGETABLE CONSUMPTION AMONG ADULTSNutrition is an important determinant of health.
Inadequate consumption of fruit and vegetables is one
factor that can play a role in increased morbidity. Proper
nutrition assists in preventing a number of obesity-related
chronic conditions, including cardiovascular disease,
hypertension, Type 2 diabetes, stroke, certain cancers,
musculoskeletal disorders and a range of mental health
conditions. A European Commission White Paper advo-
cated increasing the consumption of fruit and vegetables as
one of a number of tools to offset a worsening trend of poor
diets and low physical activity (EC, 2007).
In response to a health survey question asking “How
often do you eat fruit?”, the percentage of adults consum-
ing fruit daily varied from 45% in Bulgaria and Romania, to
75% in Italy, Malta and Slovenia, and 84% in Switzerland
around 2008 (Figure 2.8.1). Across the 19 EU member states
providing data, an average 63% of adults ate fruit daily.
Females ate fruit more often than males, with the largest
gender differences in Denmark, the Slovak Republic and
Germany (23, 20 and 19 percentage points respectively). In
Mediterranean countries (Cyprus, Greece, Italy, Malta,
Spain and Turkey), gender differences were much smaller,
at under 10%.
Among different age groups, older persons aged
65 and over were more likely to eat fruit, with consumption
lowest among young people aged 15-24 years, except in
Bulgaria and Romania, where young people ate the most
(see also Indicator 2.3 “Fruit and vegetable consumption
among children”). Fruit consumption also varies by socio-
economic status, generally being highest among persons
with higher educational levels (Figure 2.8.3). However, this
was not the case in Mediterranean countries (Cyprus,
Malta, Spain, Greece), where lower educated persons ate
fruit more often.
Daily vegetable consumption ranged from around
50% in Estonia, Germany, Malta and the Slovak Republic to
75% in France and Slovenia, with Belgium and Ireland
highest at 85% and 95% respectively (Figure 2.8.2). The
average across 18 countries was the same as for fruit, 63%.
Again, more females reported eating vegetables daily,
except in Bulgaria and Ireland, where rates were similar. In
the Czech and Slovak Republics, Germany, Italy, Malta and
Spain, gender differences exceeded 10%.
Patterns of vegetable consumption among age groups
and educational groups are similar to those for fruit. Older
persons more commonly ate vegetables daily, except in
Bulgaria, the Czech Republic, Latvia and Romania. Highly
educated persons ate vegetables more often, although the
difference between educational groups was small in
Belgium, Cyprus, Italy, Greece, Slovenia and the Slovak
Republic (Figure 2.8.4). Differences exceeded 20% in
Bulgaria, Latvia and Romania.
The availability of fruit and vegetables is the major
determinant of consumption. Despite high variability
between countries, vegetable and especially fruit availabil-
ity is higher in southern European countries, with cereals
and potatoes more available in central and eastern
European countries. Fruit and vegetable availability also
tends to be higher in families where household heads have
a higher level of education (Elmadfa, 2009).
The promotion of fruit and vegetable consumption,
especially in schools and the workplace, features in the
EU platform for action on diet, physical activity and health,
a forum for European-level organisations, ranging from the
food industry to consumer protection NGOs, willing to
commit to tackling current trends in diet and physical
activity (EC, 2011a). Policy makers and government repre-
sentatives share ideas and best practice on the promotion
of fruit and vegetable consumption in the High Level Group
on Nutrition and Physical Activity.
Definition and comparability
Estimates of daily fruit and vegetable consumption
are derived from national and European Health
Interview Survey questions, conducted in many EU
member states between 2006 and 2010. Typically,
respondents were asked “How often do you eat
fruit (excluding juice)?” and “How often do you eat
vegetables or salad (excluding juice and potatoes)?”
Response categories included: Twice or more a day/
Once a day/Less than once a day but at least four
times a week/Less than four times a week, but at least
once a week/Less than once a week/Never.
Data for France and Switzerland include juices,
soups and potatoes. Data rely on self-report, and are
subject to errors in recall. The same survey also asked
for information on age, sex and educational level.
Data are not age-standardised, with aggregate coun-
try estimates representing crude rates among respon-
dents aged 15 years and over in all countries, except
Germany which is 18 years and over.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201264
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2.8.1. Daily fruit eating among adults,
2008 (or nearest year)
Source: Eurostat Statistics Database and national health interview surveys.
1 2 http://dx.doi.org/10.1787/888932704114
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Source: Eurostat Statistics Database and national health interview surveys.
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2.8.4. Daily vegetable eating among adults, 
by educational level, 2008 (or nearest year)
Source: Eurostat Statistics Database and national health interview surveys.
1 2 http://dx.doi.org/10.1787/888932704171
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3.1. MEDICAL DOCTORSIn many European countries, there are concerns about
current or future shortages of doctors, in general or more
specifically for certain categories of doctors or in certain
locations (e.g. in rural and remote areas). This section pro-
vides data on the number of doctors per capita in European
countries in 2010 and its evolution over the past decade, as
well as a disaggregation between generalists and specialists.
In 2010, Greece had, by far, the highest number of
doctors per capita, with 6.1 doctors per 1 000 population,
nearly twice the EU average of 3.4. Following Greece was
Austria, with 4.8 doctors per 1 000 population. The number
of doctors per capita was also relatively high in Norway,
Portugal (although the number reported is an overestima-
tion as it comprises all doctors licensed to practice,
including some who may not be practising), Sweden,
Switzerland and Spain. The number of doctors per capita
was the lowest in Montenegro and Turkey, followed by
Poland, Romania and Slovenia (Figure 3.1.1).
Since 2000, the number of physicians per capita has
increased in all European countries, except in France, Estonia
and Poland. On average across EU member states, physician
density grew from 2.9 doctors per 1 000 population in 2000
to 3.4 in 2010. The growth rate was particularly rapid in
Greece, which started from the highest level in 2000, thereby
increasing the gap with other countries, and the United
Kingdom, which started from the second lowest level in 2000,
thereby narrowing the gap with other European countries.
In Greece, the number of doctors per capita has stabi-
lised since the beginning of the crisis in 2008, following
strong growth between 2000 and 2008.
In the United Kingdom, the number of doctors per
capita has gone up steadily over the past decade, from
2.0 doctors per 1 000 population in 2000 to 2.7 in 2010 (and
2.8 in 2011). The number of new registrations of foreign-
trained doctors increased up to 2003 when it peaked at
about 14 000, but has declined since then to about 5 000
in 2010 and 2011 (General Medical Council, 2012). At the
same time, the number of new graduates from medical
schools in the United Kingdom increased, from about 4 600
in 2003 to 5 800 in 2010 and in 2011, gradually exceeding
the number of new registrations of foreign-trained physi-
cians (OECD, 2012a).
In France, the number of doctors per capita has not
increased over the past decade, and it is expected to
decrease until 2020, following the reduction in the number
of new entrants and graduates from medical schools
during the 1980s and 1990s (DREES, 2009).
In nearly all countries, the balance between generalist
and specialist doctors has changed over the past few
decades, with the number of specialists increasing much
more rapidly. As a result, there are more specialists than
generalists in most countries, except in Ireland, Malta,
Portugal and Norway (Figure 3.1.2). This may be explained
by a lesser interest in the traditional mode of practice of
general practitioners (family doctors) given the workload
and constraints attached to it. In addition, in many
countries, the remuneration gap between generalists and
specialists has widened (Fujisawa and Lafortune, 2008).
The slow or negative growth in the number of generalists
per capita raises concerns about access to primary care for
certain population groups. In response to this shortage,
many countries have taken steps to improve the number of
training posts and attractiveness of general practice. For
example, in France, the number of interns in general
practice has increased markedly in recent years, with
around half of all internships allocated to general practice
in 2010 and 2011 (DREES, 2012). A number of countries are
also considering the development of new roles for other
health care providers, such as advanced practice nurses, to
respond to growing demands for primary care (Delamaire
and Lafortune, 2010).
Definition and comparability
Practising physicians are defined as doctors who are
providing care directly to patients. In some countries,
the numbers also include doctors working in adminis-
tration, management, academic and research posi-
tions (“professionally active” physicians), adding
another 5-10% of doctors. Portugal reports all physi-
cians entitled to practice, resulting in an even greater
overestimation.
Generalists include general practitioners (“family
doctors”) and other generalist/non-specialist
practitioners who may be working in hospitals or
outside hospitals. Specialists include paediatricians,
gynaecologists and obstetricians, psychiatrists,
medical specialists, surgical specialists and other
specialties. Other physicians include interns/residents
if they are not reported in the field in which they are
training, and doctors who are not classified elsewhere.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201268
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3.1.1. Practising doctors per 1 000 population, 2010 and change between 2000 and 2010 (or nearest year)
1. Data include not only doctors providing direct care to patients, but also those working in the health sector as managers, educators, researchers, etc.
(adding another 5-10% of doctors).
2. Data refer to all doctors who are licensed to practice.
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO European Health for All Database.
1 2 http://dx.doi.org/10.1787/888932704190
3.1.2. Generalists and specialists as a share of all doctors, 2010 (or nearest year)
1. Generalists include general practitioners/family doctors and other generalist (non-specialist) medical practitioners.
2. Specialists include paediatricians, obstetricians/gynaecologists, psychiatrists, medical, surgical and other specialists.
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932704209
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3.2. CONSULTATIONS WITH DOCTORSConsultations with doctors can take place in doctors’
offices or clinics, in hospital outpatient departments or, in
some cases, in patients’ own homes. In many European
countries (e.g. Denmark, Italy, the Netherlands, Norway,
Portugal, the Slovak Republic, Spain and the United Kingdom),
patients are required or given incentives to consult a general
practitioner (GP) about any new episode of illness. The GP
may then refer them to a specialist, if indicated. In other
countries (e.g. Austria, the Czech Republic and Iceland),
patients may approach specialists directly.
The number of doctor consultations per person per
year is highest in Hungary, the Czech Republic and the
Slovak Republic, while it is lowest in Cyprus, Malta and
Sweden (Figure 3.2.1). The EU average is 6.3 consultations
per person per year, with most member states reporting
4 to 7 visits per person per year. Cultural factors appear to
play a role in explaining some of the variations across
countries, although certain health system characteristics
may also play a role. Some countries which pay their
doctors mainly by fee-for-service tend to have above-
average consultation rates (e.g. Belgium and Germany),
while other countries that have mostly salaried doctors
tend to have below-average rates (e.g. Finland and Sweden).
In Sweden, the low number of doctor consultations
may also be explained partly by the fact that nurses play an
important role in primary care (Bourgueil et al., 2006).
Similarly, in Finland, nurses and other health professionals
play an important role in providing primary care to patients
in health centres, lessening the need for consultations with
doctors (Delamaire and Lafortune, 2010).
In many European countries, the average number of
doctor consultations per person has increased since 2000
(Figure 3.2.1). This is consistent with the increase in the
number of doctors per capita in most countries over the
past decade (see Indicator 3.1). In the Czech Republic and
the Slovak Republic, there has been a substantial reduction
in the number of doctor consultations per capita over the
past decade, although the number remains well above
the EU average. In Spain also, there has been a marked
decline in the number of doctor consultations per person
since 2000.
The number of doctor consultations varies not only
across countries, but also among different population
groups in each country. This is particularly the case for
consultations with medical specialists. A recent OECD study,
using health interview surveys carried out between 2006
and 2009, provides evidence on inequality in doctor consul-
tations by income group in a number of European countries
(Devaux and de Looper, 2012). Figure 3.2.2 shows the
horizontal inequity index – a measure of inequality in health
care use adjusted for differences in need – regarding the
probability of having at least one visit to a generalist or a
specialist during the year. The probability favours low
income groups when it is below zero, and high income
groups when it is above zero. The index is adjusted for
differences in need for health care because health problems
are more frequent and severe among lower income groups.
The probability of a generalist (GP) visit is equally distributed
in most countries (Figure 3.2.2). When inequality does exist,
it is often positive, indicating a pro-rich distribution, but the
degree of inequality is small. Lower income people, however,
consult a GP more frequently (results not shown). A different
story emerges for specialist visits – in nearly all countries,
high income people are more likely to see a specialist than
those with low income (Figure 3.2.2), and also more
frequently.
Definition and comparability
Consultations with doctors refer to the number of
contacts with physicians, including both generalists
and specialists. There are variations across countries in
the coverage of different types of consultations, notably
in outpatient departments of hospitals. The data come
mainly from administrative sources, although in some
countries (Ireland, Italy, the Netherlands, Spain,
Switzerland and the United Kingdom) the data come
from health interview surveys. Estimates from adminis-
trative sources tend to be higher than those from
surveys because of problems with recall and non-
response rates.
The figures for the Netherlands exclude contacts for
maternal and child care. The data for Portugal exclude
visits to private practitioners, which is also largely the
case in Malta, while those for the United Kingdom
exclude consultations with specialists outside hospital.
In Luxembourg, doctors consultations outside the
country are not included (these consultations account
for a higher number than in other countries). In
Germany, the data include only the number of cases of
physicians’ treatment according to reimbursement
regulations under the Social Health Insurance Scheme
(a treatment only counts the first contact over a three-
month period, even if the patient consults a doctor
more often). Telephone contacts are included in several
countries (e.g. the Czech Republic, Ireland, Spain and the
United Kingdom).
The horizontal inequity indices shown here refer to
the probability of a visit to a generalist or a specialist
in a given year by income group. The data come from
health interview surveys conducted between 2006
and 2009. Inequalities in doctor consultations are
assessed in terms of household income. The number
of doctor consultations is adjusted for need, based on
self-reported information about health status. Differ-
ing survey questions and response categories may
affect cross-national comparisons. The measures
used to grade income can also vary. Caution is there-
fore needed when interpreting inequalities in doctor
consultations across countries.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201270
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3.2.1. Doctors consultations per capita, 2010 and change between 2000 and 2010 (or nearest year)
Source: OECD Health Data 2012; WHO European Health for All Database.
1 2 http://dx.doi.org/10.1787/888932704228
3.2.2. Inequity index for the probability of a visit in the past 12 months, adjusted for need, 2009 (or nearest year)
1. Visits in the past three months in Denmark.
Source: Devaux and de Looper (2012).
1 2 http://dx.doi.org/10.1787/888932704247
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3.3. NURSESNurses are usually the most numerous health
profession, outnumbering physicians in most European
countries. Nurses play a critical role in providing health
care not only in traditional settings such as hospitals and
long-term care institutions but increasingly in primary care
(especially in offering care to the chronically ill) and in
home care settings. However, there are concerns in many
countries about shortages of nurses, and these concerns
may well intensify in the future as the demand for nurses
continues to increase and the ageing of the “baby boom”
generation precipitates a wave of retirements among
nurses. These concerns have prompted many countries to
increase the training of new nurses combined with efforts
to increase the retention of nurses in the profession
(OECD, 2008a).
In 2010, there were over 15 nurses per 1 000 population
in Switzerland, Denmark and Belgium. Turkey had the
fewest nurses, followed by Greece and the Former Yugoslav
Republic of Macedonia (all these countries have fewer than
four nurses per 1 000 population). The EU average was close
to eight nurses per 1 000 population.
Since 2000, the number of nurses per capita has
increased in all European countries, except in Lithuania
and the Slovak Republic. The increase was particularly
large in Portugal, Spain and Turkey. In Denmark and France,
there was also a fairly large increase in the number of
nurses, rising by over 25% in absolute terms since 2000. In
Estonia, the absolute number of nurses increased up
to 2008, but has decreased since then; this has led to a
reduction in the number of nurses per 1 000 population
from 6.4 in 2008 to 6.1 in 2010.
In 2010, the number of nurses per doctor ranged from
more than four in Denmark, Finland, Ireland and Switzerland
to less than one nurse per doctor in Greece and one in Italy
and Turkey (Figure 3.3.2). The average across EU member
states is two-and-a-half nurses per doctor, with many
countries reporting between two to four nurses per doctor. In
Greece and Italy, there is evidence of an oversupply of doctors
and undersupply of nurses, resulting in an inefficient
allocation of resources (OECD, 2009; Chaloff, 2008).
A recent survey of nurses working in hospitals in
12 European countries provides evidence about their job
satisfaction and intention to leave the profession, as well
as their perception of the quality of care provided in their
hospital. This survey found large variations in rates of job
dissatisfaction among nurses, ranging from 11% in the
Netherlands up to 56% in Greece, and their intention to
leave their positions, with rates varying from 19% in the
Netherlands up to almost 50% in Finland and Greece.
Nurses in Greece also reported a particularly high level of
burnout, and nearly half described their hospital wards as
providing poor or fair quality of care only. In all countries,
higher nurse staffing levels and better work environments
in hospital were significantly associated with better quality
and safety of care for patients, and higher job satisfaction
for nurses (Aiken et al., 2012).
In response to shortages of general practitioners,
some countries have taken the initiative to develop more
advanced roles for nurses to ensure proper access to pri-
mary care. Evaluations of the experience with (advanced)
nurse practitioners in Finland and the United Kingdom, as
well as in Canada and the United States, show that they
can improve access to care and reduce waiting times, while
providing the same quality of care as doctors for patients
with minor illnesses or those requiring routine follow-up.
Most evaluations find a high patient satisfaction rate, with
the impact on cost being either cost-reducing or cost-
neutral. The development of new advanced roles for nurses
requires the implementation of more advanced education
and training programmes to ensure that they have proper
skills (often at the master’s level at university), and also
often involve legislative or regulatory changes to remove
any barrier to the extension in their scope of practice
(Delamaire and Lafortune, 2010).
Definition and comparability
The number of nurses includes those employed in
public and private settings, who are providing
services directly to patients (“practising”) and/or are
working as managers, educators or researchers (“pro-
fessionally active”). Data for Belgium and Italy refer to
all nurses who are licensed to practice, regardless of
whether they are practising/professionally active or
not (this is resulting in a large overestimation).
In countries where there are different levels of
nurses, the data include both “professional nurses”
who have a higher level of education and perform
higher level tasks and “associate professional nurses”
who have a lower level of education but are none-
theless recognised and registered as nurses.
Midwives, as well as nursing aids who are not
recognised as nurses, are normally excluded. How-
ever, some countries include midwives because they
are considered as specialist nurses.
Austria reports only nurses working in hospitals,
resulting in an underestimation. Data for Germany
does not include about 270 000 nurses (representing
an additional 30% of nurses) who have three years of
education and are providing services for the elderly.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201272
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3.3.1. Practising nurses per 1 000 population, 2010 and change between 2000 and 2010
1. Data refer to all nurses who are licensed to practice.
2. Data include not only nurses providing direct care to patients, but also those working in the health sector as managers, educators, researchers, etc.
3. Austria reports only nurses employed in hospitals.
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO European Health for All Database.
1 2 http://dx.doi.org/10.1787/888932704266
3.3.2. Ratio of nurses to physicians, 2010 (or nearest year)
1. For those countries which have not provided data for practising nurses and/or practising physicians, the numbers relate to the same concept
(“professionally active” or “licensed to practice”) for both nurses and physicians, for the sake of consistency.
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO European Health for All Database.
1 2 http://dx.doi.org/10.1787/888932704285
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3.4. MEDICAL TECHNOLOGIES: CT SCANNERS AND MRI UNITSNew medical technologies are improving diagnosis
and treatment, but they are also increasing health spend-
ing. This section presents data on the availability and use
of two diagnostic technologies: computed tomography (CT)
scanners and magnetic resonance imaging (MRI) units.
CT scanners and MRI units help physicians diagnose a
range of conditions by producing images of internal organs
and structures of the body. Unlike conventional radio-
graphy and CT scanning, MRI exams do not expose patients
to ionising radiation.
The availability of CT scanners and MRI units has
increased rapidly in most European countries over the past
two decades. For example, in the Netherlands, the number
of MRI units per capita was multiplied by ten between 1990
and 2010, while the number of CT scanners nearly doubled.
Similarly, in Italy, the number of MRI scanners per capita
was increased by nearly six times between 1997 and 2010,
and the number of CT scanners more than doubled.
In 2010, Greece, Italy and Cyprus had the highest
number of MRI and CT scanners per capita among
EU member states. Iceland and Switzerland also had signif-
icantly more MRI and CT scanners than the EU average
(Figures 3.4.1 and 3.4.2). The numbers of MRI units and CT
scanners per population were the lowest in Hungary and
Romania.
There is no general guideline or benchmark regarding
the ideal number of CT scanners or MRI units per popula-
tion. However, if there are too few units, this may lead to
access problems in terms of geographic proximity or
waiting times. If there are too many, this may result in an
overuse of these costly diagnostic procedures, with little if
any benefits for patients.
Data on the use of these diagnostic scanners are
available only for a smaller group of countries. Based on
this more limited country coverage, the number of CT and
MRI exams per capita is the highest in Greece, consistent
with the fact that Greece also has the highest number of
these two types of scanners. The number of MRI exams per
capita is also above average in Germany and Luxembourg,
as well as in Iceland and Turkey. It is the lowest in Ireland
and Slovenia, although in these two countries only
CT exams and MRI exams carried out in hospitals are
reported, resulting in an underestimation.
In Greece, most CT and MRI scanners are installed in
privately-owned diagnostic centres and only a minority are
found in public hospitals. While there are no guidelines
regarding the use of CT and MRI scanners in Greece (Paris
et al., 2010), since late 2010, a ministerial decree has estab-
lished certain criteria concerning the purchase of imaging
equipment in the private sector (Official Gazette, No. 1918/10,
December 2010). One of the main criteria is based on a
minimum threshold of population density (30 000 population
for CT scanners and 40 000 for MRIs). These regulations do
not apply to the public sector.
Clinical guidelines have been developed in some
European countries to promote a more rational use of such
diagnostic technologies (OECD, 2010b). In the United
Kingdom, since the creation of the Diagnostic Advisory
Committee by the National Institute for Health and Clinical
Excellence (NICE), a number of guidelines have been issued
on the appropriate use of MRI and CT exams for different
purposes (NICE, 2012).
Definition and comparability
For MRI units and CT scanners, the numbers of
equipment per million population are reported.
MRI exams and CT exams relate to the number of
exams per 1 000 population. In most countries, the
data cover equipment installed both in hospitals and
the ambulatory sector.
However, there is only partial coverage for some
countries. MRI units and CT scanners outside hospitals
are not included in some countries (Belgium, Germany
and Spain, as well as Switzerland for MRI units). For
the United Kingdom, the data only include scanners in
the public sector. MRI and CT exams outside hospitals
are not included in certain countries (Austria, Ireland,
Slovenia, Spain and the United Kingdom). Further-
more, MRI and CT exams for Ireland only cover public
hospitals. The Netherlands only report data on
publicly-financed exams. HEALTH AT A GLANCE: EUROPE 2012 © OECD 201274
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3.4.1. MRI units, 2010 (or nearest year)
Note: The EU average does not include countries which only report
equipment in hospital.
1. Equipment outside hospital is not included.
2. Any equipment in the private sector is not included.
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932704304
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3.5. HOSPITAL BEDSThe number of hospital beds provides an indication of
the resources available for delivering services to inpatients
in hospitals. This section presents data on the total number
of hospital beds, including those allocated for curative care,
psychiatric care, long-term care and other types of care. It
does not capture the capacity of hospitals to provide same-
day emergency or elective interventions.
Over the past ten years, the number of hospital beds
per population has decreased in all European countries,
except Greece and Turkey. On average across EU member
states, the number fell by close to 2% per year, coming down
from 6.5 beds per 1 000 population in 2000 to 5.3 in 2010
(Figure 3.5.1). This reduction in the number of hospital beds
has been accompanied by a reduction in average length of
stays (Indicator 3.7) and, in some countries, a reduction in
hospital admissions and discharges (Indicator 3.6). The
reduction in the number of hospital beds has been parti-
cularly pronounced in Latvia (coming down from 8.7 beds
per 1 000 population in 2000 to 5.3 in 2010), Estonia, Italy and
Norway.
In all countries, progress in medical technologies has
enabled a move to same-day surgery and a reduced need for
long hospitalisation. In many countries, the financial and
economic crisis which started in 2008 also provided a further
stimulus to reduce hospital capacity as part of policies to
reduce public spending on health (European Observatory on
Health Systems and Policies, 2012). For example, in Ireland,
policies to reduce costs in the hospital sector in the after-
math of the crisis included a reduction in hospital beds, and
incentives to reduce the length of stays in hospitals and
increase day care (Thomas and Burke, 2012).
In 2010, Austria and Germany had the highest number
of hospital beds per capita, with around eight beds per
1 000 population (Figure 3.5.1). The high supply of hospital
beds in these two countries is associated with a large
number of hospital admissions/discharges, as well as long
average length of stays in Germany. Turkey had the lowest
number of beds per capita, although their number
increased markedly over the past decade. Ireland, Sweden
and the United Kingdom also have a relatively low number
of hospital beds (although the data in the United Kingdom
and Ireland do not include beds in private hospitals).
More than two-thirds of hospital beds are allocated for
curative care on average across EU member states
(Figure 3.5.2). The rest of the beds are allocated for psychi-
atric care (15%), long-term care (8%) and other types of care
(8%). However, in some countries, the share of beds
allocated for psychiatric care and long-term care is much
greater than the average. In Finland, a greater share of
hospital beds is allocated for long-term care (32%) than for
curative care (30%), because local governments (municipa-
lities) use some beds in health care centres (which are
defined as hospitals) for providing some institution-based
long-term care (OECD, 2005).
The share of beds in private for-profit hospitals has
increased in some countries over the past decade. In
Germany, the share increased from 23% of all beds in 2002
to 30% in 2010, accompanied by a decrease in the share of
beds in public hospitals from 45% to 41%. The remaining
beds were in private not-for-profit hospitals (whose share
also declined slightly). In France, the share of beds in
private for-profit hospitals also increased during the past
decade but to a lesser extent, from 20% in 2000 to 23%
in 2010, while the proportion of beds in public hospitals
decreased from 66% in 2000 to 63% in 2010 (OECD, 2012a).
In several countries, the reduction in the overall
number of hospital beds has been accompanied by an
increase in their occupancy rates. Since 2000, the occupancy
rate of curative care beds increased significantly in Ireland
(from 85% in 2000 to 91% in 2010), Norway (from 85% to 93%)
and Switzerland (from 85% to 88%) (OECD, 2012a).
Definition and comparability
Hospital beds are defined as all beds that are regu-
larly maintained and staffed and are immediately
available for use. They include beds in general hospi-
tals, mental health and substance abuse hospitals,
and other specialty hospitals. Beds in nursing and
residential care facilities are excluded.
Curative care beds are beds accommodating patients
where the principal intent is to do one or more of the
following: cure physical illness or provide definitive
treatment of injury, perform surgery, relieve symptoms
of physical illness or injury (excluding palliative care),
reduce severity of physical illness or injury, protect
against exacerbation and/or complication of physical
illness and/or injury which could threaten life or
normal functions, perform diagnostic or therapeutic
procedures, manage labour (obstetric).
Psychiatric care beds are beds accommodating
patients with mental health problems. They include
beds in psychiatric departments of general hospitals,
and all beds in mental health and substance abuse
hospitals.
Long-term care beds are hospital beds accommo-
dating patients requiring long-term care due to
chronic impairments and a reduced degree of inde-
pendence in activities of daily living. They include
beds in long-term care departments of general
hospitals, beds for long-term care in specialty
hospitals, and beds for palliative care.
Data for some countries do not cover all hospitals.
In Ireland and the United Kingdom, data are
restricted to public or publicly-funded hospitals only.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201276
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3.5.1. Hospital beds per 1 000 population, 2010 and change between 2000 and 2010
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO European Health for All Database.
1 2 http://dx.doi.org/10.1787/888932704380
3.5.2. Hospital beds by function of health care, 2010 (or nearest year)
Countries ranked from highest to lowest number of total hospital beds per capita
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932704399
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3.6. HOSPITAL DISCHARGESHospital discharges measure the number of people
who were released after staying at least one night in
hospital. Together with the average length of stay, they
are important indicators of hospital activities. Hospital
activities are affected by a number of factors, including the
capacity of hospitals to treat patients, the ability of the
primary care sector to prevent avoidable hospital admis-
sions, and the availability of post-acute care settings to
provide rehabilitative and long-term care services.
In 2010, hospital discharge rates were the highest in
Austria, Bulgaria, Germany and Romania (Figure 3.6.1).
They were the lowest in Cyprus, Portugal and Spain as well
as in the Former Yugoslav Republic of Macedonia. In
general, countries that have a greater number of hospital
beds also tend to have higher discharge rates. For example,
the number of hospital beds per capita in Austria and
Germany is more than two-times greater than in Portugal
and Spain, and discharge rates are also more than two-
times greater (see Indicator 3.5).
Trends in hospital discharge rates over the past decade
vary widely across EU member states. In about one-third of
EU member states (including Austria, Bulgaria, Germany,
Greece, Poland and Romania), discharge rates have
increased between 2000 and 2010. In a second group of
countries (including the Czech Republic, Denmark,
Slovenia, Sweden and the United Kingdom), they have
remained stable, while in the third group (including
Finland, France, Hungary, Italy and Luxembourg), discharge
rates fell between 2000 and 2010.
Trends in hospital discharges may reflect several
factors that are not easily disentangled. Demand for hospi-
talisation may grow as populations age, given that older
people account for a disproportionately high percentage of
hospital discharges in all countries. For example, in Austria
and Germany, over 40% of all hospital discharges in 2010
were for people aged 65 and over, more than twice their
share of the population (17.6% and 20.7% respectively).
However, population ageing alone may be a less important
factor in explaining trends in hospitalisation rates than
changes in medical technologies and clinical practices. A
significant body of research shows that the diffusion of
new medical interventions gradually extends to older
population groups, as interventions become safer and
more effective for people at older ages (e.g. Dormont and
Huber, 2006). However, the diffusion of new medical tech-
nologies may also involve a reduction in hospitalisation if it
entails a shift from procedures requiring overnight stays in
hospitals to same-day procedures. In the group of countries
where discharge rates have decreased over the past decade,
the reduction can be explained at least partly by a strong
rise in the number of day surgeries (see Indicator 3.9, for
example, for evidence on the rise in day surgeries for
cataracts).
Lithuania has the highest discharge rate for circulatory
diseases, followed by Bulgaria and Germany (Figure 3.6.2).
The high rates in Bulgaria and Lithuania are associated with
high mortality rates from circulatory diseases, which may be
used as a proxy indicator for the occurrence of these
diseases (see Indicator 1.4). But Germany does not have high
mortality rates for circulatory diseases, suggesting that
different clinical practices may play a role in explaining high
discharge rates.
Austria and Germany have the highest discharge rates
for cancer, followed by Hungary (Figure 3.6.3). While the
high rate in Hungary is associated with a high mortality rate
from cancer (which may also be used as a proxy for the
occurrence of the disease; see Indicator 1.5), this is not the
case for Austria and Germany. In Austria, the high rate is
associated with a high rate of hospital readmissions for fur-
ther investigation and treatment of cancer patients (EC,
2008a).
Definition and comparability
Discharge is defined as the release of a patient who
has stayed at least one night in hospital. It includes
deaths in hospital following inpatient care. Same-day
separations are usually excluded, with the exception
of Norway, Poland, the Slovak Republic and Turkey
which include some same-day separations.
Healthy babies born in hospitals are excluded
completely (or almost completely) from hospital dis-
charge rates in several countries (e.g. Austria, Cyprus,
Estonia, Finland, Greece, Ireland, Latvia, Luxembourg,
Spain, Turkey). These comprise 3-7% of all discharges.
Data for some countries do not cover all hospitals. In
Denmark, Ireland and the United Kingdom, data are
restricted to public or publicly-funded hospitals only.
Data for Portugal relate only to public hospitals on the
mainland. Data for Austria, Estonia, Luxembourg and
the Netherlands include only acute care/short-stay
hospitals.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201278
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3.6.1. Hospital discharges per 1 000 population, 2000 and 2010 (or nearest year)
1. Excludes discharges of healthy babies born in hospital (between 3-7% of all discharges).
2. Includes same-day discharges.
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO European Health for All Database.
1 2 http://dx.doi.org/10.1787/888932704418
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3.6.2. Hospital discharges for circulatory diseases 
per 1 000 population, 2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database.
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3.6.3. Hospital discharges for cancers 
per 1 000 population, 2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database.
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3.7. AVERAGE LENGTH OF STAY IN HOSPITALSThe average length of stay in hospitals is often regarded
as an indicator of efficiency, since a shorter stay may reduce
the cost per discharge and shift care from inpatient to less
expensive post-acute settings. However, shorter stays tend
to be more service intensive and more costly per day.
Too short a length of stay could also have adverse effects on
health outcomes, or reduce the comfort and recovery of the
patient. If this leads to a rising readmission rate, costs per
episode of illness may fall little, or even rise.
In 2010, the average length of stay in hospitals was the
lowest in Turkey, Norway and Denmark (Figure 3.7.1). It
was the highest in Finland, followed by the Former Yugoslav
Republic of Macedonia, Croatia, Switzerland and Germany.
The high average length of stay in Finland is due to a large
proportion of beds allocated for convalescent patients and
long-term care (see Indicator 3.5). Focusing only on stays in
acute care units, the average length of stay in Finland is not
greater, indeed is even lower than in most other European
countries.
The average length of stay in hospitals has decreased
over the past decade in all European countries, falling from
8.2 days in 2000 to 6.9 days in 2010 on average in EU member
states (Figure 3.7.1). The reduction in average length of stay
was particularly marked in Bulgaria, Croatia, the Former
Yugoslav Republic of Macedonia and Switzerland. It also
decreased in the Netherlands and the United Kingdom.
Several factors explain this general decline, including the
use of less invasive surgical procedures, changes in hospital
payment methods, and the expansion of early discharge
programmes enabling patients to return to their home to
receive follow-up care.
A growing number of countries (e.g. France, Germany,
Poland) have moved to prospective payment methods often
based on diagnosis-related groups (DRGs) to set payments
based on the estimated cost of hospital care for different
patient groups in advance of service provision. These
payment methods have the advantage of encouraging
providers to reduce the cost of each episode of care (OECD,
2010b). In Switzerland, the move from per diem payments to
diagnosis-related groups (DRG) based payments has contrib-
uted to the reduction in length of stay in those cantons that
have modified their payment system (OECD and WHO, 2011).
In the Netherlands, the introduction of a new payment
system for hospitals in 2006 also provided incentives to
reduce length of stay. Prior to the reform, hospitals were paid
on a fixed amount per bed and beddays. Since 2006, a
growing share of hospital payments is determined through
negotiations between insurers and hospitals, based on the
Dutch version of DRGs (Westert and Klazinga, 2011). While
the average length of stay in hospitals in the Netherlands
used to be above the EU average in 2000, it has now fallen
below. Still, a number of additional interventions have been
identified by hospital staff to further reduce length of stay in
Dutch hospitals, including a further increase in the share of
same-day surgery, reducing waiting times for examinations,
implementing acute stroke units, and promoting early
discharge planning and follow-up (Borghans et al., 2012).
Focusing on average length of stay for specific diseases
or conditions can remove some of the heterogeneity that
may arise from the different mix and severity of conditions
across countries. Figure 3.7.2 shows that the average length
of stay for a normal delivery ranges from less than two days
in Turkey, Iceland, the United Kingdom and the Netherlands,
to five days or more in the Slovak Republic, Romania, Croatia
and Switzerland. The length of stay for a normal delivery
has become shorter in nearly all countries over the past
decade, dropping from five days in 2000 to about three-and-
a-half days in 2010 on average in EU member states.
Lengths of stay following acute myocardial infarction
(AMI, or heart attack) also declined over the past ten years.
In 2010, it was the lowest in Denmark, Norway and Turkey,
at four days or less. At the other end of the scale, it was
highest in Estonia, Germany, Lithuania and Croatia, at over
nine days (Figure 3.7.3). In this latter group of countries,
long average length of stays may be due to the fact that
some patients originally admitted for AMI are no longer
receiving acute care, but nonetheless stay in hospitals for a
certain period to receive post-acute care.
Definition and comparability
Average length of stay (ALOS) refers to the average
number of days that patients spend in hospital. It is
generally measured by dividing the total number of
days stayed by all inpatients during a year by the
number of admissions or discharges. Day cases are
excluded.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201280
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3.7.1. Average length of stay in hospital for all causes, 2000 and 2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO European Health for All Database.
1 2 http://dx.doi.org/10.1787/888932704475
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3.7.2. Average length of stay for normal delivery, 
2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database.
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3.7.3. Average length of stay for acute myocardial 
infarction (AMI), 2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932704513
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3.8. CARDIAC PROCEDURES (CORONARY ANGIOPLASTY)Heart diseases are a leading cause of hospitalisation
and death in European countries (see Indicator 1.4). Coro-
nary angioplasty is a procedure that has revolutionised the
treatment of ischemic heart diseases over the past twenty
years, involving the use of a minimally invasive technique to
re-open the obstructed coronary arteries rather than an
open-chest bypass surgery. The placement of a stent to keep
the artery open accompanies the majority of angioplasties.
There is considerable variation across European
countries in the use of coronary angioplasty (Figure 3.8.1).
Germany, Belgium and Austria had the highest rates of
angioplasty in 2010, although the rates in these three
countries are overestimated because they are based on a
count of all procedures rather than based on a count of
patients (see the box on “Definition and comparability”).
The angioplasty rate was the lowest in Ireland, Poland,
Romania and the United Kingdom. However, in these latter
two countries, the data do not cover activities in private
hospitals, resulting in some underestimation.
The use of angioplasty has increased rapidly since 1990
in most European countries, overtaking coronary bypass
surgery as the preferred method of revascularisation around
the mid-1990s – about the same time that the first published
trials of the efficacy of coronary stenting began to appear
(Moïse, 2003). In most European countries, angioplasty
now accounts for at least 70% of all revascularisations
(Figure 3.8.2). The EU average is close to 80%. For a large
number of EU countries, the growth in angioplasty was
higher between 2000 and 2005, compared to the 2005-10
period. Countries such as Romania, Spain and Sweden,
which had low rates of angioplasty in 2000, have witnessed
high annual growth rates since then. Whilst variation in the
use of angioplasty persists, the degree of variation has
diminished over the past decade, as many countries have
caught up with the early adopters of this technology.
Coronary angioplasty has expanded surgical treatment
options to wider sections of the patient population, although
a UK study found that approximately 30% of all angioplasty
procedures are a direct substitute for bypass surgery
(McGuire et al., 2010). Angioplasty is however not a perfect
substitute since bypass surgery is still the preferred method
for treating patients with multiple-vessel obstructions,
diabetes and other conditions (Taggart, 2009).
Coronary angioplasty is an expensive intervention,
but it is much less costly than a coronary bypass surgery
because it is less invasive. The estimated price of an angio-
plasty on average across European countries was about
EUR 5 900 in 2009 compared with EUR 15 300 for a coronary
bypass. Hence, for patients who would otherwise have
received bypass surgery, the introduction of angioplasty
has not only improved outcomes but has also decreased
costs. However, because of the expansion of surgical inter-
ventions, overall costs have risen.
A number of reasons can explain cross-country varia-
tions in the rate of angioplasty, including: i) differences in
the incidence and prevalence of ischemic heart diseases;
ii) differences in the capacity to deliver and pay for these
procedures; iii) differences in clinical treatment guidelines
and practices; and iv) differences in coding and reporting
practices.
Definition and comparability
The data relate to inpatient procedures, excluding
coronary angioplasties performed or recorded as day
cases. In most countries, the data refer to the number
of patients who have received an angioplasty during a
hospital stay, except in Austria, Belgium, Germany
and Slovenia where they are based on a count of all
procedures (including possibly several procedures per
patient), leading to an overestimation compared with
other countries.
In Ireland and the United Kingdom, the data only
include activities in publicly-funded hospitals, result-
ing in an underestimation (it is estimated that over
10% of all hospital activity in Ireland is undertaken in
private hospitals). Data for Portugal relate only to
public hospitals on the mainland.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201282
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3.8.1. Coronary angioplasty per 100 000 population, 2010 and change between 2000 and 2010
Note: Some of the variations across countries are due to different classification systems and recording practices.
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932704532
3.8.2. Coronary angioplasty as a share of total revascularisation procedures, 2000 and 2010 (or nearest year)
Note: Revascularisation procedures include coronary bypass and angioplasty.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932704551
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3.9. CATARACT SURGERIESIn the past two decades, the number of surgical proce-
dures carried out on a same-day basis, without any need
for hospitalisation, has grown in European countries.
Advances in medical technologies, particularly the diffu-
sion of less invasive surgical interventions, and better
anaesthetics have made this development possible. These
innovations have also improved patient safety and health
outcomes for patients, and have in many cases reduced the
unit cost per intervention by shortening the length of stay
in hospitals. However, the impact of the rise in same-day
surgeries on health spending depends not only on changes
in their unit cost, but also on the growth in the volume of
procedures performed. There is also a need to take into
account any additional cost related to post-acute care and
community health services following the intervention.
Cataract surgery provides a good example of a high
volume surgery which is now carried out predominantly on
a same-day basis in most European countries. The operation
began to change from an inpatient to a same-day surgery in
the 1980s in some countries such as Sweden (Henning et al.,
1985), with the movement then spreading to other European
countries at different speed. From a medical point of view,
a cataract surgery using modern techniques should not
normally require an hospitalisation. However, in some
specific cases (e.g. general anesthesia or severe comorbidi-
ties), a hospital stay may be required (Lundström et al., 2012).
Day surgery now accounts for over 90% of all cataract
surgeries in many countries (Figure 3.9.1). However, the use
of day surgery is still relatively low in some countries, such
as Lithuania, Poland and the Slovak Republic. This may
be explained by more advantageous reimbursement for
inpatient stays, national regulations, obstacles to changing
individual practices of surgeons and anaesthetists, and
tradition (Castoro et al., 2007). These low rates may also
reflect limitations in data coverage of outpatient activities
in hospitals or outside hospitals.
The number of cataract surgeries performed on a same-
day basis has grown very rapidly in some countries over the
past ten years, such as in Austria and Portugal (Figure 3.9.2),
catching up to the high rates already observed in 2000 in
Nordic countries, the Netherlands and Spain. In Portugal,
the strong rise in the number of cataract surgeries
performed as day cases rather than as inpatients has led to
a sharp increase in the share of same-day surgery, rising
from less than 10% in 2000 to over 90% in 2010 (Figure 3.9.1).
In France, this share also increased from 32% in 2000 to 80%
in 2010. In Luxembourg, the number of cataract surgeries
carried out as day cases and outpatient cases (in or outside
hospitals) has also risen rapidly, although they still account
for only about half of all cataract surgeries.
Cataract surgery has now become the most frequent
surgical procedure in many European countries. The opera-
tion is performed more often in women than men (around
60% vs. 40%), because it is related to age and women live
longer (Lundström et al., 2012). While population ageing is
one of the factors behind the rise in cataract surgery, the
proven success, safety and cost-effectiveness of the opera-
tion as a day procedure has been a more important factor
(Fedorowicz et al., 2004).
In Sweden, there is evidence that cataract surgeries
are now being performed on patients suffering from less
severe vision problems compared to ten years ago. This
raises the issue of how the needs of these patients should
be prioritised relative to other patient groups (Swedish
Association of Local Authorities and Regions and National
Board of Health and Welfare, 2010). The European Registry
of Quality Outcomes for Cataract and Refractive Surgery
recently developed evidence-based guidelines to improve
treatment and standards of care for cataract surgery
(Lundström et al., 2012).
Definition and comparability
Cataract surgeries consist of removing the lens of the
eye because of the presence of cataracts which are
partially or completely clouding the lens, and replacing
it with an artificial lens. The surgery may involve in
certain cases an overnight stay in hospital (inpatient
cases), but in many countries it is now performed
mainly as day cases (defined as a patient admitted to
the hospital and discharged the same day) or outpatient
cases in hospitals or outside hospitals (without any
formal admission and discharge). However, the data for
many countries do not include such outpatient cases in
hospitals or outside hospitals, with the exception of the
Czech Republic, France, Hungary and Luxembourg
where they are included. Caution is therefore required
in making cross-country comparisons of available data,
given the incomplete coverage of same-day surgeries in
several countries.
In Denmark, Ireland, the Netherlands and the
United Kingdom, the data only include cataract
surgeries carried out in public hospitals, excluding
any procedures performed in private hospitals and in
the ambulatory sector (in Ireland, it is estimated that
over 10% of all hospital activity is undertaken in
private hospitals). The data for Spain only partially
include activities in private hospitals.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201284
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3.9.1. Share of cataract surgeries carried out as day cases, 2000 and 2010 (or nearest year)
1. Data for the Czech Republic, France, Luxembourg and Hungary include outpatient cases in hospitals and outside hospitals.
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932704570
3.9.2. Growth in cataract surgeries per capita, day cases and inpatient cases, 2000 to 2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932704589
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3.10. HIP AND KNEE REPLACEMENTSignificant advancements in surgical treatment have
provided effective options to reduce the pain and disability
associated with certain musculoskeletal conditions. Joint
replacement surgery (hip and knee replacement) is consid-
ered the most effective intervention for severe osteo-
arthritis, reducing pain and disability and restoring some
patients to near normal function.
Ostheoarthritis is one of the ten most disabling
diseases in developed countries. Worldwide estimates are
that 9.6% of men and 18.0% of women aged over 60 years
have symptomatic osteoarthritis, including moderate and
severe forms (WHO, 2010a). Age is the strongest predictor
of the development and progression of osteoarthritis. It is
more common in women, increasing after the age of 50
especially in the hand and knee. Other risk factors include
obesity, physical inactivity, smoking, excess alcohol and
injuries (EC, 2008b). While joint replacement surgery is
mainly carried out among people aged 60 and over, it can
also be performed among people at younger ages.
Austria, Belgium, Germany and Switzerland have
the highest rates of hip replacement (Figure 3.10.1). These
countries also have the highest rates of knee replacement,
along with Finland (Figure 3.10.2). Differences in population
structure may explain part of these variations across
countries, and age-standardisation reduces to some extent
the variations across countries. But still, large differences
remain and the country ranking does not change significantly
after age standardisation (McPherson et al., 2012). Beyond
different population structures, a number of other reasons
may explain cross-country variations in the rate of hip and
knee replacement: i) differences in the prevalence of osteo-
arthritis problems; ii) differences in the capacity to deliver
and pay for these expensive procedures; and iii) differences in
clinical treatment guidelines and practices.
The rate of hip and knee replacement has increased
over the past ten years in many European countries, due in
part to population ageing but also the growing use of these
interventions to improve functioning among elderly people
(Figures 3.10.3 and 3.10.4). In Denmark, the hip replace-
ment rate increased by 40% between 2000 and 2010, while
the knee replacement rate more than tripled. Similarly, in
Spain, the hip replacement rate increased by 25% and the
knee replacement rate more than doubled during the past
decade. The growth rate for both interventions was some-
what slower in France, but still the hip replacement rate
increased by nearly 10% while the knee replacement rate
rose by 60% between 2000 and 2010.
The growing volume of hip and knee replacement is
contributing to health expenditure growth since these are
expensive interventions. In 2009, the estimated price of a
hip replacement on average across European countries was
about EUR 7 300, while the price of a knee replacement was
EUR 6 800.
Definition and comparability
Hip replacement is a surgical procedure in which
the hip joint is replaced by a prosthetic implant. It is
generally conducted to relieve arthritis pain or treat
severe physical joint damage following hip fracture.
Knee replacement is a surgical procedure to replace
the weight-bearing surfaces of the knee joint to
relieve the pain and disability of osteoarthritis. It
may be performed for other knee diseases such as
rheumatoid arthritis.
Classification systems and registration practices
vary across countries which may affect the compara-
bility of the data. Some countries only include total
hip replacement (e.g. Estonia) while most also include
partial replacement. Certain countries only include
initial knee replacement while others also include
revisions.
In Ireland, the data only include activities in
publicly-funded hospitals (it is estimated that over
10% of all hospital activity is undertaken in private
hospitals).HEALTH AT A GLANCE: EUROPE 2012 © OECD 201286
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3.10.1. Hip replacement surgery,
per 100 000 population, 2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932704608
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3.10.2. Knee replacement surgery, 
per 100 000 population, 2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database.
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3.10.3. Trend in hip replacement surgery,
2000-10, selected countries
Source: OECD Health Data 2012; Eurostat Statistics Database.
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3.10.4. Trend in knee replacement surgery,
2000-10, selected countries
Source: OECD Health Data 2012; Eurostat Statistics Database.
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3.11. PHARMACEUTICAL CONSUMPTIONThe consumption of pharmaceuticals has increased
over the past decade not only in terms of expenditure (see
Indicator 5.5 “Pharmaceutical expenditure”), but also in
terms of the volume or quantity of medicines consumed.
This section reviews trends in the volume of consumption of
three categories of pharmaceuticals: antibiotics, antidiabet-
ics and antidepressants. Consumption of these medicines is
measured through the defined daily dose (DDD) unit, as
recommended by the WHO Collaborating Center for Drug
Statistics (see the box on “Definition and comparability”).
Antibiotics should not be used needlessly, as there is a
clear correlation between their use and the emergence of
resistant bacterial strains (Bronzwaer et al., 2002; Goossens
et al., 2005). As with any other prescribed medicines, over-
prescribing exposes patients unnecessarily to risks of
side-effects without achieving more rapid recovery (Fahey
et al., 2004).
The use of antibiotics varies across European countries,
ranging from 10 DDDs per 1 000 people per day in Latvia, the
Netherlands and Romania, to over 30 in Greece and Cyprus
(Figure 3.11.1). Consumption has stabilised in several
countries over the past decade, and it has decreased in some
countries including Estonia, France, Hungary, Portugal and
Slovenia. But antibiotic use has risen in other countries such
as Belgium, Greece and Italy which already had higher-than-
average consumption in 2000, thereby widening the gap with
other European countries. One way of reducing unnecessary
use is to avoid prescribing them for mild and/or viral infec-
tions. Many countries have launched information campaigns
targeting physicians and patients to reduce consumption. At
the international level, WHO launched in 2011 a campaign to
stimulate co-ordinated efforts to promote appropriate and
rational use of antibiotics (WHO, 2012b).
Clinical guidelines in different European countries
recommend the use of various medicines to treat people
with diabetes to reduce the risk of cardiovascular and micro-
vascular complications (Beckman et al., 2002; UKPDS, 1998).
There is wide variation in the use of medicines for the
treatment of diabetes across European countries, with
consumption in Iceland and Estonia almost half that in
Finland or Germany (Figure 3.11.2). This can be partly
explained by the prevalence of diabetes, which is low in
Iceland (see Indicator 1.10). However, some of the countries
with the highest consumption do not have high diabetes
prevalence (e.g. Finland, Germany and the United Kingdom).
Between 2000 and 2010, the consumption of antidiabetics
increased by 75% on average across EU member states. The
growth rate was particularly strong in Finland, Germany and
the Slovak Republic. The main reasons for this strong rise
are increases in the proportion of people treated and the
average dosages used in treatments (Melander et al., 2006).
Guidelines for the pharmaceutical treatment of
depression vary across countries, and there is also great
variation in prescribing behaviors among general practi-
tioners and psychiatrists not only across countries, but also
among individual practitioners in each country. Iceland
has the highest level of consumption of antidepressants,
followed by Denmark and Portugal (Figure 3.11.3). Part of
the explanation for the high consumption in Iceland is that
a much higher proportion of the population receives at
least one prescription for an antidepressant each year.
In 2008, almost 30% of women aged 65 and over had an
antidepressant prescription in Iceland, compared with less
than 15% in Norway (NOMESCO, 2010). But the intensity
and duration of treatments also play a role in explaining
variations across countries and trends over time. In all
European countries for which data is available, the
consumption of antidepressants has increased a lot over
the past decade, by over 80% on average across EU member
states. While some analysts interpret these findings as
evidence of a growing prevalence of depression, this also
reflects greater efforts to provide treatments to people
suffering from severe depression and greater intensity of
these treatments. This rise can also be explained by the
extension of the set of indications of some antidepressants
to milder forms of depression, generalised anxiety disor-
ders or social phobia, which have raised issues in some
countries about the appropriateness of such extensions of
prescriptions.
Definition and comparability
Defined daily dose (DDD) is the assumed average
maintenance dose per day for a medicine used for its
main indication in adults. DDDs are assigned to each
active ingredient(s) in a given therapeutic class by
international expert consensus. For instance, the
DDD for oral aspirin equals 3 grams, which is the
assumed maintenance daily dose to treat pain in
adults. DDDs do not necessarily reflect the average
daily dose actually used in a given country. DDDs can
be aggregated within and across therapeutic classes
of the Anatomic-Therapeutic Classification (ATC). For
more detail, see www.whocc.no/atcddd.
Data generally refer to outpatient consumption
except for the Czech Republic, Finland and Sweden,
where data also include hospital consumption. Greek
figures may include parallel exports.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201288
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3.11.1. Antibiotics consumption, 2000 and 2010 (or nearest year)
Source: OECD Health Data 2012; European Surveillance of Antimicrobial Consumption (ESAC) project, 2011.
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3.11.2. Antidiabetics consumption,
2000 and 2010 (or nearest year)
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932704703
2000 2010
0 25 50 75 100
45
48
51
55
56
56
57
58
59
62
63
66
68
71
74
75
81
83
32
48
Defined daily dose, per 1 000 people per day
Estonia
Denmark
Sweden
Italy
Slovenia
Spain
Belgium
Slovak Republic
Luxembourg
EU15
Portugal
France
Netherlands
Hungary
Czech Republic
United Kingdom
Germany
Finland
Iceland
Norway
3.11.3. Antidepressants consumption,
2000 and 2010 (or nearest year)
Source: OECD Health Data 2012.
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3.12. UNMET HEALTH CARE NEEDSAll European countries endorse equity of access to
health care for all people as an important policy objective.
One method of gauging to what extent this objective is
achieved is through assessing reports of unmet needs for
health care. The problems that people report in obtaining
care when they are ill or injured often reflect significant
barriers to care.
Some common reasons given for not receiving care
include excessive treatment costs, long waiting times, not
being able to take time off work or needing to look after
children, or having to travel too far to receive care. Differences
in the reporting of unmet care needs across countries may be
due partly to socio-cultural differences. However, these
factors play a lesser role in explaining any differences among
population groups within each country. It is also important to
consider self-reported unmet care needs in conjunction with
other indicators of potential barriers to access, such as the
extent of health insurance coverage and the amount of
out-of-pocket payments (see Indicators 5.1 “Coverage for
health care” and 5.6 “Financing of health care”).
In all European countries, a majority of the population
reported no unmet care needs, according to the 2010
EU Statistics on Income and Living Conditions survey
(EU-SILC). However, in some countries, significant propor-
tions of people reported having unmet needs. In Bulgaria,
Croatia, Latvia, Poland, Romania and Sweden, more than
10% of survey respondents had an unmet need for a
medical examination, and the burden fell heaviest on low
income earners, particularly in Bulgaria and Latvia
(Figure 3.12.1). On average across EU member states, twice
as many low income earners reported unmet needs as did
high income earners, indicating that affordability remains
an important issue for some population groups.
The most common reason for not obtaining care was
because of treatment costs, and this was particularly the
case in Latvia and Romania. Waiting times were an issue
for some people in Bulgaria, Estonia, Finland and Poland.
Generally, women tend to report slightly more unmet
health care needs than men. Aside from people in low-
income groups, those who are unemployed or less
educated are also more likely to report unmet needs
(Figure 3.12.3).
A larger proportion of the population indicates unmet
needs for dental care than for medical care. Often, dental
care is only partially included, or not included at all in
basic health care coverage, and so must either be paid
out-of-pocket, or covered through purchasing private health
insurance. Latvia (21.5%) reported the highest rates of unmet
need for a dental examination in 2010, followed by Bulgaria,
Portugal, Romania, Cyprus, Iceland, Italy and Poland (all
between 10-15%) (Figure 3.12.2). Large inequalities in unmet
dental care needs were evident between high and low
income groups in most of these countries. The population in
Belgium, the Netherlands, Slovenia and the United Kingdom
reported the lowest rates of unmet dental care needs in 2010
(between 1% and 3% only), according to EU-SILC.
Definition and comparability
Questions on unmet health care needs are a feature
of a number of national and cross-national health
interview surveys, including the European Union
Statistics on Income and Living Conditions survey
(EU-SILC). To determine unmet medical and dental
care, individuals are asked in EU-SILC whether there
was a time in the previous 12 months when they felt
they needed health care or dental care services but
did not receive them, followed by a question as to why
the need for care was unmet. Common reasons given
include that care was too expensive, the waiting time
was too long, or wanting to wait to see if the problem
would get better.
Cultural factors and policy debates may affect
responses to questions about unmet care. Caution is
therefore needed in comparing the magnitude of
inequalities across countries.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201290
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3.12.1. Unmet need for a medical examination, 
by income quintile, 2010
Source: Eurostat Statistics Database, based on EU-SILC.
1 2 http://dx.doi.org/10.1787/888932704741
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3.12.2. Unmet need for a dental examination,
by income quintile, 2010
Source: Eurostat Statistics Database, based on EU-SILC.
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3.12.3. Inequalities in unmet need for a medical examination, EU27 average, 2010
Source: Eurostat Statistics Database, based on EU-SILC.
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CARE FOR CHRONIC CONDITIONS • 4.1. AVOIDABLE ADMISSIONS: RESPIRATORY DISEASESBoth asthma and chronic obstructive pulmonary
disease (COPD) are, to a considerable degree, either pre-
ventable or manageable through proper prevention or
primary care interventions. Proper management of these
chronic conditions in primary care settings can reduce
exacerbation and costly hospitalisation (Menn et al., 2012).
Hospital admission rates serve as a proxy for primary care
quality, whereby high admission rates may point to poor
care co-ordination or care continuity. They may also
indicate structural constraints such as an inadequate
supply of family physicians (Rosano et al., 2012).
Asthma is a condition that affects the airways that
carry air in and out of the lungs. Asthma symptoms are
usually intermittent and treatment can be highly effective,
even often reversing the effects of bronchial irritation. A
recent survey conducted in 70 countries showed that the
global prevalence of clinically treated asthma in adults was
estimated to be 4.5%. However, asthma prevalence in some
European countries was amongst the highest in the world,
with the Netherlands, Sweden and the United Kingdom
having prevalence rates of 15% or higher (To et al., 2012).
COPD, on the other hand, is a progressive disease. It affects
around 64 million worldwide and tobacco use is a major
risk factor (WHO, 2011a). In 2008, COPD accounted for
around 3% of total deaths in the European Union (WHO,
2011b). A Danish study found that COPD patients use over
three times as many hospital bed-days and twice as many
general practice visits as similar aged patients without
COPD; overall, COPD accounted for 6% of the total annual
health care costs of treating the population aged 40 and
over (Bilde et al., 2007).
 Figure 4.1.1 shows that among the EU member states,
asthma accounts for an average of 53 hospital admissions
per 100 000 population in 2009. Asthma-related admissions
in the Slovak Republic and Latvia were more than double the
EU average, whereas Portugal, Italy, Sweden and Germany
report rates that are less than half the EU average. Adult
females experienced higher rates for asthma admissions
compared to males in all countries. On average, the female
admission rate was around 70% higher than the male
hospitalisation rate. This is in contrast to the results found
amongst children where both asthma prevalence and
hospital admissions are highest amongst boys (Lin and Lee,
2008). The reasons for gender differences in asthma-
related hospital admissions are not well understood
(Melero-Moreno et al., 2012). The incidence of asthma among
women has increased and “asthmatic women have poorer
quality of life and increased utilisation of health care
compared to males, despite having similar medical treat-
ment and baseline pulmonary function” (Kynyk et al., 2011).
As shown in Figure 4.1.2, the average COPD-related
admission rate was 184 per 100 000 population in EU member
states in 2009, nearly four times greater than for asthma. By
contrast to asthma-related admissions, males had a higher
COPD admission rates than females in most countries.
Notable exceptions were Denmark, Iceland, Norway and
Sweden where there were no statistically significant differ-
ences between males and females. Ireland and Austria have
the highest admission rates for COPD. Portugal, France and
Switzerland have rates that are less than half the EU average.
Whilst some of the variation undoubtedly reflects differences
in smoking rates, there is evidence that differences in the
quality of care may also play an important role. Based on
preliminary results of a 13 European countrywide evaluation,
both process of care and outcomes vary considerably between
and within countries. The evaluation showed that approxi-
mately 50% of COPD admissions lead to a re-admission or
death within 90 days (Hartl et al., 2011).
Definitions and comparability
The asthma and COPD indicators are defined as the
number of hospital discharges of people aged 15 years
and over per 100 000 population, adjusted to take
account of the age and sex composition of each
country’s population structure. Differences in diagnosis
and coding between asthma and COPD across countries
may limit the precision of the specific disease rates.
Differences in disease classification systems, for
example between ICD-9-CM and ICD-10-AM, may also
affect the comparability of the data.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201294
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4.1.1. Asthma hospital admission rates, population aged 15 and over, 2009 (or nearest year)
Note: Rates are age-sex standardised to the 2005 OECD standard population. 95% confidence intervals represented by H.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932704798
4.1.2. COPD hospital admission rates, population aged 15 and over, 2009 (or nearest year)
Note: Rates are age-sex standardised to the 2005 OECD standard population. 95% confidence intervals represented by H.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932704817
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CARE FOR CHRONIC CONDITIONS • 4.2. AVOIDABLE ADMISSIONS: UNCONTROLLED DIABETESThe health and economic burden of diabetes continues
to rise. Across the European Union there are an estimated
31 million adults living with diabetes and many people
remain undiagnosed (Mladovsky et al., 2009). Diabetes leads
to an increased risk of cardiovascular disease, blindness,
kidney disease, lower limb amputation and mortality. Across
Europe, the treatment and management of diabetes has
been estimated to account for approximately 10% of total
health care expenditure (Zhang et al., 2010).
There is a considerable body of evidence on how best
to prevent and treat diabetes. Modest weight loss and
dietary changes can delay or even prevent the onset of
diabetes by almost 60% (DPP, 2002). Better management of
blood glucose levels in Type 2 diabetes patients can reduce
microvascular complications by 25% (UKPDS, 1998) and
non-fatal myocardial infarctions by 17% (Ray et al., 2009).
However, health care systems have historically struggled
with optimising diabetes care and many patients do not
seek treatment until complications have set in.
 Figure 4.2.1 shows the extent to which the failure of
effectively controlling and managing diabetes manifests in
avoidable hospital admissions. The figure shows that the
EU average for uncontrolled diabetes admissions (without
complications) is 50 per 100 000 population. For admissions
with short- and long-term diabetes complications, the
EU average is 109 per 100 000 population. Males tend to have
higher admission rates than females even though evidence
suggests that there are no significant gender differences in
diabetes prevalence (DECODE Study Group, 2003).
Figure 4.2.2 examines the relationship between diabe-
tes prevalence and avoidable admissions. The line in the
graph indicates that countries with higher disease preva-
lence tend to have higher rates of diabetes-related admis-
sions. However, substantial variations remain even after
controlling for disease prevalence, with countries such as
Austria, the Czech Republic and Poland having higher rates
of admissions, whereas Spain, Switzerland and Portugal
experience lower rates. The variation in diabetes-related
hospital admissions (after taking prevalence into account)
suggests that other factors, such as adherence to high-
quality diabetes care, may also play a role.
In combating the challenges posed by diabetes, a
number of countries have introduced initiatives to reduce
the impact of the disease. For example, a number of
European countries have recently introduced taxes on
unhealthy food and drink to promote better nutrition and
reduce obesity, an important risk factor for diabetes (OECD,
2012b). Austria has introduced a disease management
programme, with early indications showing some success in
process quality and enhanced weight loss, but no significant
improvement in diabetes control (Sönnichsen et al., 2010).
As part of the United Kingdom’s Quality and Outcomes
Framework, up to 25% of British practice income is linked to
performance, including a range of diabetes indicators such
as glucose control, medication compliance and foot care
(Adler, 2012). In France, results from a two year pay-for-
performance pilot has shown positive results in diabetes
management through better medication compliance and
glucose control (Polton, 2012).
Alongside national initiatives, there are also some
recent examples of international diabetes collaborations.
In April 2012, the European Diabetes Leadership Forum
brought together a wide range of stakeholders to produce
the Copenhagen Roadmap outlining initiatives to improve
diabetes prevention, early detection and intervention as
well as management and control (see www.diabetesleader-
shipforum.eu for more information). In the European Union,
the EUBIROD Project has developed a European Diabetes
Register that brings together data from across Europe. The
registry allows comparisons across Europe on how diabetes
is treated and share knowledge to reduce the burden of
diabetes (EC, 2012b).
Definitions and comparability
The indicator for uncontrolled diabetes hospital
admission rates with and without complications is
based on the sum of the three indicators: i) short-
term diabetes complications; ii) long-term diabetes
complications; and iii) uncontrolled diabetes without
complications.
The indicator for admissions with short-term dia-
betes complications is defined as all non-maternal/
non-neonatal hospital admissions of people aged
15 years and over with a principal diagnosis code for
diabetes short-term complications including coma
and ketoacidosis, caused by a shortage of insulin in
the body. The indicator for long-term diabetes
complications is defined similarly but where the
principal diagnosis code indicates the presence of
long-term diabetes complications such as renal, eye
or circulatory complications. The indicator for
uncontrolled diabetes without complications is
defined as all non-maternal/non-neonatal hospital
admissions of people aged 15 years and over with a
principal diagnosis code for uncontrolled diabetes,
without mention of a short-term or long-term
complication.
The rates are per 100 000 population and have been
adjusted to take account of the age and sex composition
of each country’s population structure. Differences in
coding practices among countries may affect the
comparability of data. Differences in disease classifica-
tion systems, for example between ICD-9-CM and
ICD-10-AM, may also affect the comparability of the
data.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201296
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4.2.1. Uncontrolled diabetes hospital admission rates with and without complications,
population aged 15 and over, 2009 (or nearest year)
Note: Rates are age-sex standardised to the 2005 OECD standard population. Male and female rates refer to the sum of admissions with and without
diabetes complications.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932704836
4.2.2. Uncontrolled diabetes hospital admission rates and prevalence of diabetes, 2009 (or nearest year)
Note: Prevalence estimates of diabetes refer to adults aged 20-79 years and data are age-standardised to the World Standard Population. Hospital
admission rates refer to the population aged 15 and over and are age-sex standardised to the 2005 OECD standard population.
Source: IDF (2009) for prevalence estimates; OECD Health Data 2012 for hospital admission rates.
1 2 http://dx.doi.org/10.1787/888932704855
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ACUTE CARE • 4.3. IN-HOSPITAL MORTALITY FOLLOWING ACUTE MYOCARDIAL INFARCTIONCare for AMI (heart attack) has changed dramatically
in recent decades (Khush et al., 2005; Gil et al., 1999). Clini-
cal practice guidelines, such as those developed by the
European Society of Cardiology, provide clinicians with the
best available evidence on how to optimise care. Numerous
studies have shown that greater compliance with guide-
lines improves health outcomes (e.g. Schiele et al., 2005;
Eagle et al., 2005). However, a considerable proportion of
AMI patients do not receive recommended care (Brekke
and Gjelsvik, 2009; Kotseva et al., 2009).
AMI case-fatality rates refer to the percentage of
patients who die within 30 days after a hospital admission
for AMI. This rate is a good measure of acute care quality
because there is a clear link between the processes of care
and health outcomes (Bradley et al., 2006). AMI case-fatality
rates have been used for hospital benchmarking in several
countries including Denmark and the United Kingdom, and
have been used in the academic literature as a wider
marker for hospital quality (e.g. Kessler and Geppert, 2005;
Cooper et al., 2011). However, the indicator is influenced by
not only the quality of care provided in hospitals but also
differences in hospital transfers, average length of stay,
emergency retrieval times and average severity of AMI.
 Figure 4.3.1 shows the crude and age-standardised
AMI case-fatality rates, when the death occurs within a
30-day period and in the same hospital as the initial AMI
admission. The average age-standardised AMI case-fatality
rate across the European Union is 5% but rates vary widely
between countries. The lowest age-standardised rates are
found in Denmark and Norway (2.3% and 2.5%, respec-
tively) and the highest rate is in Belgium (8.6%), although
some of the variation between countries may be explained
by differences in data definitions (see box on “Definitions
and comparability”). The Minister of Health in Belgium
introduced new reforms in 2012 that aim to minimise
response time for cardiac interventions, improve
co-operation within provider networks, set new care
standards, as well as new minimum activity thresholds in
hospitals which are aimed at reducing AMI case-fatality
rates (Onkelinx, 2012).
Patient-based data, which follow patients in and out of
hospitals and across hospitals, is a more robust indicator
for international comparison than admission-based data,
as admission-based data may bias case-fatality rates
downwards if unstable cardiac patients are commonly
transferred to tertiary care centres. Unfortunately, patient-
based data is only available for a relatively small group of
countries. Figure 4.3.2 presents AMI case-fatality rates for
the nine countries for which both admission-based and
patient-based data are available. It confirms that patient-
based indicators are higher than hospital-based rates,
but the degree of cross-country variation is considerably
less compared to the admission-based indicator. The
average patient-based AMI case-fatality rate is 6.9% and
ranges from 5.5% (Sweden) to 7.8% (Slovenia).
Case-fatality rates for AMI have decreased over time,
with almost all countries recording sizeable reductions
between 2000 and 2009 (Figure 4.3.3). The AMI case-fatality
rate for the ten EU member states reporting data over this
period fell by nearly 50% between 2000 and 2009. These
substantial improvements reflect better and more reliable
processes of care, in particular with respect to rapid
re-opening of the occluded arteries. Most of these improve-
ments were made between 2000 and 2005, with fewer gains
in more recent years.
Definitions and comparability
In-hospital case-fatality rate following AMI is
defined as the number of people who die within
30 days of being admitted (including same day admis-
sions) to hospital with an AMI. Ideally, rates would
be based on individual patients; however, not all
countries have the ability to track patients in and out
of hospitals, across hospitals or even within the same
hospital because they do not currently use a unique
patient identifier. In order to increase country
coverage, this indicator is also presented based on
individual hospital admissions and restricted to
mortality within the same hospital, so differences in
practices in discharging and transferring patients
may influence the findings. In counting the number
of AMI admissions, Belgium excludes transfers to
other hospitals from the denominator leading to
some over-estimation.
Both crude and age-sex standardised rates are
presented for admission-based data. Standardised
rates adjust for differences in age (45+ years) and sex
and facilitate more meaningful international compar-
isons. Crude rates are likely to be more meaningful for
internal consideration by individual countries.HEALTH AT A GLANCE: EUROPE 2012 © OECD 201298
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4.3.1. Admission-based in-hospital case-fatality rates within 30 days after admission for AMI,
2009 (or nearest year)
Note: Rates are age-sex standardised to the 2005 OECD standard population (45+). 95% confidence intervals represented by H.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932704874
4.3.2. Comparing admission-based and patient-based in-hospital case-fatality rates within 30 days 
after admission for AMI, selected EU countries, 2009 (or nearest year)
Note: Rates are age-sex standardised to the 2005 OECD standard population (45+). 95% confidence intervals represented by H.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932704893
4.3.3. Reduction in in-hospital case-fatality rates within 30 days after admission for AMI,
2000-09 (or nearest year)
Note: Rates are age-sex standardised to the 2005 OECD standard population (45+). 95% confidence intervals represented by H.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932704912
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ACUTE CARE • 4.4. IN-HOSPITAL MORTALITY FOLLOWING STROKEIn Europe, stroke and other cerebrovascular diseases
account for around 9% of all deaths and are the third most
common cause of death (OECD, 2012a, based on the WHO
Mortality Database). Stroke is also a major cause of adult
disability. Around one third of all stroke incidents lead to
permanent sequelae and dependency (WHO, 2004b). In
ischemic stroke, representing about 85% of cases, the blood
supply to a part of the brain is interrupted, leading to a
necrosis of the affected part, while in hemorrhagic stroke,
the rupture of a blood vessel causes bleeding into the brain,
usually causing more widespread damage.
Treatment for ischemic stroke has advanced dramati-
cally over the last decades. Since the 1990s, clinical trials
have demonstrated clear benefits of thrombolytic treat-
ment for ischemic stroke in both European (e.g. Hacke et al.,
1995) and non-European countries (e.g. Mori et al., 1992;
NINDS, 1995). Dedicated stroke units were introduced in
many countries, to facilitate timely and aggressive diagno-
sis and therapy for ischemic and haemorrhagic stroke
victims, achieving better survival than usual care (Seenan
et al., 2007). Whilst there is only limited international data
on stroke unit access, there are some indications that
access varies across and within countries (OECD, 2003;
Abilleira et al., 2012; Rudd et al., 2007).
Stroke survival reflects quality of acute care, parti-
cularly effective treatment methods such as thrombolysis
and prompt and adequate care delivery (Abilleira et al.,
2012). Consequently, stroke case-fatality rates have been
used for hospital benchmarking within and between OECD
countries.
While the standardised case-fatality rate for ischemic
stroke was about 5.4% on average across EU member states
in 2009, there were large differences between the highest
rate in Slovenia (9.7%) and the lowest rate in Denmark
(2.6%) (Figure 4.4.1). The average standardised rate for
hemorrhagic stroke is 20.2% (Figure 4.4.2), about four times
greater than the rate for ischemic stroke, reflecting the
more severe effects of intracranial bleeding. There is a
six-fold cross-country difference between the highest and
lowest percentage of in-hospital case-fatality for hemor-
rhagic stroke. In Finland, 6.5% of hemorrhagic stroke
admissions lead to a death within 30 days, whereas in
Belgium the corresponding figure is 38.6%. One potential
reason for this is that patients are not systematically trans-
ported to hospitals with dedicated stroke units in Belgium
so that some patients miss out on optimal care. The
variation between countries may also, in part, be explained
by differences in data definitions (see box on “Definitions
and comparability”).
There is a high degree of correlation between the two
case-fatality indicators for ischemic and hemorrhagic
stroke, with countries that achieve better survival for one
type of stroke tending to do well for the other type. This
suggests that system-based factors such as access to speci-
alised stroke care, average length of stay, emergency
retrieval times as well as stroke severity may also influence
the case-fatality rates.
Between 2000 and 2009, case-fatality rates for isch-
emic stroke declined by over 20% across EU member states
(Figure 4.4.3). These reductions suggest overall improve-
ments in the quality of care for stroke patients, with gains
made in most countries for which data is available. How-
ever, improvements were not uniform across countries.
Improvements in Ireland and Portugal were below the
EU average, while the rate in Luxembourg did not change
significantly over the period. On the other hand, Norway
was able to reduce its fatality rate by 55% between 2000
and 2009. The improvements in case-fatality rates can at
least be partially attributed to the high level of access to
dedicated stroke units in countries such as Norway,
Denmark and Sweden (Indredavik, 2009).
Definitions and comparability
In-hospital case-fatality rate following ischemic
and hemorrhagic stroke is defined as the number of
people who die within 30 days of being admitted
(including same day admissions) to hospital. Ideally,
rates would be based on individual patients; however,
not all countries have the ability to track patients in
and out of hospitals, across hospitals or even within
the same hospital because they do not currently use a
unique patient identifier. Therefore, this indicator is
based on unique hospital admissions and restricted
to mortality within the same hospital, so differences
in practices in discharging and transferring patients
may influence the findings. In counting the number
of stroke admissions, Belgium excludes transfers to
other hospitals from the denominator leading to
some over-estimation.
The Czech Republic, Denmark, Finland, Luxembourg,
the Netherlands, Poland, Slovenia, Sweden and the
United Kingdom also provided patient-based (in and out
of hospitals) data. Their relative performance is gener-
ally similar as the case-fatality rate within the same
hospital, although the rates are obviously higher.
Both crude and age and sex standardised rates are
presented. Standardised rates adjust for differences
in age (45+ years) and sex and facilitate more mean-
ingful international comparisons. Crude rates are
likely to be more meaningful for internal consider-
ation by individual countries.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012100
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4.4.1. In-hospital case-fatality rates within 30 days after 
admission for ischemic stroke, 2009 (or nearest year)
Note: Rates are age-sex standardised to the 2005 OECD standard
population (45+). 95% confidence intervals represented by H.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932704931
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4.4.2. In-hospital case-fatality rates within 30 days after 
admission for hemorrhagic stroke, 2009 (or nearest year)
Note: Rates are age-sex standardised to the 2005 OECD standard
population (45+). 95% confidence intervals represented by H.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932704950
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4.4.3. Reduction in in-hospital case-fatality rates within 30 days after admission for ischemic stroke,
2000-09 (or nearest year)
Note: Rates are age-sex standardised to the 2005 OECD standard population (45+). 95% confidence intervals represented by H.
Source: OECD Health Data 2012.
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PATIENT SAFETY • 4.5. PROCEDURAL OR POSTOPERATIVE COMPLICATIONSSeveral European studies have documented that
between 8% and 12% of patients admitted to hospitals
suffer from adverse effects whilst receiving health care
(UK Department of Health, 2000; WHO Europe, 2012b). The
European Commission estimates that without any policy
changes, there are likely to be 10 million adverse events
related to hospitalisations (including infection-related
ones) in the European Union per year, of which almost
4.4 million would be preventable (EC, 2008d).
Patient safety has, in recent years, become an impor-
tant part of the policy agenda in Europe. In 2009, the
Council of the European Union adopted a recommendation
on patient safety, including the prevention and control of
health care associated infections (European Union, 2009).
This recommendation is intended to bring about a political
commitment from all EU member states to address the
patient safety challenge.
Figures 4.5.1 to 4.5.4 show reported complication rates
related to surgical and medical care for four patient safety
indicators: i) sentinel events, such as a foreign body left in a
person during a surgical procedure, are those that in theory
and practice should never happen and thus whose occur-
rence indicates failure of safeguards to protect patients
during care delivery; ii) accidental puncture or laceration
during a surgical procedure is a recognised risk, but increased
rates of such complications may indicate system problems;
iii) postoperative pulmonary embolism and deep vein
thrombosis cause unnecessary pain and death, but can be
prevented through the appropriate use of anticoagulants and
other preventive measures; and iv) sepsis after elective
surgery is a severe complication that can lead to multiple
organ dysfunction and death. Many cases of postoperative
sepsis can be prevented through infection prevention
measures such as hand hygiene, sterile surgical techniques,
good postoperative care and, where necessary, the appro-
priate use of prophylactic antibiotics.
Comparable data are available for between eight and
thirteen European countries, depending on the indicator.
There are considerable differences across countries for
these four patient safety indicators. Whereas Denmark and
Germany report complication rates that are below the
EU average for each of the four patient safety indicators,
other countries show less consistent results. For example,
Belgium, France, Ireland and Switzerland perform well on
some indicators but report worse than EU average results
for others.
Differences in the prevalence of patient safety compli-
cations across countries may reflect – at least in part –
differences in the willingness of health workers to admit to
medical errors as well as differences in the sensitivity of
monitoring or surveillance systems across countries.
Nevertheless, these indicators do show that numerous
patients have been affected by patient safety events. Inter-
national efforts to harmonise documentation and data
systems, and the results of ongoing validation studies, will
provide more information on the validity and reliability of
patient safety measures based on administrative hospital
data in the future.
Definitions and comparability
Patient safety indicators are derived from the Quality
Indicators developed by the US Agency for Healthcare
Research and Quality (AHRQ). AHRQ’s patient safety
indicators are a set of indicators that provide informa-
tion on hospital complications and adverse events
following surgeries, procedures, and childbirth. The
indicators were developed after a comprehensive liter-
ature review, analysis of ICD-9-CM codes, clinician
panel review, implementation of risk adjustment, and
empirical analyses (AHRQ, 2006).
All procedural or postoperative complications are
defined as the number of discharges with ICD codes
for complication in any secondary diagnosis field,
divided by the total number of discharges (medical
and surgical or surgical only) for patients aged 15 and
older. Data are based on administrative hospital
discharge data. The rates have been age/sex stan-
dardised, apart from postoperative sepsis rate (this is
due to the use of modified exclusion criteria within
the algorithm for the calculation of this indicator).The
patient safety rates have also been adjusted by the
average number of secondary diagnoses (SDx)
(Drösler et al., 2011) in order to improve cross-country
comparability. Despite this adjustment, the results for
the two countries (Finland and Italy) that are report-
ing less than 1.5 diagnoses per record may be under-
estimated. Differences in coding practice, coding
rules (e.g. definition of principal and secondary
diagnoses), coding for billing purposes and the use of
diagnosis type markers (e.g. “present at admission”)
may also influence indicators.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012102
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4.5.1. Foreign body left in during procedure,
2009 (or nearest year)
Note: Some of the variations across countries are due to different
classification systems and recording practices. 95% confidence intervals
represented by H.
SDx: Secondary diagnoses adjustment.
1. The average number of secondary diagnoses is < 1.5.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932704988
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4.5.2. Accidental puncture or laceration,
2009 (or nearest year)
Note: Some of the variations across countries are due to different
classification systems and recording practices. 95% confidence intervals
represented by H.
SDx: Secondary diagnoses adjustment.
1. The average number of secondary diagnoses is < 1.5.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932705007
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4.5.3. Postoperative pulmonary embolism
or deep vein thrombosis, 2009 (or nearest year)
Note: Some of the variations across countries are due to different
classification systems and recording practices. 95% confidence intervals
represented by H.
SDx: Secondary diagnoses adjustment.
1. The average number of secondary diagnoses is < 1.5.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932705026
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4.5.4. Postoperative sepsis,
2009 (or nearest year)
Note: Some of the variations across countries are due to different
classification systems and recording practices.
SDx: Secondary diagnoses adjustment.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932705045
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PATIENT SAFETY • 4.6. OBSTETRIC TRAUMAThe patient safety indicators related to obstetric trauma
flag cases of potentially preventable third- and fourth-degree
perineal tears during vaginal delivery. Such tears extending to
the perineal muscles, anal sphincter and bowel wall require
surgical treatment after birth. Possible complications include
continued perineal pain and anal incontinence. A recent
study found that around 10% of women who had such tears
will suffer from faecal incontinence initially (compared to
3% of women who do not have a tear). Almost 45% of women
with initial symptoms had remaining problems after four to
eight years (Sundquist, 2012).
The proportion of deliveries involving higher degree
lacerations is a useful indicator of the quality of obstetrical
care. These types of tears are not possible to prevent in all
cases, but can be reduced by employing appropriate labour
management and care standards. A third- or fourth-degree
trauma is more likely to occur in the case of first vaginal
delivery, baby’s high birth weight, labour induction, occiput
posterior position, prolonged second stage of labour and
instrumental delivery. Obstetric trauma indicators have
been used by the US Joint Commission as well as by differ-
ent international quality initiatives analysing obstetric
data (AHRQ, 2007). As the risk of a perineal laceration is
significantly increased in instrument-assisted labour
(vacuum, forceps), rates for this patient population are
reported separately.
 Figures 4.6.1 and 4.6.2 show the variation in reported
rates of obstetric trauma during vaginal delivery with and
without instrument. The rate of obstetric trauma after
vaginal delivery with instrument shows high variability
among countries. Reported rates vary from below 3%
(Slovenia, Portugal, France, Belgium, and Italy) to more
than 10% (Sweden). Rates of obstetric trauma after vaginal
delivery without instrument range from 0.2% to 3.2%.
Denmark, Sweden and Switzerland stand out as having
the highest reported rates for obstetric trauma without
instrument. The lower rate of obstetric trauma in Finland
compared to other Nordic countries (Denmark, Norway,
and Sweden) may be explained by the variation in delivery
method and episiotomy practice (Laine et al., 2009).
Furthermore, findings from a recent study showed that
enhanced midwifery skills in managing vaginal delivery
reduce the risk of obstetric anal sphincter injuries (Hals
et al., 2010).
There is a strong relationship between the two obste-
tric trauma indicators shown in Figures 4.6.1 and 4.6.2.
Countries such as Belgium, Finland, France, Italy, Portugal,
Slovenia and Spain report lower than EU average obstetric
trauma rates for both indicators. Latvia, on the other hand,
has high rates of trauma when an instrument was used but
low rates when an instrument was not used during deliv-
ery. This makes it more difficult to draw any clear conclu-
sions from these two indicators for Latvia.
Definitions and comparability
The two obstetric trauma indicators are defined as
the proportion of instrument assisted/non-assisted
vaginal deliveries with third- and fourth-degree
obstetric trauma codes in any diagnosis and proce-
dure field. Therefore, any differences in the definition
of principal and secondary diagnoses have no influ-
ence on the calculated rates.
Several differences in data reporting across countries
may influence the calculated rates of obstetric patient
safety indicators. These relate primarily to differences
in coding practice and data sources. Some countries
report the obstetric trauma rates based on administra-
tive hospital data and others based on obstetric regis-
ter. There is some evidence that registries produce
higher quality data and report a greater number of
obstetric trauma events compared to administrative
datasets (Baghestan et al., 2007).
See box on “Definitions and comparability” for
Indicator 4.5 “Procedural or postoperative compli-
cations”, for more information on patient safety
indicators.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012104
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4.6.1. Obstetric trauma, vaginal delivery with instrument, 2009 (or nearest year)
1. Obstetric register data.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932705064
4.6.2. Obstetric trauma, vaginal delivery without instrument, 2009 (or nearest year)
1. Obstetric register data.
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932705083
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CANCER CARE • 4.7. SCREENING, SURVIVAL AND MORTALITY FOR CERVICAL CANCERCervical cancer is mainly the outcome of persistent
infection with human papillomavirus (HPV), which
accounts for approximately 95% of all cases (IARC, 1995;
Franco et al., 1999). Every year 61 000 new cervical cancers
are diagnosed in Europe (IARC, 2011).
Precancerous changes can be detected and treated
before progression to cancer occurs, making cervical
cancer highly preventable. Population-based cervical
screening programmes have been promoted by the Council
of the European Union and the European Commission
(European Union, 2003; EC, 2008c), but the periodicity and
target groups vary among member states.
 Figure 4.7.1 shows cervical screening rates across
European countries in the years 2000 and 2010 for women
aged 20-69 years. In 2010, Latvia, Germany, the United
Kingdom, and Norway reported coverage close to 80% of the
target population. Whilst overall screening rates across the
European Union improved slightly over the past decade,
several countries, including Finland, Hungary, Iceland,
Norway, the Slovak Republic and the United Kingdom
witnessed a decline in screening rates between 2000
and 2010.
Survival rates reflect both how early the cancer was
detected and the effectiveness of the treatment. It is a key
measure of the effectiveness of health care systems to treat
potentially fatal diseases and track progress over time.
Figure 4.7.2 shows a small gain in five-year cervical cancer
survival rates in the European Union between 1997-2002
and 2004-09, although gains were not uniform across
countries. Of the 11 EU member states reporting data in
both periods, seven recorded modest gains in survival rates
whereas four countries (Denmark, Finland, France and
Germany) reported a small decline, although the reduction
was not statistically significant. Norway reported the
highest rates as well as the highest gain in cervical cancer
survival, with 78.2% of patients surviving five years after
diagnosis.
Mortality rates reflect the effect of cancer care in past
years, the impact of screening, improved diagnosis of
early-stage cancers as well as incidence. Mortality rates for
cervical cancer declined in most European countries
between 2000 and 2010, apart from Bulgaria, the Former
Yugoslav Republic of Macedonia and Croatia, Greece and
Ireland (Figure 4.7.3). For some countries such as Lithuania
and Romania, mortality rates remain well above the
EU average.
Since the development of a vaccine against some HPV
types, vaccination programmes have been implemented in
most EU countries. By May 2012, 17 out of 27 EU member
states had implemented routine HPV vaccination
programmes. In most cases the vaccination programmes
are financed by the national health systems. However, in
Austria the vaccination is entirely covered by the recipient,
and in Belgium and France recipients contribute 25% and
35% of the payment, respectively (ECDC, 2012b). Since its
introduction, there has been an active policy and research
debate about the impact of the vaccine on cervical cancer
screening strategies (Goldhaber-Fiebert et al., 2008; Wheeler
et al., 2009).
Definitions and comparability
Screening rates for cervical cancer reflect the
proportion of women who are eligible for a screening
test and actually receive the test. As policies regarding
screening periodicity and target population differ
across countries, the rates are based on each country’s
specific policy. Some countries ascertain screening
based on surveys and others based on encounter data,
which may influence the results. Survey-based results
may be affected by recall bias. If a country has an
organised programme, but women receive a screening
outside the programme, rates may also be under-
reported. Survey data are reported only when
programme data are not available.
Relative cancer survival rates reflect the proportion
of patients with a certain type of cancer who are still
alive after a specified time period (commonly five
years) compared to those still alive in absence of the
disease. Relative survival rates capture the excess
mortality that can be attributed to the diagnosis. For
example, a relative survival rate of 80% does not
mean that 80% of the cancer patients are still alive
after five years, but that 80% of the patients that were
expected to be alive after five years, given their age
at diagnosis and sex, are in fact still alive. All
the survival rates presented here have been age-
standardised using the International Cancer Survival
Standard (ICSS) population. The survival rates are not
adjusted for tumour stage at diagnosis, hampering
assessment of the relative impact of early detection
and better treatment.
See Indicator 1.5 “Mortality from cancer” for defini-
tion, source and methodology underlying the cancer
mortality rates.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012106
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4.7.1. Cervical screening, percentage women screened 
aged 20-69, 2000 to 2010 (or nearest year)
1. Programme. 2. Survey.
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932705102
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4.7.2. Cervical cancer five-year relative survival rate, 
1997-2002 and 2004-09 (or nearest period)
Note: 95% confidence intervals represented by H.
Source: OECD Health Data 2012.
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4.7.3. Cervical cancer mortality, females, 2000 to 2010 (or nearest year)
Source: Eurostat Statistics Database.
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CANCER CARE • 4.8. SCREENING, SURVIVAL AND MORTALITY FOR BREAST CANCERBreast cancer is the most prevalent form of cancer
among women, with 425 000 new cases diagnosed each
year in Europe (IARC, 2011). Risk factors that increase a
person’s chance of getting this disease include, but are not
limited to, age, family history of breast cancer, oestrogen
replacement therapy and alcohol. Annual incidence in
Europe is expected to rise to 466 000 cases by 2020. Varia-
tion in breast cancer care across European countries is
indicated by mammography screening rates in women
aged 50-69 years, relative survival rates, and mortality
rates.
EU guidelines (EC, 2006) promote a desirable target
screening rate of at least 75% of eligible women in European
member states but in 2010 only three countries had reached
this target. There is considerable uniformity amongst
national breast screening programmes, in terms of the target
age group and recommended time interval between screens.
Participation, however, continues to vary considerably across
European countries, ranging from 8% in Romania, 15% in
Turkey and 16% in the Slovak Republic, to over 80% in Finland,
Slovenia and the Netherlands (Figure 4.8.1). This variation
may, in part, be explained by programme longevity, with
some countries having well established programmes and
others commencing programmes more recently (von Karsa
et al., 2008). However, screening rates fell in a number of
countries in the past decade including Norway and the United
Kingdom. Rates in Hungary and the Slovak Republic have
increased substantially, although they remain well below the
EU average.
Breast cancer survival rates reflect advances in public
health interventions, such as greater awareness of the
disease, screening programmes, and improved treatment. In
particular, the introduction of combined breast conserving
surgery with local radiation and advances in adjuvant and
neoadjuvant therapy has increased survival as well as the
quality of life of survivors (Mauri et al., 2008). Figure 4.8.2
shows that the average EU relative five-year breast
cancer survival rate around the period 2004-09 was 82%.
Between 1997-2002 and 2004-09, survival rates have
improved in all countries. Survival rates around 2004-09
were highest in France, Finland, Belgium, Sweden, Norway
and Iceland (with rates reaching 86% to 87%). Whilst survival
rates remain below 80% in Latvia, the Czech Republic and
Slovenia, the data shows that for the latter two countries
survival rates improved considerably over that period.
Breast cancer mortality rates have declined in all EU
member states over the past decade (Figure 4.8.3). The
reduction in mortality rates is a reflection of improvements
in early detection and treatment of breast cancer. Countries
that reported relatively high mortality rates in 2000 recorded
the biggest declines in breast cancer mortality. These
countries include the Czech Republic, Estonia, Luxembourg,
the Netherlands, Norway and the United Kingdom.
Denmark also recorded substantial falls over the last decade
but its mortality rate was the highest in 2010. The level of
variation across the European Union has declined substan-
tially over the period. In 2000, eight EU member states
reported mortality rates higher than 30 deaths per
100 000 females, but in 2010 mortality rates were below this
rate in all countries. Despite these gains over the past
decade, around 129 000 deaths are caused by breast cancer
each year in European countries.
Definitions and comparability
Mammography screening rates reflect the propor-
tion of eligible women who are actually screened. As
policies regarding target age groups and screening
periodicity differ across countries, the rates are based
on each country’s specific policy. Some countries
ascertain screening based on surveys and others
based on encounter data, and this may influence
results. Survey-based results may be affected by recall
bias. If a country has an organised programme, but
women receive a screen outside of the programme,
rates may also be underreported.
Survival rates are defined in Indicator 4.7 “Screen-
ing, survival and mortality for cervical cancer”. See
Indicator 1.5 “Mortality from cancer” for definition,
source and methodology underlying the cancer
mortality rates.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012108
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4.8.1. Mammography screening, percentage of women 
aged 50-69 screened, 2000 to 2010 (or nearest year)
1. Programme. 2. Survey.
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932705159
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4.8.3. Breast cancer mortality, females, 2000 to 2010 (or nearest year)
Source: Eurostat Statistics Database.
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CANCER CARE • 4.9. SCREENING, SURVIVAL AND MORTALITY FOR COLORECTAL CANCERColorectal cancer is the most commonly diagnosed
form of cancer in Europe, with over 432 000 new cases
diagnosed each year. By 2020, annual incidence is expected
to rise to 502 000 cases (IARC, 2011). The annual incidence
rate varies from 21 new cases per 100 000 population in
Greece to 64 new cases in the Czech Republic. There are
several factors that place certain individuals at increased
risk for the disease, including age, the presence of polyps,
ulcerative colitis, a diet high in fat and genetic background.
Furthermore, males are at higher risk of developing
colorectal cancer than females (IARC, 2011).
The European Council has recommended implemen-
tation of population-based primary screening programmes
using the faecal occult blood test (FOBT) for men and
women aged 50-74 years (EC, 2010d). Organised screening
programmes are being introduced or piloted in several
countries and data on screening rates have become
available for some European countries. Figure 4.9.1 shows
colorectal screening rates using the FOBT test. The use of
colonoscopy, which is part of several national policy cancer
screening programmes for those with elevated risk, is not
captured by these data (ECHIM, 2012). Based on survey
data, participation is still relatively low across Europe when
compared to long-standing screening programmes for
cervical and breast cancer (see Indicators 4.7 and 4.8).
Germany is a notable exception where screening rates have
reached nearly 55% of the target population in 2010. The
low rates observed in most countries may not only reflect
the relatively recent implementation of many colorectal
cancer screening programmes, but also the organisation
and objectives of these programmes. The European Cancer
Observer has previously noted that there was considerable
variation in the way colorectal cancer screening pro-
grammes have been implemented across EU member
states (von Karsa et al., 2008).
Advances in diagnosis and treatment of colorectal
cancer have increased survival over the last decade. There is
compelling evidence in support of the clinical benefit of
improved surgical techniques, radiation therapy and
combined chemotherapy. Figure 4.9.2 shows the five-year
relative survival rate following colorectal cancer diagnosis
between 1997-2002 and 2004-09. In the 2004-09 period, the
highest survival rate was observed in Belgium, at nearly 65%.
The figures indicate that survival rates improved in all
eleven countries for which survival data was available for
both periods, with countries such as Slovenia, the Czech
Republic and Germany witnessing substantial gains in
survival rates.
Mortality rates reflect the effect of cancer care, screening
and diagnosis as well as changes in incidence (Dickman and
Adami, 2006). Between 2000 and 2010, average EU mortality
rates fell from 22.2 to 20.5 per 100 000 population, although
the trend was not uniform across all countries. Figure 4.9.3
reveals that out of 25 EU member states for which data were
available, 15 countries saw a decrease whereas ten countries
saw an increase in colorectal cancer mortality. It is note-
worthy that the Czech Republic and Germany reported
substantial declines in mortality rates and also have the
highest screening rates in the European Union. Despite a
decrease in their mortality rates for colorectal cancer over the
past decade, Hungary continues to have the highest mortality
rate for colorectal cancer, followed by the Slovak Republic and
the Czech Republic. The number of annual deaths in Europe
due to colorectal cancer is expected to rise from 212 000
in 2008 to 248 000 in 2020 (IARC, 2011).
Definitions and comparability
Colorectal screening rates reflect the proportion of
persons, aged 50-74, who have undergone a colorectal
cancer screening test (faecal occult blood test) in the
last two years. Screening rates are based on self-
reported responses to the European Health Interview
Survey (EHIS) and national health interview surveys.
Survival rates are defined in Indicator 4.7 “Screen-
ing, survival and mortality for cervical cancer”. See
Indicator 1.5 “Mortality from cancer” for definition,
source and methodology underlying the cancer
mortality rates. Deaths from colorectal cancer are
classified to ICD-10 Codes C18-C21.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012110
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4.9.1. Colorectal screening, percentage of people 
screened aged 50-74, 2010 (or nearest year)
Note: Data based on surveys in all countries.
Source: Eurostat Statistics Database (based on ECHI).
1 2 http://dx.doi.org/10.1787/888932705216
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4.9.3. Colorectal cancer mortality, 2000 to 2010 (or nearest year)
Source: Eurostat Statistics Database.
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CARE FOR COMMUNICABLE DISEASES • 4.10. CHILDHOOD VACCINATION PROGRAMMESAll EU member states have established childhood
vaccination programmes. All programmes include vaccina-
tions against diseases such as pertussis, diphtheria, teta-
nus and measles. Reviews of the evidence supporting the
efficacy of vaccines against these diseases have concluded
that the respective vaccines are safe and highly effective.
For example, Peltola et al. (1994) reported that 12 years after
the introduction of a comprehensive national vaccination
programme in Finland measles had virtually been eradi-
cated. Numerous studies have also shown that childhood
vaccines can be highly cost-effective (e.g. Beutels and Gay,
2003; Banz et al., 2003; Lieu et al., 1994).
 Figures 4.10.1 and 4.10.2 show that the overall vacci-
nation of children against diphtheria, tetanus and pertussis
(whooping cough) as well as measles is generally high in
European countries. In the European Union, more than 93%
of children aged around 1 year receive the recommended
vaccinations for these diseases. Whilst most countries
have been able to increase or maintain their rate of
childhood vaccinations over the last twenty years, some
countries such as Austria and Denmark have witnessed a
decline in coverage for diphtheria, tetanus and pertussis
(see Indicator 1.11 for more information on pertussis
notifications).
The European Centre for Disease Control (ECDC) reports
that Europe has not met its target of eliminating measles
by 2010. Measles is a highly infectious disease that can lead
to serious complications and, in rare cases, death. Compared
to the five years prior, the numbers of measles cases were
high in 2010 and 2011 with 30 265 and 30 567 cases, respec-
tively. In 2010, the outbreak in the Roma community in
Bulgaria accounted for most of the cases and in 2011, France
accounted for 50% of cases. The ECDC argues that efforts to
increase and maintain vaccination coverage at a high level
will need to be strengthened in order to achieve the renewed
target for eliminating measles by 2015 in the WHO European
Region (ECDC, 2011).
In 2009, there were 5 837 confirmed cases of hepatitis B
virus infection reported in the European Union and EEA/EFTA
member states. With 1.3 notifications per 100 000 population
in EU member states, infection with the hepatitis B virus is
relatively uncommon, but can cause acute or long-term
illness, which is sometimes fatal (see Indicator 1.11 for more
information on hepatitis B notifications). A vaccination for
hepatitis B has been available since 1982 and is considered to
be 95% effective in preventing infection and its chronic
consequences, such as cirrhosis and liver cancer. The WHO
recommends that hepatitis B be part of national infant
immunisation programme, or in countries with low levels of
hepatitis B that routine hepatitis B vaccination should still be
given high priority (WHO, 2004c). Figure 4.10.3 shows that
the average percentage of children aged around 1 year who
are vaccinated for hepatitis B across countries with national
programmes is 95%. Countries such as Belgium, Germany and
Turkey have been able to expand coverage in a relatively short
period of time. Between 2000 and 2010, these countries
increased coverage from less than 70% to 90% and more.
A number of countries do not currently require
children to be vaccinated against hepatitis B, or do not have
routine programmes and consequently the rates for these
countries are significantly lower compared to other
European countries. For example, in Sweden, vaccination
against hepatitis B is not part of the general vaccination
programme, and is only recommended to specific risk
groups. In France, hepatitis B vaccination has been contro-
versial but vaccination coverage among children has
increased in recent years. Alongside the systematic intro-
duction of hepatitis B vaccinations in many countries,
there has been decreasing trend of hepatitis B cases, with
EU-wide surveillance showing a fall of 17% in the number
of cases between 2006 and 2009 (ECDC, 2011).
Definitions and comparability
Vaccination rates reflect the percentage of children at
either age 1 or 2 who receive the respective vaccination
in the recommended timeframe. Childhood vaccination
policies differ slightly across countries. Thus, these
indicators are based on the actual policy in a given
country. Some countries administer combination
vaccines (e.g. DTP for diphtheria, tetanus and pertussis)
while others administer the vaccinations separately.
Some countries ascertain vaccinations based on surveys
and others based on encounter data, which may
influence the results.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012112
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4.10.1. Vaccination rates for diphteria, tetanus 
and pertussis, children aged around 1, 2010
Source: OECD Health Data 2012 (based on WHO/UNICEF data).
1 2 http://dx.doi.org/10.1787/888932705273
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4.10.2. Vaccination rates for measles, 
children aged around 1, 2010
Source: OECD Health Data 2012 (based on WHO/UNICEF data).
1 2 http://dx.doi.org/10.1787/888932705292
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4.10.3. Vaccination rates for hepatitis B, children aged around 1, 2010
Note: OECD average only includes countries with required or routine immunisation.
Source: OECD Health Data 2012 (based on WHO/UNICEF data).
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CARE FOR COMMUNICABLE DISEASES • 4.11. INFLUENZA VACCINATION FOR OLDER PEOPLEInfluenza is a common infectious disease and affects
people of all ages. WHO Europe reports that each year
seasonal influenza affects between 5 to 15% of the population
in the northern hemisphere. Most people with the illness
recover quickly, but elderly people and those with chronic
medical conditions are at higher risk of complications and
even death. In any particular year, influenza can have a sub-
stantial impact on the health of the population and the health
care system (Nicholson et al., 2003; Simonsen et al., 2000).
Vaccines have been used for more than 60 years, and
provide a safe and effective means of preventing influenza,
and reducing the impact of epidemics. Among the elderly,
appropriate influenza vaccines will, in general, reduce the
risk of serious complications or death by 70-85% (Ryan,
2006). In 2003, all World Health Assembly (WHA) countries,
including all EU member states, committed to the goal of
attaining vaccination coverage of the elderly population of at
least 50% by 2006 and 75% by 2010 (WHA, 2003; Mereckiene
et al., 2008).
 Figure 4.11.1 shows that around 2010, across 22 EU
member states for which data was available, the average
influenza vaccination rate for people aged 65 and over was
45.3%. Vaccination rates across Europe range from 1% in
Estonia to 74% in the Netherlands. Whilst there is still some
uncertainty about the reasons for the cross-national differ-
ences in vaccination rates, studies have highlighted that
the lack of public health insurance coverage may be an
important determinant in explaining low uptake in some
countries (Mereckiene et al., 2008; Kroneman et al., 2003;
Kunze et al., 2007). Studies have also shown that personal
contact with a doctor is a key determinant of uptake, and
that better information through mass-media campaigns,
patient and provider education initiatives, and recall and
reminder systems can play an important role in improving
vaccination rates (Kohlhammer et al., 2007).
Figure 4.11.2 indicates that between 2000 and 2005, vac-
cination rates across the European Union increased from
45% to 54% of the elderly population but fell between 2005
and 2010. There appears to be no uniform trend across
Europe. Some countries such as France and the Netherlands
have maintained their vaccination rates over the decade,
countries such as Belgium and Portugal have seen a rise in
the rate, and a large number of countries witnessed their
rates increase between 2000 and 2005 but then fall again
in 2010. No country attained the 75% coverage target in 2010.
In late 2009, the Health Ministers of the European Union
adopted an EU Council Recommendation to reach the target
of 75% vaccination coverage amongst the elderly as early as
possible and preferably by the 2014-15 winter season. The
recommendation also proposed that the target of 75%
coverage should, if possible, be extended to people with
chronic conditions.
In June 2009, the WHO declared the first influenza
pandemic since 1968-69 (WHO, 2009b). Within 23 weeks of
the first diagnosis of the H1N1 influenza virus (also referred
to as “swine flu”), there were over 53 000 confirmed cases
across all EU member states, Iceland, Liechtenstein and
Norway (ECDC, 2011). The estimated infection attack rates
remained low in the overall population but were high
amongst young people aged 5-19 years. Following the
development, testing and production of a H1N1 vaccine,
most EU member states included the 2009-10 seasonal
influenza vaccine and the pandemic vaccine into their
influenza vaccination programmes (Valenciano et al., 2011).
Despite the worldwide focus on H1N1, numerous studies
have shown that vaccination rates against the virus were
lower than expected in a large number of countries (Poland,
2011; Mereckiene et al., 2012). In part, this may be due to the
easing of concerns about the threat of H1N1 amongst the
general population by the time the vaccine became
available. The most important determinant for individuals
to take-up H1N1 vaccine was previous exposure to
seasonal flu vaccine, leading some researchers to argue
that higher vaccination rates for seasonal flu may help
uptake during potential future pandemics (Poland, 2011;
Nguyen et al., 2011; Bish et al., 2011).
Definitions and comparability
Influenza vaccination rate refers to the number of
people aged 65 and older who have received an
annual influenza vaccination, divided by the total
number of people over 65 years of age. The main
limitation in terms of data comparability arises from
the use of different data sources, whether survey or
programme, which are susceptible to different types
of errors and biases. For example, data from popu-
lation surveys may reflect some variation due to recall
errors and irregularity of administration.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012114
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4.11.1. Vaccination rates for influenza, population aged 65 and over, 2010 (or nearest year)
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932705330
4.11.2. Trends in vaccination rates for influenza, population aged 65 and over, 2000-10 (or nearest year)
Source: OECD Health Data 2012.
1 2 http://dx.doi.org/10.1787/888932705349
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5.1. COVERAGE FOR HEALTH CAREHealth care coverage enables access to medical goods
and services and provides financial security against
unexpected or serious illness. However, the share of the
population with health insurance coverage – be it public or
private – is an imperfect indicator of accessibility, since the
range of services covered and the degree of cost-sharing
applied to those services vary across countries.
Most European countries have achieved universal (or
near-universal) coverage of health care costs for a core set
of services, which usually include consultations with
doctors, tests and examinations, and hospital care
(Figure 5.1.1). In most countries, dental care and the
purchase of prescribed pharmaceuticals are also at least
partially covered (Paris et al., 2010). Two European countries
do not yet have universal health coverage. In Cyprus, an
estimated 83% of the population are entitled to public
health services, although many currently seek medical care
in the private sector and pay out-of-pocket. A new National
Health Insurance System has been proposed to modernise
public health care and extend coverage (Cyprus National
Reform Programme, 2012; Theodorou et al., 2012). In Turkey,
public coverage has increased rapidly since reforms to
implement universal health insurance began in 2003 under
the ten-year Health Transformation Programme (OECD,
2008b; Tatar et al., 2011). The population covered rose from
70% in 2002 to 83% in 2010 and is continuing to move
towards full coverage estimated to be 98% in 2012.
Basic primary health coverage, whether provided
through public or private insurance, generally covers a
defined “basket” of benefits, in many cases with cost-
sharing. In some countries, additional health coverage can
be purchased through private insurance to cover any cost-
sharing left after basic coverage (complementary insur-
ance), add additional services (supplementary insurance)
or provide faster access or larger choice to providers (dupli-
cate insurance). In most European countries, only a small
proportion of the population has an additional private
health insurance. But in six countries, half or more of
the population had a private health insurance in 2010
(Figure 5.1.2).
In France, nearly all the population (96%) has a comple-
mentary private health insurance to cover cost-sharing in
the social security system. A large proportion of the popu-
lation in Belgium, Luxembourg and Slovenia also make use
of complementary health insurance. The Netherlands has
the largest supplementary market (89% of the population),
whereby private insurance pays for prescribed pharmaceu-
ticals and dental care that are not publicly reimbursed.
Duplicate markets, providing faster private-sector access to
medical services where there are waiting times in public
systems, are largest in Ireland (50%). The population
covered by private health insurance has been growing over
the past decade in some countries including France,
Belgium and Germany, but not in Ireland and Luxembourg
(Figure 5.1.3).
The importance of private health insurance is not
linked to a countries’ economic development. Other factors
are more likely to explain market development, including
the history of health care financing arrangements and
government interventions directed at private health insur-
ance markets (OECD, 2004).
Definition and comparability
Coverage for health care is the share of the popula-
tion receiving a defined set of health care goods and
services under public programmes and through
private health insurance. It includes those covered in
their own name and their dependents. Public cover-
age refers both to government programmes, generally
financed by taxation, and social health insurance,
generally financed by payroll taxes. Take-up of private
health insurance is often voluntary, although it may
be mandatory by law or compulsory for employees as
part of their working conditions. Premiums are gener-
ally non-income-related, although the purchase of
private cover can be subsidised by the government.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012118
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5.1.1. Health insurance coverage for a core set of services, 
2010 (or nearest year)
Source: OECD Health Data 2012; WHO Europe (2012).
1 2 http://dx.doi.org/10.1787/888932705368
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5.2. HEALTH EXPENDITURE PER CAPITAThere are large variations in the level and in the rate of
growth of health spending across European countries.
Health expenditure per capita tends to be related with
overall income per capita. Hence, it is not surprising that
Norway and Switzerland are the two European countries
that spent the most on health in 2010, with spending of over
EUR 4 000 per person (Figure 5.2.1). Among EU member
states, the Netherlands (EUR 3 890), Luxembourg (EUR 3 607)
and Denmark (EUR 3 439) were the highest spenders,
exceeding by a wide margin the EU average (EUR 2 171).
Romania and Bulgaria were the lowest spending countries
among EU members. Health spending per capita was also
relatively low in the Former Yugoslav Republic of Macedonia
and Turkey.
Growth in health spending per capita slowed or fell in
real terms in 2010 in almost all European countries, revers-
ing a trend of steady increases in many countries. Health
spending per capita had already started to fall in 2009 in
some countries that were hardest hit by the economic crisis
(e.g. Estonia and Iceland), but this was followed by further
and deeper cuts in 2010. On average across EU member
states, health spending per capita increased by 4.6% per
year in real terms between 2000 and 2009, but this was
followed by a reduction of 0.6% in 2010 (Figure 5.2.2). While
government health spending tended to be maintained at
the start of the economic crisis, cuts in spending really
began to take effect in 2010 in response to budgetary
pressures and the need to reduce large deficits and debts.
In Ireland, cuts in government spending drove total
health spending per capita down by nearly 8% in 2010,
compared with an average growth rate of 6.5% per year
between 2000 and 2009. In Estonia, expenditure on health
per capita dropped by 7.3% in 2010 due to reductions in both
public and private spending, following an average annual
growth rate of 7.2% between 2000 and 2009. In Greece, health
spending per capita fell by 6.7% in 2010, after a yearly growth
rate of 5.7% during the 2000-09 period. In several other
countries (e.g. in Belgium, Finland, the Netherlands, Poland,
the Slovak Republic and Sweden), there was a marked
slowdown in the rate of growth of health spending per
capita, although it remained positive.
Reductions in public spending on health were
achieved through a range of measures. In Ireland, most of
the reductions have been achieved through cuts in wages
and a reduction in the number of healthcare workers as
well as the fees paid to professionals and pharmaceutical
companies. Estonia cut administrative costs in the Ministry
of Health and the prices of publicly-reimbursed health
services. Investment in health infrastructure has also
been put on hold in a number of countries, including the
Czech Republic, Estonia, Iceland and Ireland, while gains in
efficiency have been pursued through mergers of hospitals
or accelerating the move from inpatient care in hospital
to outpatient care and day surgery. Other measures have
been introduced to make people pay more out of their
pockets. For example, Ireland increased the share of direct
payments by households for prescribed pharmaceuticals
and appliances, while the Czech Republic increased users’
charges for hospital stays.
As a result of the slowdown or negative growth in
health spending per capita in 2010, the percentage of GDP
devoted to health stabilised or declined slightly in many
EU member states (see Indicator 5.3 “Health expenditure in
relation to GDP”).
Definition and comparability
Total expenditure on health measures the final
consumption of health goods and services (i.e. current
health expenditure) plus capital investment in health
care infrastructure, as defined in the System of Health
Accounts manual (OECD, 2000; OECD, Eurostat and
WHO, 2011). This includes spending by both public
and private sources on medical services and goods,
public health and prevention programmes, and
administration.
The vast majority of countries now produce health
spending data according to the boundaries and defini-
tions proposed in the System of Health Accounts (SHA)
manual. The comparability of the functional break-
down of health expenditure data has improved over
recent years. However, limitations remain, as some
countries have not yet implemented the SHA classifi-
cations and definitions. Even among those countries
that are submitting data according to the SHA, the
comparability of data sometimes needs to be
improved. Different practices regarding the treatment
of capital expenditure and the inclusion of long-term
care in health or social expenditure are some of the
main factors affecting data comparability.
Countries’ health expenditures are converted to a
common currency (Euro) and are adjusted to take
account of the different purchasing power of the
national currencies, in order to compare spending
levels. Economy-wide (GDP) PPPs are used to compare
relative expenditure on health in relation to the rest
of the economy.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012120
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5.2.1. Health expenditure per capita, 2010 (or nearest year)
1. Health expenditure is for the insured population rather than resident population.
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO Global Health Expenditure Database.
1 2 http://dx.doi.org/10.1787/888932705425
5.2.2. Annual average growth rate in health expenditure per capita, in real terms,
2000 to 2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO Global Health Expenditure Database.
1 2 http://dx.doi.org/10.1787/888932705444
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5.3. HEALTH EXPENDITURE IN RELATION TO GDPIn 2010, EU member states devoted on average
(unweighted) 9.0% of their GDP to health spending in 2010
(Figure 5.3.1), up significantly from 7.3% in 2000, but down
slightly from the peak of 9.2% reached in 2009 following the
economic crisis which started in many countries in the
middle of 2008. In many countries, public spending on
health was maintained in 2009 while GDP was falling
strongly, but this was followed in 2010 by the implemen-
tation of a range of measures to reduce government health
spending as part of broader efforts to reduce large budgetary
deficits and debts (see Indicator 5.2).
The Netherlands had the highest share of its GDP
allocated to health in 2010 (12%), followed by France and
Germany (both at 11.6%). This share remains well below the
United States where health expenditure accounted for
17.6% of GDP in 2010. The share of health spending in GDP
was lowest in Romania and Turkey, at around 6%.
With the exception of Cyprus, public funding remains
the main source of financing of health expenditure in all
EU member states, with close to three-quarters of all
spending being paid by public sources (see Indicator 5.6).
The ranking of countries in terms of public expenditure on
health as a share of GDP is not very different from total
expenditure on health. The Netherlands (9.6%) and
Denmark (9.5%) had the highest share of public expendi-
ture on health to GDP, followed by France (9.0%) and
Germany (8.9%). Cyprus had the lowest share of public
spending on health to GDP (3.2%), followed by Bulgaria
(4.0%) and Latvia (4.1%).
For a more complete understanding of the level of
health spending, the health spending to GDP ratio should
be considered together with health spending per capita
(see Indicator 5.2). Countries having a relatively high health
spending to GDP ratio might have relatively low health
expenditure per capita, and the converse also holds. For
example, Belgium and Portugal both spent around 10.5% of
their GDP on health in 2010; however, per capita spending
(adjusted to EUR PPP) was nearly 50% higher in Belgium
(see Figure 5.2.1).
Changes in the ratio of health spending to GDP are the
result of the combined effect of growth in both GDP and
health expenditure. Between 2000 and 2010, the annual
average growth in health expenditure per capita in real
terms was about 4% on average in EU member states,
nearly two-times greater than the growth rate in GDP
per capita. With the exception of Bulgaria, Iceland and
Luxembourg, annual growth in health spending outpaced
GDP growth in all European countries over the past decade
(Figure 5.3.2). This explains why the share of GDP allocated
to health increased from 7.3% to 9.0% during that period.
In France and Germany, the health spending to GDP
ratio increased from just over 10% in 2000 to 11.6% in both
countries in 2010 (Figure 5.3.3). Health spending per capita
grew slightly faster in Germany than in France over the past
decade, but so did GDP per capita. The share of GDP was
relatively stable in both countries between 2003 and 2008,
but it then increased by 1 percentage point in 2009 as health
spending continued to grow while GDP fell in both countries.
In the United Kingdom, the health spending share of
GDP used to be below the EU average, but since 2006, it is
now above average. As in many other European countries,
the share of health spending allocated to GDP in the United
Kingdom increased by a full percentage point in 2009
following the financial and economic crisis, but came down
slightly in 2010.
Definition and comparability
See Indicator 5.2 for the definition of total health
expenditure.
Gross domestic product (GDP) = final consumption
+ gross capital formation + net exports. Final
consumption of households includes goods and
services used by households or the community to
satisfy their individual needs. It includes final
consumption expenditure of households, general
government and non-profit institutions serving
households.
In countries, such as Ireland and Luxembourg,
where a significant proportion of GDP refers to profits
exported and not available for national consumption,
gross national income (GNI) may be a more meaning-
ful measure than GDP.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012122
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5.3.1. Total health expenditure as a share of GDP, 2010 (or nearest year)
1. In the Netherlands, it is not possible to clearly distinguish the public and private share related to investments.
2. Public and private expenditures are current expenditures (excluding investments).
3. Health expenditure is for the insured population rather than resident population.
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO Global Health Expenditure Database.
1 2 http://dx.doi.org/10.1787/888932705463
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5.3.2. Annual average growth in health expenditure 
and GDP per capita, in real terms,
2000-10 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO Global
Health Expenditure Database.
1 2 http://dx.doi.org/10.1787/888932705482
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5.4. HEALTH EXPENDITURE BY FUNCTIONIn 2010, curative and rehabilitative care provided either
as inpatient care (including day care) or outpatient care,
accounted for 61% of current health spending (excluding
capital investment) on average across EU member states
(Figure 5.4.1). A further 23% of health spending was allocated
to medical goods (including mainly pharmaceuticals, which
accounted for 19% of total health spending), 10% to long-
term care and the remaining 6% on collective services
including public health services and administration.
The allocation of spending by type of care varies
significantly across European countries. Spending for
inpatient care, day care and outpatient care depends on the
institutional arrangements for health care provision. In
Portugal and Sweden, for example, the majority of curative
and rehabilitative spending is on outpatient care, with
relatively low levels of hospital inpatient activity. In some
other countries, such as Bulgaria and Romania, inpatient
activity (including day care) plays a more dominant role
accounting for over two-thirds of all curative and rehabili-
tative care expenditure.
The other major category of health expenditure
is on medical goods, mainly pharmaceuticals (see
Indicator 5.5). In Hungary and the Slovak Republic, expen-
diture on medical goods is in fact a larger spending
category than inpatient care or outpatient care, represent-
ing 37% of current health expenditure. In Norway and
Switzerland, on the other hand, spending on medical goods
represents only 12% of total health spending. Differences in
the consumption pattern of pharmaceuticals and relative
prices play a role in explaining some of the variations
between countries.
There are some large differences between countries in
their expenditure on long-term care. Countries such as
Denmark, the Netherlands and Norway, which have
established formal arrangements for the elderly and the
dependent population, allocate more than 20% of current
health spending to long-term care. In countries with less
comprehensive formal long-term care services such as
Portugal, the expenditure on long-term care accounts for a
much smaller share of total spending.
 Figure 5.4.2 compares the real growth rates in inpa-
tient and outpatient spending over the last decade. With
inpatient care being highly labour and capital intensive
and, therefore, expensive, certain high-income countries
with developed health systems have sought to reduce the
share of spending in hospitals by shifting to more out-
patient and home based care and improving primary care
to prevent hospital admissions in the first place. In Iceland,
spending on inpatient services decreased by over 3% per
year on average between 2000 and 2010, while outpatient
care grew on average at an annual rate of 3.2%. In other
countries such as the Czech Republic and Poland, spending
for both inpatient and outpatient care increased strongly
over the past decade, but the growth in inpatient services
exceeded outpatient care. On average across EU member
states, the growth in inpatient spending was slightly above
the growth in outpatient spending during the past decade.
Figure 5.4.3 shows the share of health expenditure
allocated to organised public health and prevention
programmes. On average, EU member states allocated less
than 3% of their spending on health to prevention activities
such as vaccination programmes and public health
campaigns on alcohol abuse and smoking. However, where
such initiatives are carried out at the primary care level,
such as in Spain, the prevention function might not be
captured separately and may be included under spending
on curative care. Countries adopting a more centralised
approach to public health and prevention campaigns are
better able to identify spending on such programmes.
Definition and comparability
The System of Health Accounts (OECD, 2000; OECD,
Eurostat and WHO, 2011) defines the boundaries of the
health system. Current health expenditure comprises
personal health care (curative care, rehabilitative care,
long-term care, ancillary services and medical goods)
and collective services (public health services and
health administration). Curative, rehabilitative and
long-term care can also be classified by mode of
production (inpatient, day care, outpatient and home
care). Day care comprises health care services
delivered to patients who are formally admitted to
hospitals, ambulatory premises or self standing cen-
tres but with the intention to discharge the patient on
the same day. An outpatient is not formally admitted
to a facility (physician’s private office, hospital out-
patient centre or ambulatory-care centre) and does not
stay overnight. Concerning long-term care, only the
health aspect is normally reported as health expendi-
ture. This is the reason why some countries with
comprehensive long-term care packages focusing on
social care might be ranked surprisingly low when
analyzing long-term care expenditure based on
SHA data.
Factors limiting the comparability across countries
include estimations of long-term care expenditure.
Also, expenditure in hospitals may be used as a proxy
for inpatient care services, although hospital expen-
diture may include spending on outpatient, ancillary,
and in some cases drug dispensing services (Orosz
and Morgan, 2004).HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012124
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5.4.1. Current health expenditure by function of health care, 2010 (or nearest year)
Countries are ranked by inpatient curative care as a share of current expenditure on health
1. Refers to curative and rehabilitative inpatient and day care provided in hospitals, day surgery clinics, etc.
2. Refers to curative and rehabilitative care in doctors’ offices, clinics, outpatient departments of hospitals, home care and ancillary services.
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932705520
100
90
80
70
60
50
40
30
20
10
0
%
41 40 38 37 36 35 34 33 32 32 31 31 30 30 29 29 28 28 27 26 25 25 21
31 30 28
16 13 22
28 28
18
28 28
34
27 30
36
26
31 29
35
42
37
45
27
37
33
25 31 33
37
13
1
10
6
15
24 4 9
4
9
10
4
20
24
12
11
8 20 1
4
11 18
29 20
37
25
20
21
27
17
14
29 24 24
30 23 24 17
11
20
18
16
12
24
37
22
37
12
18 12
6 8 4 9
3 5 10 6 7 7
3 6 5 7 4 9 7 6
4 4 7 5 9
3 4 7
Inpatient (including day care)1 Outpatient2 Long-term care Medical goods Collective services
Bu
lga
ria
Ro
ma
nia
Cy
pr
us
Fra
nc
e
Po
lan
d
Au
str
ia
Ne
the
rla
nd
s
La
tvi
a
Slo
ve
nia
Cz
ec
h R
ep
ub
lic
Lit
hu
an
ia
EU
22
Es
ton
ia
Be
lgi
um
De
nm
ark
Ge
rm
an
y
Fin
lan
d
Sw
ed
en
Lu
xe
mb
ou
rg
Po
rtu
ga
l
Hu
ng
ary
Sp
ain
Slo
va
k R
ep
ub
lic
No
rw
ay
Ice
lan
d
Sw
itz
erl
an
d
5.4.2. Growth in inpatient and outpatient expenditure 
per capita, in real terms, 2000-10 (or nearest year)
1. Including day care.
2. Including home care and ancillary services.
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932705539
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5.4.3. Expenditure on organised public health 
and prevention programmes, 2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO Global
Health Expenditure Database.
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5.5. PHARMACEUTICAL EXPENDITUREPharmaceutical expenditure accounted for almost a
fifth (19%) of all health expenditure on average in
EU member states in 2010, making it the third biggest
spending component after inpatient and outpatient care.
Increased spending on pharmaceuticals has contributed to
the overall rise in total health expenditure over the past
decade, although the growth rate turned negative in several
countries in 2010. The relationship between pharma-
ceutical expenditure and other health expenditure is a
complex one, in that increased expenditure on pharma-
ceuticals to tackle different diseases may reduce the need
for costly hospitalisations and interventions now or in the
future.
The total pharmaceutical bill across the European Union
reached more than EUR 190 billion in 2010. However, there are
wide variations in pharmaceutical spending per capita across
countries, reflecting differences in volume, structure of
consumption and pharmaceutical prices (Figure 5.5.1, left
panel). At EUR 528, Ireland spent more on pharmaceuticals
than any other European country on a per capita basis. This is
50% above the average across EU member states of EUR 349.
Other countries with relatively high pharmaceutical expen-
diture include Germany (EUR 492), Belgium (EUR 479) and
France (EUR 468). At the other end of the scale, Romania spent
only EUR 164 per capita. Denmark, Estonia, Latvia and Poland
are also among the countries that have relatively low
pharmaceutical spending per capita, at less than 70% of the
EU average.
Pharmaceutical spending accounted for 1.6% of GDP
on average across EU member states, ranging from below
1% in countries such as Denmark, Luxembourg and
Norway, to more than 2% in Bulgaria, Hungary, the Slovak
Republic and Serbia (Figure 5.5.1, right panel).
The economic crisis in many European countries has
had a significant effect on pharmaceutical spending
(Figure 5.5.2). Between 2000 and 2009, pharmaceutical
spending increased on average in EU member states by
3.2% per year in real terms (slightly below the growth rate
in total health spending), but the average growth in
pharmaceutical spending in 2010 came to a halt (0.0%). In
Ireland, pharmaceutical spending per capita increased
at a rate of over 8% per year in real terms on average
between 2000 and 2009, but the growth rate slowed down
markedly to less than 2% in 2010. This slowdown followed
the introduction of a series of measures to control pharma-
ceutical spending in Ireland, including large price reduc-
tions and increases in co-payments by households. Several
other countries severely affected by the economic crisis cut
their spending on pharmaceuticals drastically in 2010:
Iceland (–6.3%), Lithuania (–4.6%) and Portugal (–3.3%).
Many European countries have attempted to control
pharmaceutical expenditures even before the recession via
a mix of price and volume controls directed at physicians
and pharmacies, as well as policies targeting specific prod-
ucts (OECD, 2010b). In Germany, pharmaceutical compa-
nies must now enter into rebate negotiations with health
insurance funds for new innovative medicines, putting an
end to the previous free-pricing regime. Spain mandated a
price reduction for generics and introduced a general
rebate applicable for all medicines prescribed by NHS
physicians in 2010. In France, price reductions or rebates on
pharmaceuticals have often been used as adjustment
variables to contain health spending growth while in the
United Kingdom caps were introduced on pharmaceutical
companies’ profits relating to NHS sales.
Definition and comparability
Pharmaceutical expenditure covers spending on pre-
scription medicines and self-medication, often referred
to as over-the-counter products. In some countries, the
data also include other medical non-durable goods
(adding approximately 5% to the spending). The expen-
diture also includes pharmacists’ remuneration when
the latter is separate from the price of medicines.
Pharmaceuticals consumed in hospitals are excluded
(their inclusion would add another 15% to pharmaceu-
tical spending approximately). Final expenditure on
pharmaceuticals includes wholesale and retail margins
and value-added tax.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012126
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5.5.1. Expenditure on pharmaceuticals per capita and as a share of GDP, 2010 (or nearest year)
1. Includes medical non-durables.
2. Total medical goods.
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932705577
5.5.2. Average annual growth in pharmaceutical expenditure per capita, in real terms, 2000 to 2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database.
1 2 http://dx.doi.org/10.1787/888932705596
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5.6. FINANCING OF HEALTH CAREAll European countries use a mix of public and private
financing to pay for health care. In some countries, public
purchasing of health care is generally confined to the use
of government revenues. In others where there is social
insurance, public financing uses these social contributions, in
addition to any general government revenues. Private financ-
ing of health care consists of payments by households (either
as stand-alone payments or co-payments) as well as various
forms of private health insurance intended to replace,
complement or supplement publicly financed coverage. In
addition, occupational health care may be directly provided
by employers, and other health care benefits may be provided
by charities and other non-government organisations.
The public sector is the main source of health
care financing in all European countries, except Cyprus
(Figure 5.6.1). In 2010, on average in the European Union,
73% of health care was publicly financed. Public financing
accounted for over 80% in the Netherlands, the Nordic
countries (except Finland), Luxembourg, the Czech Republic,
the United Kingdom and Romania. The share was the lowest
in Cyprus (43%), and Bulgaria, Greece and Latvia (55-60%).
The economic crisis has had an effect on the mix of
public and private health financing as public spending has
been contained or cut in many countries severely affected
by the recession. In Ireland, the share of public spending
decreased by nearly 6 percentage points between 2008
and 2010 and stands now at 70%. Substantial falls have also
been observed in the Slovak Republic and Bulgaria. On the
other hand, some countries saw their public spending
share rise since 2008, including Cyprus and Norway.
Although public funding is the main source of funds
for health spending in nearly all European countries, this
does not imply that the public sector plays the dominant
financing role for all health services and goods. Figure 5.6.2
shows the shares of financing for medical services and
medical goods separately. On average across the European
Union, the public sector covers a much higher proportion of
the costs of medical services compared with medical goods
(comprising mainly pharmaceutical products). Over 80% of
the costs of health care services are covered by public
funds compared with just over 50% for medical goods. In
Romania, public funding covers more than 90% of expendi-
ture on medical services, but only about 40% of spending
on medical goods. Germany, Luxembourg and the
Netherlands are the only countries where public spending
coverage for medical goods exceeds 70%.
After public financing, the main source of funding for
health expenditure is out-of-pocket payments. In 2010, the
share of out-of-pocket payments was highest in Cyprus,
Bulgaria and Greece. It was the lowest in the Netherlands
(6%), France (7%) and the United Kingdom (9%). The share of
out-of-pocket spending has increased over the past decade
in about half of EU member states while it has decreased in
the other half. The Slovak Republic has seen the biggest
increase in the share of health spending paid directly
by households, with a rise of over 15 percentage points
between 2000 and 2010. This increase is due to a rise in
co-payments on prescribed pharmaceuticals, higher spend-
ing by households on non-prescribed medicines, increased
use of private providers and informal payments to public
providers (Szalay et al., 2011). The share of out-of-pocket
payments has also increased substantially in Bulgaria,
Cyprus and Malta. In some countries hard hit by the eco-
nomic crisis, the public coverage for certain services has
been reduced in recent years, with a growing share of pay-
ments being transferred to households. In Iceland, the share
of out-of-pocket spending has increased by 2.2 percentage
points between 2008 and 2010, although this has not totally
offset the previous reduction in this share between 2000
and 2008. In Ireland, the share of out-of-pocket spending
increased by 1.7 percentage points between 2008 and 2010,
and is now 2.1 percentage points greater than in 2000.
On the other hand, some other countries have
extended public coverage for health services in recent
years to improve access to care, resulting in a lower share
of health spending paid directly by households. Turkey is
the most striking example; it has moved since 2003 to
extend public coverage for health services for a larger
proportion of the population (see Indicator 5.1), with public
funding now accounting for 73% of total health spending,
equal to the EU average. This has led to a reduction of
nearly 10 percentage points in the share of direct payments
by households over the past decade. The share of
out-of-pocket payments has also come down substantially
in Poland and Switzerland, although it still remains slightly
above the EU average.
Definition and comparability
There are three elements of health care financing:
sources of funding (households, employers and the
state), financing schemes (e.g. compulsory or voluntary
insurance), and financing agents (organisations manag-
ing financing schemes). Here “financing” is used in the
sense of financing schemes as defined in the System of
Health Accounts (OECD, 2000; OECD, Eurostat and WHO,
2011). Public financing includes general government
revenues and social security funds. Private financing
covers households’ out-of-pocket payments, private
health insurance and other private funds (NGOs and
private corporations). Out-of-pocket payments are
expenditures borne directly by the patient. They include
cost-sharing and, in certain countries, estimations of
informal payments to health care providers.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012128
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5.6.1. Expenditure on health by type of financing, 2010 (or nearest year)
1. Data refer to current expenditure.
Source: OECD Health Data 2012; WHO Global Health Expenditure Database.
1 2 http://dx.doi.org/10.1787/888932705615
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5.6.2. Public share of expenditure on medical services 
and goods, 2010 (or nearest year)
Source: OECD Health Data 2012; Eurostat Statistics Database.
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5.6.3. Change in share of out-of-pocket spending
in total health spending, 2000 to 2010 (or nearest year)
1. Data refer to current expenditure.
Source: OECD Health Data 2012; WHO Global Health Expenditure Database.
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5.7. TRADE IN HEALTH SERVICESTrade in health services and its most high-profile
component, medical tourism, has attracted a great deal of
media attention in recent years. The growth in “imports” and
“exports” has been fuelled by a number of factors. Technolog-
ical advances in information systems and communication
allow patients or third party purchasers of health care to seek
out quality treatment at lower cost and/or more immediately
from health care providers in other countries. An increase in
the portability of health cover, whether as a result of regional
arrangements with regard to public health insurance
systems, or developments in the private insurance market,
are also poised to further increase patient mobility. All this is
coupled with a general increase in the temporary movement
of populations for business, leisure or specifically for medical
purposes between countries.
While the major part of international trade in health
services does involve the physical movement of patients
across borders to receive treatment, to get a full measure of
imports and exports, there is also a need to consider goods
and services delivered remotely such as pharmaceuticals
ordered from another country or diagnostic services
provided from a doctor in one country to a patient in
another. The magnitude of such trade remains small, but
advances in technology mean that this area also has the
potential to grow rapidly.
Data on imports of health services and goods are
available for most European countries and amounted to
more than EUR 3 billion in 2010. The vast majority of this
trade is between European countries. However, due to data
gaps and under-reporting, this is likely to be a significant
underestimate. With health-related imports reaching
nearly EUR 1 500 million, Germany is by far the greatest
importer in absolute terms, followed by the Netherlands
and France. Nevertheless, in comparison to the size of the
health sector as a whole, trade in health goods and services
remains marginal for most countries. Even in the case of
Germany, reported imports represent only around 0.5% of
Germany’s health expenditure. The share rises above 1% of
health spending only in Cyprus and Iceland, as these
smaller countries see a higher level of cross-border move-
ment of patients. Luxembourg is a particular case because
a large part of its insured population is living and consum-
ing health services in neighbouring countries.
A smaller number of countries report total exports of
health-related travel expenditure and other health services,
totalling around EUR 2.5 billion in 2010 (Figure 5.7.2). For
many countries these figures are, again, likely to be signifi-
cant underestimates. In absolute values, the Czech Republic
and France reported exports in excess of EUR 400 million,
while the exports of Turkey, Poland and the United Kingdom
exceeded EUR 200 million. In relation to overall health
spending, health-related exports remain marginal in most
countries, except in the Czech Republic and Croatia where
they equate to 4.2% and 2.8% of overall health spending.
These countries have become popular destinations for
patients from other European countries, particularly for
services such as dental surgery. The growth rate in health-
related exports has exceeded 20% per year over the past five
years in the Czech Republic.
Patient mobility in Europe may see further growth as a
result of an EU directive adopted in 2011 which supports
patients in exercising their right to cross border health care
and promotes co-operation between health systems
(Directive 2011/24/EU).
Definition and comparability
The System of Health Accounts includes imports
within current health expenditure, defined as
imports of medical goods and services for final
consumption. Of these the purchase of medical
services and goods, by resident patients while abroad,
is currently the most important in value terms.
In the balance of payments, trade refers to goods
and services transactions between residents and
non-residents of an economy. According to the
Manual on Statistics of International Trade in Services,
“Health-related travel” is defined as “goods and
services acquired by travellers going abroad for
medical reasons”. This category has some limitations
in that it covers only those persons travelling for the
specific purpose of receiving medical care, and does
not include those who happen to require medical
services when abroad. The additional item “Health
services” covers those services delivered across
borders but can include medical services delivered
between providers as well as to patients.HEALTH AT A GLANCE: EUROPE 2012 © OECD 2012130
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5.7.1. Imports of health care services as share of total health expenditure, 2010 and annual growth rate in real terms, 
2005-10 (or nearest year)
1. Refers to balance of payments concept of health-related travel and health services of personal, recreational and cultural services.
Source: OECD Health Data 2012 and OECD-Eurostat Trade in Services Database.
1 2 http://dx.doi.org/10.1787/888932705672
5.7.2. Exports of health-related travel or other services as share of total health expenditure,
2010 and annual growth rate in real terms, 2005-10 (or nearest year)
Note: Health-related exports occur when domestic providers supply medical services to non-residents.
Source: OECD-Eurostat Trade in Services Database.
1 2 http://dx.doi.org/10.1787/888932705691
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ANNEX AANNEX A 
Additional information on demographic 
and economic context
Table A.1. Total population, mid-year, thousands, 1960 to 2010
1960 1970 1980 1990 2000 2010
Austria 7 048 7 467 7 549 7 678 8 012 8 390
Belgium 9 154 9 656 9 859 9 967 10 251 10 896
Bulgaria 7 867 8 490 8 862 8 718 8 170 7 534
Cyprus 573 615 509 580 694 804
Czech Republic 9 607 9 856 10 303 10 333 10 272 10 520
Denmark 4 580 4 929 5 123 5 141 5 340 5 548
Estonia 1 216 1 361 1 477 1 569 1 369 1 340
Finland 4 430 4 606 4 780 4 986 5 176 5 363
France 45 684 50 772 53 880 56 709 59 062 62 959
Germany1 55 608 61 098 61 549 62 679 | 82 212 81 777
Greece 8 322 8 793 9 643 10 157 10 918 11 308
Hungary 9 984 10 338 10 711 10 374 10 211 10 000
Ireland 2 829 2 957 3 411 3 514 3 804 4 475
Italy 50 200 53 822 56 434 56 719 56 942 60 483
Latvia 2 121 2 359 2 512 2 663 2 373 2 239
Lithuania 2 779 3 140 3 413 3 698 3 500 3 287
Luxembourg 314 339 364 382 436 507
Malta 327 303 317 354 386 416
Netherlands 11 487 13 039 14 150 14 952 15 926 16 615
Poland 29 561 32 526 35 578 38 111 38 454 38 184
Portugal 8 858 8 680 9 766 9 983 10 226 10 637
Romania 18 407 20 250 22 207 23 202 22 443 21 438
Slovak Republic 4 068 4 538 4 980 5 299 5 389 5 430
Slovenia 1 580 1 670 1 832 1 998 1 989 2 049
Spain 30 455 33 815 37 439 38 850 40 263 46 071
Sweden 7 485 8 043 8 311 8 559 8 872 9 378
United Kingdom 52 350 55 663 56 314 57 248 58 893 62 231
EU 386 892 419 123 441 271 454 423 481 581 499 879
Croatia 4 140 4 412 4 600 4 777 4 468 4 419
FYR of Macedonia 1 392 1 629 1 891 1 882 2 026 2 055
Iceland 176 204 228 255 281 318
Montenegro . . . . . . . . 614 617
Norway 3 581 3 876 4 086 4 242 4 491 4 889
Serbia . . . . . . . . 7 516 7 291
Switzerland 5 328 6 181 6 319 6 712 7 184 7 822
Turkey 27 438 35 294 44 522 56 104 67 393 73 142
| Break in series.
1. Population figures for Germany prior to 1991 refer to West Germany.
Source: OECD Health Data 2012; Eurostat Statistics Database.
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ANNEX ATable A.2. Share of the population aged 65 and over, mid-year, 1960 to 2010
1960 1970 1980 1990 2000 2010
Austria 12.2 14.1 15.4 14.9 15.4 17.6
Belgium 12.0 13.4 14.3 14.9 16.8 17.2
Bulgaria 7.5 9.6 11.9 13.2 16.3 17.6
Cyprus1 . . . . 10.8 10.9 11.3 13.0
Czech Republic 9.5 12.0 13.4 12.5 13.8 15.4
Denmark 10.6 12.3 14.4 15.6 14.8 16.6
Estonia 10.5 11.7 12.5 11.6 15.1 17.0
Finland 7.3 9.2 12.0 13.4 14.9 17.3
France 11.6 12.9 13.9 14.0 16.1 16.9
Germany2 10.8 13.1 15.5 15.5 | 16.4 20.6
Greece 8.2 11.1 13.1 13.7 16.6 19.1
Hungary 9.0 11.6 13.4 13.3 15.1 16.7
Ireland 11.1 11.1 10.7 11.4 11.2 11.5
Italy 9.3 10.9 13.1 14.9 18.3 20.3
Latvia . . 12.0 12.9 11.8 15.0 17.4
Lithuania . . 10.0 11.2 10.9 13.9 16.3
Luxembourg 10.9 12.5 13.6 13.4 14.1 13.9
Malta . . . . 8.3 10.4 12.2 15.2
Netherlands 9.0 10.2 11.5 12.8 13.6 15.4
Poland 5.8 8.2 10.1 10.1 12.2 13.5
Portugal 7.9 9.4 11.3 13.4 16.2 18.0
Romania . . 8.6 10.3 10.4 13.3 14.9
Slovak Republic 6.9 9.1 10.5 10.3 11.4 12.3
Slovenia 7.8 9.9 11.4 10.7 14.0 16.5
Spain 8.2 9.6 11.0 13.6 16.8 17.0
Sweden 11.8 13.7 16.3 17.8 17.3 18.3
United Kingdom 11.7 13.0 14.9 15.7 15.8 16.5
EU . . . . 12.5 13.0 14.7 16.4
Croatia3 . . . . . . . . 16.0 17.1
FYR of Macedonia . . . . . . . . 10.0 11.7
Iceland 8.1 8.8 9.9 10.6 11.6 12.1
Montenegro4 . . . . . . . . 11.9 12.7
Norway 11.0 12.9 14.8 16.3 15.2 15.0
Serbia . . . . . . . . 16.1 16.9
Switzerland 10.2 11.4 13.8 14.6 15.3 17.5
Turkey 3.6 4.4 4.7 4.4 5.4 7.1
| Break in series.
1. Data for Cyprus in 1980 refers to 1982.
2. Population figures for Germany prior to 1991 refer to West Germany.
3. Data for Croatia in 2000 refers to 2002.
4. Data for Montenegro in 2000 refers to 2003.
Source: OECD Health Data 2012; Eurostat Statistics Database.
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ANNEX ATable A.3. Crude birth rate, per 1 000 population, 1960 to 2010
1960 1970 1980 1990 2000 2010
Austria 17.9 15.0 12.0 11.8 9.8 9.4
Belgium 16.8 14.7 12.6 12.4 11.4 11.9
Bulgaria 17.8 16.3 14.5 12.1 9.0 10.0
Cyprus1 26.2 19.2 20.4 18.3 12.2 11.8
Czech Republic 13.4 15.0 14.9 12.6 8.8 11.1
Denmark 16.6 14.4 11.2 12.3 12.6 11.4
Estonia 16.6 15.8 15.0 14.2 9.5 11.8
Finland 18.5 14.0 13.2 13.1 11.0 11.4
France 17.9 16.7 14.9 13.4 13.1 12.7
Germany2 17.4 13.3 10.1 11.5 | 9.3 8.3
Greece 18.9 16.5 15.4 10.1 9.5 10.1
Hungary 14.7 14.7 13.9 12.1 9.6 9.0
Ireland 21.5 21.8 21.7 15.1 14.4 16.5
Italy 18.1 16.7 11.3 10.0 9.5 9.3
Latvia 16.7 14.6 14.1 14.2 8.5 8.6
Lithuania 22.5 17.7 15.2 15.4 9.8 10.8
Luxembourg 16.0 13.0 11.4 12.9 13.1 11.6
Malta 26.2 17.6 17.7 15.2 11.5 9.6
Netherlands 20.8 18.3 12.8 13.2 13.0 11.1
Poland 22.6 16.8 19.6 14.4 9.8 10.8
Portugal 24.1 20.8 16.2 11.7 11.7 9.5
Romania 19.1 21.1 17.9 13.6 10.4 9.9
Slovak Republic 21.7 17.8 19.1 15.1 10.2 11.1
Slovenia 17.6 15.9 15.7 11.2 9.1 10.9
Spain 21.7 19.5 15.3 10.3 9.9 10.5
Sweden 13.7 13.7 11.7 14.5 10.2 12.3
United Kingdom 17.5 16.2 13.4 13.9 11.5 13.0
EU 19.0 16.6 14.9 13.1 10.7 10.9
Croatia 18.4 13.8 14.8 11.6 9.8 9.8
FYR of Macedonia 31.7 23.2 21.0 18.8 14.5 11.8
Iceland 28.0 19.7 19.8 18.7 15.3 15.4
Montenegro . . . . . . . . 15.0 12.0
Norway 17.3 16.7 12.5 14.4 13.2 12.6
Serbia . . . . . . . . 9.8 9.4
Switzerland 17.7 16.1 11.7 12.5 10.9 10.3
Turkey . . . . . . . . 20.2 16.9
| Break in series.
1. Data for Cyprus in 1960 refers to 1961.
2. Population figures for Germany prior to 1991 refer to West Germany.
Source: Eurostat Statistics Database.
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ANNEX ATable A.4. Fertility rate, number of children per women aged 15-49, 1960 to 2010
1960 1970 1980 1990 2000 2010
Austria 2.7 2.3 1.7 1.5 1.4 1.4
Belgium 2.5 2.3 1.7 1.6 1.7 1.9
Bulgaria 2.3 2.2 2.1 1.8 1.3 1.5
Cyprus1 . . . . 2.5 2.4 1.6 1.5
Czech Republic 2.1 1.9 2.1 1.9 1.1 1.5
Denmark 2.5 2.0 1.5 1.7 1.8 1.9
Estonia . . . . 2.0 2.0 1.4 1.6
Finland 2.7 1.8 1.6 1.8 1.7 1.9
France 2.7 2.5 1.9 1.8 1.9 2.0
Germany 2.4 2.0 1.6 1.5 1.4 1.4
Greece 2.2 2.4 2.2 1.4 1.3 1.5
Hungary 2.0 2.0 1.9 1.8 1.3 1.3
Ireland 3.8 3.9 3.2 2.1 1.9 2.1
Italy 2.4 2.4 1.7 1.4 1.3 1.4
Latvia2 . . . . . . . . 1.2 1.2
Lithuania . . 2.4 2.0 2.0 1.4 1.6
Luxembourg 2.3 2.0 1.5 1.6 1.8 1.6
Malta . . . . 2.0 2.0 1.7 1.4
Netherlands 3.1 2.6 1.6 1.6 1.7 1.8
Poland 3.0 2.2 2.3 2.0 1.4 1.4
Portugal 3.1 2.8 2.2 1.6 1.6 1.4
Romania3 . . . . 2.4 1.8 1.3 1.4
Slovak Republic 3.1 2.4 2.3 2.1 1.3 1.4
Slovenia 2.2 2.2 2.1 1.5 1.3 1.6
Spain 2.9 2.9 2.2 1.4 1.2 1.4
Sweden 2.2 1.9 1.7 2.1 1.5 2.0
United Kingdom 2.7 2.4 1.9 1.8 1.6 2.0
EU . . . . 2.0 1.8 1.5 1.6
Croatia2 . . . . . . . . 1.3 1.5
FYR of Macedonia . . . . . . . . 1.9 1.6
Iceland 4.3 2.8 2.5 2.3 2.1 2.2
Montenegro . . . . . . . . . . 1.7
Norway 2.9 2.5 1.7 1.9 1.9 2.0
Serbia . . . . . . . . 1.5 1.4
Switzerland 2.4 2.1 1.6 1.6 1.5 1.5
Turkey 6.4 5.0 4.6 3.1 2.3 2.0
1. Data for Cyprus in 1980 and 2010 refer to 1982 and 2009 respectively.
2. Data for Latvia and Croatia in 2000 refer to 2002.
3. Data for Romania in 2010 refers to 2009.
Source: OECD Health Data 2012; Eurostat Statistics Database.
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ANNEX ATable A.5. GDP per capita in 2010 and average annual growth rates, 1980 to 2010
GDP per capita in EUR PPP Annual growth rate in real terms
2010 1980-90 1990-2000 2000-10
Austria 30 793 2.0 2.2 1.1
Belgium 28 943 1.9 1.9 0.8
Bulgaria 10 678 . . . . 4.9
Cyprus 24 223 . . . . 1.3
Czech Republic 19 431 . . 0.5 3.1
Denmark 30 941 2.0 2.2 0.2
Estonia3 15 678 . . 6.5 3.7
Finland 28 095 2.6 1.7 1.4
France 26 268 1.9 1.5 0.5
Germany2, 4 28 769 2.1 1.3 1.0
Greece 21 898 0.2 1.6 1.8
Hungary4 15 806 . . 1.9 2.2
Ireland 31 147 3.3 6.0 0.7
Italy 24 561 2.4 1.6 -0.2
Latvia 12 469 . . . . 4.3
Lithuania 13 848 . . . . 4.9
Luxembourg 66 207 4.5 3.6 1.2
Malta 20 293 . . . . 0.7
Netherlands 32 442 1.7 2.5 0.9
Poland 15 286 . . 3.7 4.0
Portugal 19 549 3.0 2.7 0.2
Romania 11 353 . . . . 4.6
Slovak Republic5 17 914 . . 3.7 4.7
Slovenia 20 728 . . 1.9 2.4
Spain 24 477 2.6 2.4 0.7
Sweden 30 287 1.9 1.7 1.5
United Kingdom 27 400 2.6 2.6 1.1
EU27 (unweighted) 24 055 . . . . 2.0
EU27 (weighted)1 24 474 . . . . 1.0
Croatia 14 505 . . . . 2.7
FYR of Macedonia 8 872 . . . . 2.4
Iceland 27 188 1.6 1.5 0.9
Montenegro 10 142 . . . . 4.5
Norway 44 149 2.1 3.1 0.6
Serbia6 8 405 . . . . 4.7
Switzerland 35 718 1.6 0.4 0.8
Turkey 11 970 2.8 1.8 3.0
1. The weighted average is calculated based on total GDP divided by the total population of the 27 EU member states.
2. Data prior to 1990 refers to Western Germany.
3. Data available from 1993.
4. Data available from 1991.
5. Data available from 1992.
6. Latest year 2009.
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO Global Health Expenditure Database.
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ANNEX ATable A.6. Total expenditure on health per capita in 2010,
average annual growth rates, 2000 to 2010
Total health expenditure 
per capita in EUR PPP
Annual growth rate per capita in real terms1
2010 2006/07 2007/08 2008/09 2009/10
2000-10 
(or latest year)
Austria 3 383 3.7 3.2 2.3 0.1 2.0
Belgium9 3 052 2.5 4.2 2.8 0.2 3.4
Bulgaria5 745 5.8 9.3 -1.7 . . 4.1
Cyprus7 1 783 -0.3 16.4 4.4 -0.2 2.2
Czech Republic 1 450 2.4 6.8 11.1 -4.4 4.9
Denmark 3 439 1.8 0.6 5.3 -2.1 2.7
Estonia 995 10.7 12.7 -0.5 -7.3 5.6
Finland 2 504 1.1 3.1 0.7 0.4 3.6
France 3 058 1.5 -1.4 2.7 0.8 1.9
Germany 3 337 1.8 3.4 4.3 2.7 2.1
Greece 2 244 3.6 2.6 0.5 -6.7 4.4
Hungary 1 231 -6.8 -1.7 -3.2 2.2 3.0
Ireland 2 862 5.6 9.6 2.7 -7.9 5.0
Italy 2 282 -2.8 1.0 -1.6 1.0 1.3
Latvia6 821 13.6 -8.1 -14.8 . . 2.7
Lithuania8 972 10.8 9.7 -2.2 -5.0 6.4
Luxembourg3 3 607 -4.9 -7.1 7.5 . . 0.6
Malta 1 758 -3.3 -0.2 -0.8 3.6 3.5
Netherlands 3 890 . . 3.2 3.6 2.0 5.2
Poland 1 068 9.1 14.3 6.4 0.5 6.4
Portugal 2 097 1.7 2.1 2.7 0.5 1.7
Romania7 677 9.6 11.5 -3.0 4.2 5.4
Slovak Republic 1 614 16.5 9.2 8.2 2.4 10.0
Slovenia 1 869 1.0 9.2 1.9 -2.0 3.3
Spain 2 345 2.8 4.6 2.8 -0.9 3.6
Sweden 2 894 2.2 2.1 1.4 1.2 3.1
United Kingdom 2 636 3.0 1.5 6.3 -0.5 4.3
EU27 (unweighted) 2 171 3.6 4.5 1.9 -0.6 3.8
EU27 (weighted)2 2 470 1.7 2.3 3.4 0.4 2.8
Croatia 1 152 12.7 5.2 -5.9 -1.2 2.7
FYR of Macedonia 619 -7.2 3.9 -0.6 5.7 0.1
Iceland 2 524 3.2 -0.9 -1.4 -7.1 0.7
Montenegro3 899 0.4 8.1 11.7 . . 5.9
Norway 4 156 2.7 2.6 1.6 -2.0 2.4
Serbia3 902 18.1 6.0 -1.3 . . 8.9
Switzerland 4 056 1.2 2.0 2.9 1.4 1.9
Turkey4 714 10.2 0.0 . . . . 6.4
1. Using national currency units at 2005 GDP price level.
2. The weighted average is calculated based on total health spending divided by the total population of the 27 EU
member states.
3. Most recent year 2009.
4. Most recent year 2008.
5. Data for 2003-09.
6. Data for 2004-09.
7. Data since 2003.
8. Data since 2004.
9. Excluding investment.
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO Global Health Expenditure Database.
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ANNEX ATable A.7. Total expenditure on health, percentage of GDP, 1980 to 2010
1980 1990 2000 2005 2007 2008 2009 2010
Austria 7.4 | 8.4 10.0 10.4 10.3 10.5 11.2 | 11.0
Belgium2 6.3 7.2 8.1 10.1 9.6 10.0 10.7 10.5
Bulgaria . . . . 6.2 7.3 6.8 7.0 7.2 . .
Cyprus . . . . 5.8 6.4 6.1 6.9 7.4 7.4
Czech Republic . . 4.5 | 6.3 | 6.9 6.5 6.8 8.0 7.5
Denmark 8.9 8.3 8.7 | 9.8 10.0 10.2 11.5 11.1
Estonia . . . . 5.3 5.0 5.2 6.0 7.0 | 6.3
Finland 6.3 7.7 | 7.2 8.4 8.0 8.3 9.2 8.9
France 7.0 8.4 | 10.1 11.2 11.1 11.0 11.7 11.6
Germany 8.4 8.3 | 10.4 10.8 10.5 10.7 11.7 11.6
Greece 5.9 6.7 8.0 9.7 9.8 10.1 10.6 10.2
Hungary3 . . 7.1 7.2 8.4 7.7 7.5 7.7 7.8
Ireland 8.2 6.0 6.1 7.6 7.8 8.9 9.9 9.2
Italy . . 7.7 8.0 8.9 8.6 | 8.9 9.3 9.3
Latvia . . . . 6.0 6.4 7.0 6.6 6.8 . .
Lithuania . . . . 6.5 5.8 6.2 6.6 7.5 7.0
Luxembourg 5.2 5.4 | 7.5 7.9 7.1 6.8 7.9 . .
Malta . . . . 6.7 9.3 8.7 8.3 8.5 8.6
Netherlands 7.4 8.0 | 8.0 9.8 | 10.8 11.0 11.9 12.0
Poland . . 4.8 5.5 | 6.2 6.3 6.9 7.2 | 7.0
Portugal 5.1 5.7 | 9.3 10.4 10.0 10.2 10.8 10.7
Romania . . . . 5.2 5.5 5.2 5.4 5.6 6.0
Slovak Republic . . . . 5.5 7.0 7.8 8.0 9.2 9.0
Slovenia . . . . 8.3 | 8.3 7.8 8.3 9.3 9.0
Spain 5.3 6.5 | 7.2 | 8.3 8.5 8.9 9.6 9.6
Sweden 8.9 8.2 | 8.2 9.1 8.9 9.2 9.9 9.6
United Kingdom 5.6 5.9 | 7.0 8.2 8.5 8.8 9.8 9.6
EU27 (unweighted) . . . . 7.3 8.3 8.2 8.4 9.2 9.04
EU27 (weighted)1 . . . . 8.6 9.5 9.4 9.6 10.4 10.3
Croatia . . . . 7.8 7.0 7.5 7.8 7.8 7.8
FYR of Macedonia . . . . 8.8 8.1 6.9 6.8 6.9 7.1
Iceland 6.3 7.8 9.5 9.4 9.1 9.1 9.6 9.3
Montenegro . . . . 7.9 9.1 7.8 8.0 9.4 9.1
Norway 7.0 7.6 | 8.4 | 9.0 8.7 8.6 9.8 9.4
Serbia . . . . 7.4 9.1 10.4 10.4 10.5 10.4
Switzerland 7.4 8.2 | 10.2 11.2 10.6 10.7 11.4 11.4
Turkey 2.4 2.7 | 4.9 5.4 6.0 6.1 . . . .
| Break in series.
1. The weighted average is calculated based on total health spending divided by total GDP across the 27 EU member
states.
2. Excluding investment.
3. Data for 1990 refers to 1991.
4. The average is calculated on the most recent data available.
Source: OECD Health Data 2012; Eurostat Statistics Database; WHO Global Health Expenditure Database.
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